cancer.type	eQTL.type	tagSNP	LD	SNP.ID	SNP.position.hg19	Gene.symbol	Gene.position.hg19	Beta	t-stat	P-value	GWAS-Traits	
PAAD	cis	1	rs1000113	chr5:150240076	LOC134466	chr5:150310000-150326146:-	0.75	6.27	3.56E-9	Crohn's disease	
PAAD	cis	1	rs10002332	chr4:129875301	C4orf33	chr4:130014829-130033842:+	0.51	6.02	1.27E-8	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs10006789	chr4:1330333	CRIPAK	chr4:1385340-1389782:+	0.53	7.13	3.77E-11	Systolic blood pressure	
PAAD	cis	1	rs10008757	chr4:76903036	NAAA	chr4:76831809-76862166:-	-0.45	-5.5	1.53E-7	Longevity	
PAAD	cis	1	rs10009541	chr4:17682218	MED28	chr4:17616273-17629791:+	-0.39	-4.45	1.65E-5	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10011865	chr4:17645710	MED28	chr4:17616273-17629791:+	0.46	5.49	1.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10012335	chr4:17628630	MED28	chr4:17616273-17629791:+	0.48	5.77	4.25E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10019856	chr4:17615742	MED28	chr4:17616273-17629791:+	0.43	5.06	1.2E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10027755	chr4:17615954	MED28	chr4:17616273-17629791:+	0.48	5.77	4.25E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10032326	chr4:17630717	MED28	chr4:17616273-17629791:+	0.47	5.76	4.44E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs1003719	chr21:38491095	PIGP	chr21:38437664-38445458:-	-0.49	-6.28	3.29E-9	Eye color traits	
PAAD	cis	1	rs10041072	chr5:150259642	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs10051747	chr5:56083289	C5orf35	chr5:56205103-56213010:+	1.04	9.89	3.83E-18	Type 2 diabetes	
PAAD	cis	1	rs10051804	chr5:150226424	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs10051924	chr5:150226639	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs10052606	chr5:150272217	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs10053750	chr5:150270051	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs10057988	chr5:150272062	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs10058821	chr5:150226385	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs10058943	chr5:150226586	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs10061105	chr5:150255185	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs10065172	chr5:150227998	LOC134466	chr5:150310000-150326146:-	0.65	5.73	5.25E-8	Crohn's disease	
PAAD	cis	1	rs1006722	chr4:17618713	MED28	chr4:17616273-17629791:+	-0.5	-6	1.4E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10078968	chr5:150244273	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs1008374	chr4:17683219	MED28	chr4:17616273-17629791:+	0.45	5.25	5.08E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs1008375	chr4:17682834	MED28	chr4:17616273-17629791:+	0.46	5.33	3.44E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10117059	chr9:123653477	LOC253039	chr9:123605320-123616644:+	-0.57	-7.62	2.46E-12	Rheumatoid arthritis	
PAAD	cis	1	rs1012376	chr14:65294790	CHURC1	chr14:65381140-65411309:+	0.53	4.02	9.04E-5	Daytime sleep phenotypes	
PAAD	cis	1	rs10138183	chr14:75615227	EIF2B2	chr14:75469612-75476292:+	0.39	4.38	2.18E-5	Height	
PAAD	cis	1	rs10140433	chr14:74659989	LIN52	chr14:74551656-74667117:+	-0.42	-7.21	2.4E-11	Common traits (Other)	
PAAD	cis	1	rs10142626	chr14:75555636	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs10142865	chr14:75555624	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs10144220	chr14:74647904	LIN52	chr14:74551656-74667117:+	-0.43	-7.66	2.01E-12	Common traits (Other)	
PAAD	cis	1	rs10146482	chr14:75574087	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs10149880	chr14:75633008	EIF2B2	chr14:75469612-75476292:+	-0.37	-4.07	7.49E-5	Height	
PAAD	cis	1	rs10150201	chr14:74649157	LIN52	chr14:74551656-74667117:+	-0.44	-7.49	4.99E-12	Common traits (Other)	
PAAD	cis	1	rs10151596	chr14:22723198	HAUS4	chr14:23415438-23426335:-	-0.57	-4.1	6.7E-5	Periodontal disease-related phenotypes	
PAAD	cis	1	rs10157597	chr1:45990278	CCDC163P	chr1:45960581-45965646:-	-0.96	-13.34	2.03E-27	Homocysteine levels	
PAAD	cis	1	rs1016669	chr3:41894440	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs10178409	chr2:73855507	ALMS1P	chr2:73872046-73912692:+	0.48	4.27	3.42E-5	Urinary metabolites	
PAAD	cis	1	rs1018184	chr6:86648475	SNHG5	chr6:86386726-86388451:-	0.85	11.58	1.18E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs10193373	chr2:281886	SH3YL1	chr2:218138-264810:-	-0.47	-7.75	1.2E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs10212536	chr3:41827026	ULK4	chr3:41288091-42003660:-	0.88	8.15	1.18E-13	Diastolic blood pressure	
PAAD	cis	1	rs10218795	chr1:145416056	NOTCH2NL	chr1:145209111-145295525:+	0.69	4.35	2.52E-5	Coronary heart disease	
PAAD	cis	1	rs10229552	chr7:99234899	CYP3A5	chr7:99245818-99332821:-	0.76	7.4	8.45E-12	Blood metabolite levels	
PAAD	cis	1	rs10234309	chr7:135311167	PL-5283	chr7:135347221-135378160:+	0.81	8.59	9.15E-15	Paget's disease	
PAAD	cis	1	rs10234309	chr7:135311167	SLC13A4	chr7:135365993-135412933:-	-0.5	-4.48	1.43E-5	Paget's disease	
PAAD	cis	1	rs10242455	chr7:99240179	CYP3A5	chr7:99245818-99332821:-	-0.72	-7.03	6.31E-11	Blood metabolite levels	
PAAD	cis	1	rs1025646	chr3:41754422	ULK4	chr3:41288091-42003660:-	0.83	7.23	2.18E-11	Diastolic blood pressure	
PAAD	cis	1	rs10278546	chr7:100516003	TRIP6	chr7:100464950-100471070:+	0.33	4.16	5.29E-5	Resting heart rate	
PAAD	cis	1	rs1028449	chr14:35512995	PPP2R3C	chr14:35554679-35591679:-	0.56	5.79	3.87E-8	Atopic dermatitis	
PAAD	cis	1	rs1030831	chr4:130025037	C4orf33	chr4:130014829-130033842:+	-0.54	-7.09	4.75E-11	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1034219	chr1:93022678	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs1037147	chr4:130025873	C4orf33	chr4:130014829-130033842:+	-0.54	-7.09	4.75E-11	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1039664	chr7:65449716	CCT6P1	chr7:65216092-65228661:+	0.44	4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs1040726	chr20:3264267	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs1040727	chr20:3264292	ITPA	chr20:3190056-3204504:+	-0.4	-5.71	5.63E-8	IFN-related cytopenia	
PAAD	cis	1	rs10409485	chr19:41920765	B3GNT8	chr19:41931265-41934635:-	0.3	4.73	4.97E-6	Height	
PAAD	cis	1	rs10413735	chr19:41921071	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.73	4.97E-6	Height	
PAAD	cis	1	rs10416218	chr19:33599127	GPATCH1	chr19:33571786-33621318:+	0.45	4.01	9.34E-5	Bone properties (heel)	
PAAD	cis	1	rs10416265	chr19:33605300	GPATCH1	chr19:33571786-33621318:+	0.46	4.06	7.79E-5	Bone properties (heel)	
PAAD	cis	1	rs10417311	chr19:41902038	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.69	5.94E-6	Height	
PAAD	cis	1	rs10417997	chr19:41902361	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.67	6.58E-6	Height	
PAAD	cis	1	rs10422783	chr19:41906436	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.69	5.94E-6	Height	
PAAD	cis	1	rs10422956	chr19:41901261	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.67	6.64E-6	Height	
PAAD	cis	1	rs10423531	chr19:33600140	GPATCH1	chr19:33571786-33621318:+	0.45	4.01	9.34E-5	Bone properties (heel)	
PAAD	cis	1	rs1042658	chr17:38173902	GSDMA	chr17:38119226-38134019:+	-0.56	-6.21	4.72E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs10431505	chr12:58178589	FAM119B	chr12:58166383-58176323:+	0.47	5.72	5.52E-8	Multiple sclerosis	
PAAD	cis	1	rs1043413	chr19:41939297	B3GNT8	chr19:41931265-41934635:-	0.32	4.96	1.82E-6	Height	
PAAD	cis	1	rs1043674	chr14:75549370	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs10440301	chr4:17663199	MED28	chr4:17616273-17629791:+	0.44	5.19	6.59E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10445300	chr17:2114587	SRR	chr17:2207248-2228553:+	-0.5	-8.77	3.2E-15	Esophageal cancer (squamous cell)	
PAAD	cis	1	rs1044717	chr1:45976587	CCDC163P	chr1:45960581-45965646:-	-0.96	-13.52	6.53E-28	Homocysteine levels	
PAAD	cis	1	rs10454142	chr2:48646399	GTF2A1L	chr2:48844948-48960284:+	-0.43	-4.79	3.97E-6	Sex hormone-binding globulin levels	
PAAD	cis	1	rs10455158	chr6:86672825	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs10455449	chr6:86592226	SNHG5	chr6:86386726-86388451:-	-0.87	-11.99	9.11E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs10455455	chr6:86670214	SNHG5	chr6:86386726-86388451:-	-0.86	-11.92	1.38E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs10455456	chr6:86670322	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs10456362	chr6:28221816	ZSCAN23	chr6:28393287-28411279:-	-0.41	-4.15	5.59E-5	Depression	
PAAD	cis	1	rs10456622	chr6:49396453	CENPQ	chr6:49431096-49460820:+	-0.35	-4.09	6.9E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs10461617	chr5:56104308	C5orf35	chr5:56205103-56213010:+	1.04	9.75	9.0E-18	Type 2 diabetes	
PAAD	cis	1	rs10462794	chr5:4488245	KIAA0947	chr5:5422807-5490337:+	-0.22	-4.27	3.42E-5	DNA methylation (variation)	
PAAD	cis	1	rs10462795	chr5:4488309	KIAA0947	chr5:5422807-5490337:+	-0.22	-4.25	3.68E-5	DNA methylation (variation)	
PAAD	cis	1	rs10463240	chr5:150256853	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs10463307	chr5:150254620	LOC134466	chr5:150310000-150326146:-	0.7	5.99	1.46E-8	Crohn's disease	
PAAD	cis	1	rs10463310	chr5:150260905	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs10465756	chr1:93029698	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs1046875	chr17:80685426	FN3KRP	chr17:80674582-80685889:+	0.44	4.25	3.74E-5	Glycated hemoglobin levels	
PAAD	cis	1	rs1046896	chr17:80685533	FN3KRP	chr17:80674582-80685889:+	0.45	4.37	2.27E-5	Glycated hemoglobin levels	
PAAD	cis	1	rs1046917	chr17:80685655	FN3KRP	chr17:80674582-80685889:+	0.44	4.25	3.74E-5	Glycated hemoglobin levels	
PAAD	cis	1	rs10470686	chr3:48449956	TREX1	chr3:48501186-48509043:+	-0.38	-5.55	1.21E-7	Longevity	
PAAD	cis	1	rs1047418	chr14:75605792	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs10492096	chr12:6580582	ANO2	chr12:5671817-6055398:-	0.42	4.08	7.16E-5	Hip geometry	
PAAD	cis	1	rs10494874	chr1:205754688	PM20D1	chr1:205797154-205819245:-	-0.4	-4.3	2.97E-5	Prostate-specific antigen levels	
PAAD	cis	1	rs10498958	chr6:86649705	SNHG5	chr6:86386726-86388451:-	0.87	12.12	3.99E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs10500303	chr19:50512033	SIGLEC16	chr19:50472912-50479075:+	1	5.46	1.86E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs10509741	chr10:101917366	CWF19L1	chr10:101992055-102027437:-	-0.51	-4.39	2.06E-5	Schizophrenia	
PAAD	cis	1	rs10509744	chr10:102271579	SEC31B	chr10:102246403-102289636:-	-0.35	-5.7	6.08E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10517073	chr4:25417371	ANAPC4	chr4:25378848-25420119:+	-0.32	-4.36	2.35E-5	Rheumatoid arthritis	
PAAD	cis	1	rs1052501	chr3:41925398	ULK4	chr3:41288091-42003660:-	-0.83	-7.34	1.17E-11	Diastolic blood pressure	
PAAD	cis	1	rs1054399	chr10:102312565	SEC31B	chr10:102246403-102289636:-	-0.34	-5.4	2.54E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10732856	chr11:116907113	PCSK7	chr11:117075789-117102811:-	-0.39	-4.17	5.06E-5	Protein quantitative trait loci	
PAAD	cis	1	rs10736426	chr1:45984353	CCDC163P	chr1:45960581-45965646:-	0.9	11.9	1.55E-23	Homocysteine levels	
PAAD	cis	1	rs10747783	chr12:58176614	FAM119B	chr12:58166383-58176323:+	0.45	5.42	2.24E-7	Multiple sclerosis	
PAAD	cis	1	rs10749860	chr1:46328210	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.87E-9	Body mass index	
PAAD	cis	1	rs10750100	chr11:116917244	PCSK7	chr11:117075789-117102811:-	-0.4	-4.39	2.1E-5	Protein quantitative trait loci	
PAAD	cis	1	rs10760021	chr9:100697648	C9orf156	chr9:100666772-100684852:-	-0.34	-4.71	5.4E-6	Quantitative traits	
PAAD	cis	1	rs10760118	chr9:123641616	LOC253039	chr9:123605320-123616644:+	-0.56	-7.64	2.25E-12	Rheumatoid arthritis	
PAAD	cis	1	rs10760121	chr9:123647915	LOC253039	chr9:123605320-123616644:+	-0.57	-7.71	1.46E-12	Rheumatoid arthritis	
PAAD	cis	1	rs10760589	chr9:131906293	PPP2R4	chr9:131873244-131911223:+	0.43	4.29	3.12E-5	Blood metabolite ratios	
PAAD	cis	1	rs10761723	chr10:64955581	NRBF2	chr10:64893007-64914785:+	-0.38	-5.12	8.86E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs10761727	chr10:64995493	NRBF2	chr10:64893007-64914785:+	-0.38	-5.16	7.4E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs10761742	chr10:65085048	NRBF2	chr10:64893007-64914785:+	-0.38	-5.16	7.4E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs10782922	chr1:92974595	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs10783847	chr12:58196447	FAM119B	chr12:58166383-58176323:+	0.47	5.72	5.52E-8	Multiple sclerosis	
PAAD	cis	1	rs10783848	chr12:58196528	FAM119B	chr12:58166383-58176323:+	0.47	5.72	5.52E-8	Multiple sclerosis	
PAAD	cis	1	rs10786596	chr10:102282126	SEC31B	chr10:102246403-102289636:-	-0.35	-5.75	4.71E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10786597	chr10:102291287	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10786598	chr10:102291579	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10789475	chr1:46304177	CCDC163P	chr1:45960581-45965646:-	-0.52	-6.55	8.13E-10	Body mass index	
PAAD	cis	1	rs10789481	chr1:46383583	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.03	1.17E-8	Body mass index	
PAAD	cis	1	rs10789487	chr1:46420221	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs1078968	chr3:53123486	RFT1	chr3:53122503-53164470:-	-0.49	-5.69	6.25E-8	Height	
PAAD	cis	1	rs10790268	chr11:118729391	TREH	chr11:118528942-118550381:-	0.47	4.99	1.63E-6	Rheumatoid arthritis	
PAAD	cis	1	rs10804632	chr3:134294501	ANAPC13	chr3:134196547-134204865:-	0.86	11.36	4.41E-22	Height	
PAAD	cis	1	rs10805357	chr4:17652352	MED28	chr4:17616273-17629791:+	0.46	5.49	1.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10805358	chr4:17652450	MED28	chr4:17616273-17629791:+	0.46	5.49	1.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10805359	chr4:17684886	MED28	chr4:17616273-17629791:+	0.46	5.44	2.02E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs1080698	chr10:102295114	SEC31B	chr10:102246403-102289636:-	-0.36	-5.94	1.83E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10818480	chr9:123643170	LOC253039	chr9:123605320-123616644:+	-0.57	-7.69	1.66E-12	Rheumatoid arthritis	
PAAD	cis	1	rs10819464	chr9:131876277	PPP2R4	chr9:131873244-131911223:+	0.42	4.2	4.57E-5	Blood metabolite ratios	
PAAD	cis	1	rs10819466	chr9:131881492	PPP2R4	chr9:131873244-131911223:+	0.43	4.33	2.67E-5	Blood metabolite ratios	
PAAD	cis	1	rs10819469	chr9:131882067	PPP2R4	chr9:131873244-131911223:+	0.5	5.08	1.07E-6	Blood metabolite ratios	
PAAD	cis	1	rs10819471	chr9:131896325	PPP2R4	chr9:131873244-131911223:+	0.43	4.26	3.53E-5	Blood metabolite ratios	
PAAD	cis	1	rs10822145	chr10:64934548	NRBF2	chr10:64893007-64914785:+	-0.38	-5.16	7.39E-7	Triglycerides	
PAAD	cis	1	rs10822149	chr10:64987412	NRBF2	chr10:64893007-64914785:+	-0.38	-5.16	7.4E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs10822161	chr10:65118203	NRBF2	chr10:64893007-64914785:+	-0.38	-5.16	7.4E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs10822163	chr10:65124098	NRBF2	chr10:64893007-64914785:+	-0.38	-5.16	7.4E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs10824026	chr10:75421208	NUDT13	chr10:74870210-74891580:+	-0.45	-4.5	1.36E-5	Atrial fibrillation	
PAAD	cis	1	rs10849462	chr12:6575992	ANO2	chr12:5671817-6055398:-	0.43	4.27	3.45E-5	Hip geometry	
PAAD	cis	1	rs10851599	chr15:56154064	PRTG	chr15:55903748-56035177:-	0.32	4.99	1.61E-6	Keloid	
PAAD	cis	1	rs1085243	chr1:46544768	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.18	5.61E-9	Body mass index	
PAAD	cis	1	rs1085244	chr1:46563680	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.99	1.48E-8	Body mass index	
PAAD	cis	1	rs10853751	chr19:41903220	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.69	5.94E-6	Height	
PAAD	cis	1	rs10857712	chr10:135225666	MTG1	chr10:135207621-135234173:+	0.3	4.15	5.56E-5	Systemic lupus erythematosus	
PAAD	cis	1	rs10865914	chr3:41919499	ULK4	chr3:41288091-42003660:-	-0.84	-7.48	5.46E-12	Diastolic blood pressure	
PAAD	cis	1	rs10874656	chr1:92947024	EVI5	chr1:92974255-93257961:-	-0.4	-4.24	3.8E-5	Cholesterol, total	
PAAD	cis	1	rs10877012	chr12:58162085	FAM119B	chr12:58166383-58176323:+	0.44	5.42	2.24E-7	Multiple sclerosis	
PAAD	cis	1	rs10877013	chr12:58165085	FAM119B	chr12:58166383-58176323:+	0.47	5.87	2.61E-8	Multiple sclerosis	
PAAD	cis	1	rs10877014	chr12:58167661	FAM119B	chr12:58166383-58176323:+	0.47	5.88	2.46E-8	Multiple sclerosis	
PAAD	cis	1	rs10877015	chr12:58167788	FAM119B	chr12:58166383-58176323:+	0.45	5.54	1.32E-7	Multiple sclerosis	
PAAD	cis	1	rs10877019	chr12:58172929	FAM119B	chr12:58166383-58176323:+	-0.46	-5.72	5.43E-8	Multiple sclerosis	
PAAD	cis	1	rs10883492	chr10:102206089	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883493	chr10:102208188	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883496	chr10:102221931	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883497	chr10:102228519	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883499	chr10:102232188	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883500	chr10:102238324	SEC31B	chr10:102246403-102289636:-	-0.34	-5.7	6.05E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883501	chr10:102238326	SEC31B	chr10:102246403-102289636:-	-0.34	-5.7	6.05E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883502	chr10:102238343	SEC31B	chr10:102246403-102289636:-	-0.34	-5.7	6.05E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883503	chr10:102275504	SEC31B	chr10:102246403-102289636:-	-0.36	-5.98	1.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883504	chr10:102280687	SEC31B	chr10:102246403-102289636:-	-0.36	-5.94	1.83E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883505	chr10:102280772	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883506	chr10:102289743	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883507	chr10:102291275	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883508	chr10:102294413	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883509	chr10:102296461	SEC31B	chr10:102246403-102289636:-	-0.36	-5.79	3.77E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883510	chr10:102297018	SEC31B	chr10:102246403-102289636:-	-0.36	-5.84	3.06E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883511	chr10:102299407	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.56E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883512	chr10:102308516	SEC31B	chr10:102246403-102289636:-	-0.34	-5.46	1.9E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10883513	chr10:102316964	SEC31B	chr10:102246403-102289636:-	-0.36	-5.56	1.18E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs10888527	chr1:153001363	SPRR1A	chr1:152956557-152958289:+	-0.42	-4.96	1.88E-6	Inflammatory skin disease	
PAAD	cis	1	rs10890352	chr1:46283628	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.5	1.1E-9	Body mass index	
PAAD	cis	1	rs10890354	chr1:46305347	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.5	1.06E-9	Body mass index	
PAAD	cis	1	rs10890361	chr1:46346234	CCDC163P	chr1:45960581-45965646:-	-0.47	-5.43	2.12E-7	Body mass index	
PAAD	cis	1	rs10890363	chr1:46356148	CCDC163P	chr1:45960581-45965646:-	0.5	6.03	1.2E-8	Body mass index	
PAAD	cis	1	rs10890383	chr1:46588503	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.04	1.15E-8	Body mass index	
PAAD	cis	1	rs10896043	chr11:65543827	SNX32	chr11:65601410-65621170:+	-0.66	-5.64	7.99E-8	Systemic lupus erythematosus	
PAAD	cis	1	rs10901513	chr10:127699936	UROS	chr10:127477148-127511837:-	-0.34	-4.2	4.54E-5	Visceral fat	
PAAD	cis	1	rs10901514	chr10:127700066	UROS	chr10:127477148-127511837:-	-0.34	-4.2	4.54E-5	Visceral fat	
PAAD	cis	1	rs10934800	chr3:126795751	CHST13	chr3:126243176-126262133:+	0.43	4.09	6.88E-5	Amyotrophic lateral sclerosis (sporadic)	
PAAD	cis	1	rs10935120	chr3:134233092	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.86	2.04E-23	Height	
PAAD	cis	1	rs10939738	chr4:17604295	MED28	chr4:17616273-17629791:+	0.39	4.48	1.48E-5	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10939740	chr4:17617490	MED28	chr4:17616273-17629791:+	0.47	5.66	7.15E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10939742	chr4:17659936	MED28	chr4:17616273-17629791:+	0.46	5.5	1.59E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10939743	chr4:17662731	MED28	chr4:17616273-17629791:+	0.45	5.28	4.35E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10939744	chr4:17664473	MED28	chr4:17616273-17629791:+	0.45	5.28	4.33E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10939746	chr4:17684951	MED28	chr4:17616273-17629791:+	-0.45	-5.4	2.48E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10939747	chr4:17691166	MED28	chr4:17616273-17629791:+	0.39	4.47	1.5E-5	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10939748	chr4:17691230	MED28	chr4:17616273-17629791:+	0.39	4.47	1.5E-5	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10939749	chr4:17692319	MED28	chr4:17616273-17629791:+	0.41	4.68	6.2E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10939750	chr4:17692422	MED28	chr4:17616273-17629791:+	0.42	4.8	3.8E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10939756	chr4:17693867	MED28	chr4:17616273-17629791:+	0.41	4.68	6.2E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs10944161	chr6:86630376	SNHG5	chr6:86386726-86388451:-	-0.84	-11.44	2.8E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs10944163	chr6:86658693	SNHG5	chr6:86386726-86388451:-	-0.86	-11.79	3.04E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs10944169	chr6:86683036	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs10944170	chr6:86685469	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs10957375	chr8:67355484	ADHFE1	chr8:67344718-67381042:+	0.3	4.08	7.19E-5	Blood metabolite levels	
PAAD	cis	1	rs10984361	chr9:100681490	C9orf156	chr9:100666772-100684852:-	-0.34	-4.66	6.76E-6	Quantitative traits	
PAAD	cis	1	rs10984506	chr9:100716140	C9orf156	chr9:100666772-100684852:-	-0.34	-4.66	6.71E-6	Quantitative traits	
PAAD	cis	1	rs10988125	chr9:131572903	ENDOG	chr9:131580779-131584954:+	0.31	5.08	1.07E-6	Blood metabolite levels	
PAAD	cis	1	rs10988214	chr9:131883752	PPP2R4	chr9:131873244-131911223:+	0.43	4.41	1.91E-5	Blood metabolite ratios	
PAAD	cis	1	rs10988223	chr9:131903021	PPP2R4	chr9:131873244-131911223:+	0.5	5.05	1.22E-6	Blood metabolite ratios	
PAAD	cis	1	rs10988224	chr9:131903334	PPP2R4	chr9:131873244-131911223:+	0.43	4.29	3.12E-5	Blood metabolite ratios	
PAAD	cis	1	rs1106287	chr1:113242122	ST7L	chr1:113066142-113162405:-	0.45	5.92	2.06E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs11064210	chr12:6576721	ANO2	chr12:5671817-6055398:-	0.44	4.36	2.41E-5	Hip geometry	
PAAD	cis	1	rs11064218	chr12:6586261	ANO2	chr12:5671817-6055398:-	0.44	4.35	2.44E-5	Hip geometry	
PAAD	cis	1	rs11064881	chr12:120146925	PRKAB1	chr12:120105757-120119428:+	-0.58	-4.07	7.4E-5	Ulcerative colitis;Inflammatory bowel disease	
PAAD	cis	1	rs1106565	chr10:102211613	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11067231	chr12:109993603	MYO1H	chr12:109826524-109886176:+	0.5	4.63	7.71E-6	HDL cholesterol	
PAAD	cis	1	rs11072603	chr15:76881138	SCAPER	chr15:76640529-77197744:-	-0.24	-4.45	1.64E-5	Blood metabolite levels	
PAAD	cis	1	rs1108431	chr16:31054607	MYST1	chr16:31128985-31142713:+	0.38	4.84	3.11E-6	Response to metformin (IC50)	
PAAD	cis	1	rs11085466	chr19:21751811	ZNF429	chr19:21688437-21739068:+	0.4	4.61	8.36E-6	Colorectal or endometrial cancer	
PAAD	cis	1	rs1109227	chr3:48479207	TREX1	chr3:48501186-48509043:+	-0.36	-5.33	3.45E-7	Longevity	
PAAD	cis	1	rs1110042	chr1:113236534	ST7L	chr1:113066142-113162405:-	0.45	5.92	2.06E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs1112137	chr1:247215375	ZNF670	chr1:247200087-247242069:-	-0.5	-5.54	1.3E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs11121382	chr1:9411469	ENO1	chr1:8921063-8938780:-	-0.31	-4.24	3.87E-5	Immune response to anthrax vaccine	
PAAD	cis	1	rs11123170	chr2:113978940	LOC654433	chr2:113993107-114024579:+	-0.52	-5.75	4.71E-8	Renal function-related traits (BUN)	
PAAD	cis	1	rs11123170	chr2:113978940	PAX8	chr2:113973575-114036498:-	-0.51	-5.71	5.74E-8	Renal function-related traits (BUN)	
PAAD	cis	1	rs11127188	chr2:28972852	TRMT61B	chr2:29072690-29093175:-	-0.49	-5.97	1.57E-8	Body mass index	
PAAD	cis	1	rs11130170	chr3:48449897	TREX1	chr3:48501186-48509043:+	-0.38	-5.55	1.21E-7	Longevity	
PAAD	cis	1	rs11130171	chr3:48462461	TREX1	chr3:48501186-48509043:+	-0.35	-5.22	5.71E-7	Longevity	
PAAD	cis	1	rs11130338	chr3:53120924	RFT1	chr3:53122503-53164470:-	-0.49	-5.63	8.27E-8	Height	
PAAD	cis	1	rs111315781	chr2:201738724	PPIL3	chr2:201735680-201753999:-	-1.01	-6.92	1.18E-10	Triptolide cytotoxicity	
PAAD	cis	1	rs11132254	chr4:185611592	MLF1IP	chr4:185615220-185655286:-	-0.43	-6.97	8.64E-11	Kawasaki disease	
PAAD	cis	1	rs11148252	chr13:53009048	CKAP2	chr13:53029495-53050763:+	-0.35	-5.75	4.79E-8	Lewy body disease	
PAAD	cis	1	rs11156875	chr14:35619816	PPP2R3C	chr14:35554679-35591679:-	0.48	4.99	1.64E-6	Atopic dermatitis	
PAAD	cis	1	rs11159067	chr14:74637444	LIN52	chr14:74551656-74667117:+	0.41	7.1	4.34E-11	Common traits (Other)	
PAAD	cis	1	rs11159117	chr14:75584867	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs11159183	chr14:76662902	ESRRB	chr14:76837690-76968178:+	0.46	4.04	8.39E-5	Blood pressure	
PAAD	cis	1	rs11167515	chr5:150239471	LOC134466	chr5:150310000-150326146:-	0.75	6.27	3.56E-9	Crohn's disease	
PAAD	cis	1	rs11167518	chr5:150258920	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs11167519	chr5:150265407	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs11167520	chr5:150265639	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs11167521	chr5:150271785	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs11167526	chr5:150332481	LOC134466	chr5:150310000-150326146:-	0.76	5.8	3.77E-8	Crohn's disease	
PAAD	cis	1	rs111696803	chr9:100696636	C9orf156	chr9:100666772-100684852:-	-0.33	-4.61	8.38E-6	Quantitative traits	
PAAD	cis	1	rs11172333	chr12:58170335	FAM119B	chr12:58166383-58176323:+	0.45	5.53	1.33E-7	Multiple sclerosis	
PAAD	cis	1	rs11172333	chr12:58170335	TSFM	chr12:58176536-58191367:+	-0.34	-4.18	4.86E-5	Multiple sclerosis	
PAAD	cis	1	rs11172335	chr12:58175201	FAM119B	chr12:58166383-58176323:+	0.45	5.44	2.09E-7	Multiple sclerosis	
PAAD	cis	1	rs11172342	chr12:58187758	FAM119B	chr12:58166383-58176323:+	0.45	5.44	2.09E-7	Multiple sclerosis	
PAAD	cis	1	rs11172343	chr12:58188157	FAM119B	chr12:58166383-58176323:+	0.45	5.44	2.09E-7	Multiple sclerosis	
PAAD	cis	1	rs11172344	chr12:58193448	FAM119B	chr12:58166383-58176323:+	0.47	5.72	5.52E-8	Multiple sclerosis	
PAAD	cis	1	rs11172349	chr12:58212528	FAM119B	chr12:58166383-58176323:+	0.46	5.57	1.14E-7	Multiple sclerosis	
PAAD	cis	1	rs11172351	chr12:58213485	FAM119B	chr12:58166383-58176323:+	0.48	5.84	2.98E-8	Multiple sclerosis	
PAAD	cis	1	rs11172351	chr12:58213485	TSFM	chr12:58176536-58191367:+	-0.34	-4.11	6.51E-5	Multiple sclerosis	
PAAD	cis	1	rs1117367	chr15:76872330	SCAPER	chr15:76640529-77197744:-	-0.24	-4.45	1.64E-5	Blood metabolite levels	
PAAD	cis	1	rs11180559	chr12:75920285	GLIPR1L2	chr12:75784889-75825591:+	0.56	4.03	8.92E-5	Daytime sleep phenotypes	
PAAD	cis	1	rs111899361	chr7:1112348	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs111902838	chr19:50496614	SIGLEC16	chr19:50472912-50479075:+	0.98	5.37	2.92E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs11190540	chr10:102202629	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190541	chr10:102203071	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190551	chr10:102204734	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190552	chr10:102206607	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190555	chr10:102209160	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190556	chr10:102209223	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190557	chr10:102209369	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190558	chr10:102209397	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190569	chr10:102227409	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190570	chr10:102227702	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190572	chr10:102232879	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190578	chr10:102238953	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.62E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190587	chr10:102266638	SEC31B	chr10:102246403-102289636:-	-0.36	-5.9	2.2E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190589	chr10:102275471	SEC31B	chr10:102246403-102289636:-	-0.35	-5.8	3.65E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190592	chr10:102291059	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190595	chr10:102291761	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190597	chr10:102293676	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190599	chr10:102295420	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190601	chr10:102296730	SEC31B	chr10:102246403-102289636:-	-0.35	-5.69	6.21E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190602	chr10:102297256	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190604	chr10:102302457	SEC31B	chr10:102246403-102289636:-	-0.35	-5.64	8.15E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190607	chr10:102303614	SEC31B	chr10:102246403-102289636:-	-0.34	-5.46	1.9E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11190613	chr10:102313997	SEC31B	chr10:102246403-102289636:-	0.32	5.06	1.19E-6	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11191419	chr10:104612335	AS3MT	chr10:104613967-104661653:+	-0.42	-4.85	2.97E-6	Schizophrenia	
PAAD	cis	1	rs11191419	chr10:104612335	C10orf32	chr10:104613967-104624718:+	-0.38	-5.15	7.9E-7	Schizophrenia	
PAAD	cis	1	rs11201297	chr10:81793749	LOC219347	chr10:81805991-81838949:-	0.89	8.4	2.83E-14	Chronic obstructive pulmonary disease-related biomarkers	
PAAD	cis	1	rs11201298	chr10:81793751	LOC219347	chr10:81805991-81838949:-	0.89	8.49	1.73E-14	Chronic obstructive pulmonary disease-related biomarkers	
PAAD	cis	1	rs11201312	chr10:81795778	LOC219347	chr10:81805991-81838949:-	0.91	8.57	1.07E-14	Chronic obstructive pulmonary disease-related biomarkers	
PAAD	cis	1	rs11201660	chr10:81854531	LOC219347	chr10:81805991-81838949:-	-0.83	-9.09	4.89E-16	Chronic obstructive pulmonary disease-related biomarkers	
PAAD	cis	1	rs11201799	chr10:81881954	LOC219347	chr10:81805991-81838949:-	-0.72	-6.82	2.01E-10	Chronic obstructive pulmonary disease-related biomarkers	
PAAD	cis	1	rs11204971	chr1:152259078	FLG	chr1:152274651-152297679:-	0.48	4.82	3.48E-6	Atopic dermatitis	
PAAD	cis	1	rs1121089	chr4:17676476	MED28	chr4:17616273-17629791:+	0.45	5.21	6.11E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs1121090	chr4:17676437	MED28	chr4:17616273-17629791:+	0.45	5.21	6.11E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs1121091	chr4:17676386	MED28	chr4:17616273-17629791:+	0.45	5.21	6.11E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs11211132	chr1:45990516	CCDC163P	chr1:45960581-45965646:-	-0.96	-13.34	2.03E-27	Homocysteine levels	
PAAD	cis	1	rs11211199	chr1:46287869	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.52	9.62E-10	Body mass index	
PAAD	cis	1	rs11211208	chr1:46334256	CCDC163P	chr1:45960581-45965646:-	-0.52	-6.32	2.79E-9	Body mass index	
PAAD	cis	1	rs11211230	chr1:46406767	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs11211234	chr1:46438787	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs11211241	chr1:46452683	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs11227284	chr11:65503224	SNX32	chr11:65601410-65621170:+	0.67	5.61	9.06E-8	Systemic lupus erythematosus	
PAAD	cis	1	rs11227288	chr11:65516588	SNX32	chr11:65601410-65621170:+	0.68	5.78	4.11E-8	Systemic lupus erythematosus	
PAAD	cis	1	rs11242	chr3:53125922	RFT1	chr3:53122503-53164470:-	0.46	5.33	3.48E-7	Height	
PAAD	cis	1	rs1125203	chr3:41760895	ULK4	chr3:41288091-42003660:-	0.83	7.26	1.79E-11	Diastolic blood pressure	
PAAD	cis	1	rs11264203	chr1:36239234	C1orf216	chr1:36179477-36184790:-	-0.31	-4.05	8.27E-5	Schizophrenia	
PAAD	cis	1	rs11264211	chr1:36270607	C1orf216	chr1:36179477-36184790:-	-0.31	-4.03	8.77E-5	Schizophrenia	
PAAD	cis	1	rs11264213	chr1:36283954	C1orf216	chr1:36179477-36184790:-	-0.31	-4.07	7.6E-5	Schizophrenia	
PAAD	cis	1	rs11292	chr10:102313607	SEC31B	chr10:102246403-102289636:-	-0.32	-5.06	1.19E-6	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs113066613	chr7:1094128	ZFAND2A	chr7:1192544-1199855:-	-0.5	-4.21	4.41E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs113143821	chr5:127893353	FBN2	chr5:127593602-127873916:-	0.71	4.95	1.94E-6	Multiple system atrophy	
PAAD	cis	1	rs113146460	chr7:1105164	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.26	3.61E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs113315674	chr9:100720053	C9orf156	chr9:100666772-100684852:-	-0.34	-4.69	5.89E-6	Quantitative traits	
PAAD	cis	1	rs113333037	chr17:2200106	SRR	chr17:2207248-2228553:+	-0.53	-9.19	2.61E-16	Esophageal cancer (squamous cell)	
PAAD	cis	1	rs113575110	chr7:1084394	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.32	2.74E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs113638727	chr15:40706101	C15orf23	chr15:40674922-40686488:+	0.72	8.66	6.14E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs1138273	chr3:134261437	ANAPC13	chr3:134196547-134204865:-	0.88	11.82	2.55E-23	Height	
PAAD	cis	1	rs113858334	chr7:1073476	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs114200987	chr14:35586916	PPP2R3C	chr14:35554679-35591679:-	0.56	5.49	1.63E-7	Atopic dermatitis	
PAAD	cis	1	rs114244137	chr5:150264753	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs114304428	chr1:152254010	FLG	chr1:152274651-152297679:-	0.48	4.82	3.48E-6	Atopic dermatitis	
PAAD	cis	1	rs114490726	chr4:17680898	MED28	chr4:17616273-17629791:+	0.45	5.18	6.83E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs11485508	chr1:152253167	FLG	chr1:152274651-152297679:-	-0.55	-5.88	2.48E-8	Atopic dermatitis	
PAAD	cis	1	rs114960066	chr3:41882323	ULK4	chr3:41288091-42003660:-	0.86	7.94	3.93E-13	Diastolic blood pressure	
PAAD	cis	1	rs11538349	chr7:65421871	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs11541642	chr15:40683702	C15orf23	chr15:40674922-40686488:+	0.68	7.27	1.74E-11	Heschl's gyrus morphology	
PAAD	cis	1	rs11553746	chr2:272203	SH3YL1	chr2:218138-264810:-	-0.47	-7.62	2.43E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs11557072	chr15:40713374	C15orf23	chr15:40674922-40686488:+	0.72	8.66	6.14E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs11579634	chr1:46466391	CCDC163P	chr1:45960581-45965646:-	0.5	5.84	3.0E-8	Body mass index	
PAAD	cis	1	rs11588170	chr1:152286032	FLG	chr1:152274651-152297679:-	0.47	4.49	1.37E-5	Atopic dermatitis	
PAAD	cis	1	rs11589562	chr1:46466721	CCDC163P	chr1:45960581-45965646:-	0.5	5.78	4.11E-8	Body mass index	
PAAD	cis	1	rs11589562	chr1:46466721	MUTYH	chr1:45794915-45806142:-	-0.26	-4	9.93E-5	Body mass index	
PAAD	cis	1	rs11590365	chr1:152165489	FLG	chr1:152274651-152297679:-	0.47	4.93	2.12E-6	Atopic dermatitis	
PAAD	cis	1	rs115965884	chr22:24594662	SUSD2	chr22:24577444-24585074:+	0.85	6.51	1.04E-9	Amyotrophic lateral sclerosis	
PAAD	cis	1	rs116139393	chr7:6771660	PMS2CL	chr7:6749757-6793492:+	-0.55	-4.71	5.56E-6	Alzheimer's disease (APOE e4 interaction)	
PAAD	cis	1	rs11622962	chr14:65299145	CHURC1	chr14:65381140-65411309:+	0.57	4.27	3.46E-5	Daytime sleep phenotypes	
PAAD	cis	1	rs11623413	chr14:75588824	EIF2B2	chr14:75469612-75476292:+	-0.37	-4.16	5.28E-5	Height	
PAAD	cis	1	rs11626499	chr14:93702632	SLC24A4	chr14:92788925-92962594:+	-0.41	-4.36	2.37E-5	Body mass index	
PAAD	cis	1	rs11628273	chr14:65509878	CHURC1	chr14:65381140-65411309:+	0.34	4.01	9.38E-5	Red blood cell traits	
PAAD	cis	1	rs11628710	chr14:74649280	LIN52	chr14:74551656-74667117:+	0.43	7.66	2.01E-12	Common traits (Other)	
PAAD	cis	1	rs11632096	chr15:56210499	PRTG	chr15:55903748-56035177:-	0.32	4.93	2.15E-6	Keloid	
PAAD	cis	1	rs11632465	chr15:85282045	LOC388152	chr15:84867600-84898920:-	-0.34	-4.1	6.59E-5	Schizophrenia	
PAAD	cis	1	rs11633263	chr15:56135559	PRTG	chr15:55903748-56035177:-	0.32	4.93	2.11E-6	Keloid	
PAAD	cis	1	rs11633313	chr15:56135709	PRTG	chr15:55903748-56035177:-	0.32	4.93	2.11E-6	Keloid	
PAAD	cis	1	rs11638290	chr15:85227636	LOC388152	chr15:84867600-84898920:-	-0.35	-4.25	3.75E-5	Schizophrenia	
PAAD	cis	1	rs11638297	chr15:84782417	LOC388152	chr15:84867600-84898920:-	-0.35	-4.16	5.29E-5	Schizophrenia	
PAAD	cis	1	rs11638394	chr15:84778928	LOC388152	chr15:84867600-84898920:-	-0.35	-4.19	4.68E-5	Schizophrenia	
PAAD	cis	1	rs116418977	chr6:25365888	BTN3A2	chr6:26365398-26378546:+	-0.9	-5.16	7.62E-7	Schizophrenia	
PAAD	cis	1	rs11645002	chr16:20617841	ACSM1	chr16:20634559-20709066:-	0.74	5.83	3.25E-8	Urinary metabolites	
PAAD	cis	1	rs11650372	chr17:45721795	C17orf57	chr17:45401142-45518675:+	0.42	4.9	2.39E-6	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs11650372	chr17:45721795	TBKBP1	chr17:45772630-45789427:+	-0.26	-4.08	7.2E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs11651264	chr17:79576394	TSPAN10	chr17:79609349-79615778:+	-0.74	-9.99	2.09E-18	Eye color traits	
PAAD	cis	1	rs11652797	chr17:79574124	TSPAN10	chr17:79609349-79615778:+	0.74	9.99	2.09E-18	Eye color traits	
PAAD	cis	1	rs11668269	chr19:22513960	ZNF98	chr19:22573899-22605148:-	0.29	4.2	4.54E-5	Telomere length	
PAAD	cis	1	rs11670668	chr19:41920454	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.72	5.24E-6	Height	
PAAD	cis	1	rs11670757	chr19:41913431	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.67	6.41E-6	Height	
PAAD	cis	1	rs1167613	chr7:65487439	CCT6P1	chr7:65216092-65228661:+	0.44	4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs1167827	chr7:75163169	NSUN5P1	chr7:75039646-75046065:+	0.24	4.51	1.27E-5	Body mass index	
PAAD	cis	1	rs1167827	chr7:75163169	PMS2L3	chr7:75137070-75157418:-	-0.39	-7.22	2.33E-11	Body mass index	
PAAD	cis	1	rs11681497	chr2:242344333	SEPT2	chr2:242254723-242293439:+	0.62	6.34	2.41E-9	Chronic lymphocytic leukemia	
PAAD	cis	1	rs11688129	chr2:28952581	TRMT61B	chr2:29072690-29093175:-	0.49	5.93	1.97E-8	Body mass index	
PAAD	cis	1	rs11690423	chr2:28951537	TRMT61B	chr2:29072690-29093175:-	0.49	5.93	1.97E-8	Body mass index	
PAAD	cis	1	rs11696845	chr20:43371320	WISP2	chr20:43343475-43356451:+	-0.38	-4.71	5.44E-6	Obesity-related traits	
PAAD	cis	1	rs116988415	chr14:65292145	CHURC1	chr14:65381140-65411309:+	0.54	4.01	9.52E-5	Daytime sleep phenotypes	
PAAD	cis	1	rs11706117	chr3:134212526	ANAPC13	chr3:134196547-134204865:-	0.87	11.61	9.4E-23	Height	
PAAD	cis	1	rs11706766	chr3:121088873	STXBP5L	chr3:120627050-121143607:+	-0.22	-4.29	3.14E-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)	
PAAD	cis	1	rs11708531	chr3:134224902	ANAPC13	chr3:134196547-134204865:-	0.87	11.61	9.26E-23	Height	
PAAD	cis	1	rs11712561	chr3:48435272	TREX1	chr3:48501186-48509043:+	-0.39	-5.64	7.81E-8	Longevity	
PAAD	cis	1	rs11714406	chr3:121372513	IQCB1	chr3:121488610-121553926:-	0.59	6.2	5.1E-9	Cognitive performance	
PAAD	cis	1	rs11715767	chr3:126795125	CHST13	chr3:126243176-126262133:+	0.44	4.17	5.16E-5	Amyotrophic lateral sclerosis (sporadic)	
PAAD	cis	1	rs11719458	chr3:121382005	IQCB1	chr3:121488610-121553926:-	0.57	5.99	1.46E-8	Cognitive performance	
PAAD	cis	1	rs11721318	chr3:121429485	IQCB1	chr3:121488610-121553926:-	0.57	5.99	1.46E-8	Cognitive performance	
PAAD	cis	1	rs11722037	chr4:17683811	MED28	chr4:17616273-17629791:+	0.45	5.25	5.08E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs11724495	chr4:17621310	MED28	chr4:17616273-17629791:+	0.48	5.76	4.56E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs11727312	chr4:17669185	MED28	chr4:17616273-17629791:+	0.45	5.32	3.58E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs11733284	chr4:48028097	CNGA1	chr4:47937996-48018610:-	0.45	5.12	8.95E-7	Renal underexcretion gout;Gout	
PAAD	cis	1	rs11733284	chr4:48028097	NIPAL1	chr4:48018791-48039078:+	0.41	6.97	9.11E-11	Renal underexcretion gout;Gout	
PAAD	cis	1	rs11737138	chr4:17657986	MED28	chr4:17616273-17629791:+	0.46	5.5	1.59E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs11739344	chr5:56111087	C5orf35	chr5:56205103-56213010:+	1.08	10.09	1.16E-18	Type 2 diabetes	
PAAD	cis	1	rs11739619	chr5:150264662	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs11739677	chr5:150294883	LOC134466	chr5:150310000-150326146:-	0.88	7.27	1.77E-11	Crohn's disease	
PAAD	cis	1	rs11740172	chr5:150300278	LOC134466	chr5:150310000-150326146:-	0.84	7.01	7.22E-11	Crohn's disease	
PAAD	cis	1	rs11741861	chr5:150277909	LOC134466	chr5:150310000-150326146:-	-0.91	-6.99	7.84E-11	Crohn's disease	
PAAD	cis	1	rs11743488	chr5:150279218	LOC134466	chr5:150310000-150326146:-	0.91	7.05	5.78E-11	Crohn's disease	
PAAD	cis	1	rs11746108	chr5:150264622	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs11746560	chr5:150185925	LOC134466	chr5:150310000-150326146:-	0.85	6.85	1.72E-10	Crohn's disease	
PAAD	cis	1	rs11746807	chr5:150300419	LOC134466	chr5:150310000-150326146:-	0.84	7.01	7.22E-11	Crohn's disease	
PAAD	cis	1	rs11747065	chr5:150295486	LOC134466	chr5:150310000-150326146:-	0.84	7.01	7.22E-11	Crohn's disease	
PAAD	cis	1	rs11747270	chr5:150258867	LOC134466	chr5:150310000-150326146:-	-0.68	-5.84	3.03E-8	Crohn's disease	
PAAD	cis	1	rs11748151	chr5:150226292	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs11748158	chr5:150226345	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs11748553	chr5:150184553	LOC134466	chr5:150310000-150326146:-	0.85	6.85	1.72E-10	Crohn's disease	
PAAD	cis	1	rs11749391	chr5:150229066	LOC134466	chr5:150310000-150326146:-	0.65	5.73	5.25E-8	Crohn's disease	
PAAD	cis	1	rs11752297	chr6:33735154	LEMD2	chr6:33738991-33756906:-	-0.32	-4.66	6.71E-6	Crohn's disease	
PAAD	cis	1	rs11753083	chr6:33761111	LEMD2	chr6:33738991-33756906:-	0.36	4.33	2.67E-5	Body mass index	
PAAD	cis	1	rs11754690	chr6:33744157	LEMD2	chr6:33738991-33756906:-	0.36	4.33	2.67E-5	Body mass index	
PAAD	cis	1	rs11755593	chr6:33740325	LEMD2	chr6:33738991-33756906:-	0.36	4.33	2.67E-5	Body mass index	
PAAD	cis	1	rs11758849	chr6:86708262	SNHG5	chr6:86386726-86388451:-	-0.88	-11.41	3.33E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs11759855	chr6:86610841	SNHG5	chr6:86386726-86388451:-	-0.87	-12.06	5.92E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs11761941	chr7:1097183	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs11763020	chr7:1060288	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.39	2.11E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs11763793	chr7:1094342	ZFAND2A	chr7:1192544-1199855:-	-0.5	-4.21	4.41E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs11763835	chr7:1094513	ZFAND2A	chr7:1192544-1199855:-	-0.5	-4.21	4.41E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs11764748	chr7:1094508	ZFAND2A	chr7:1192544-1199855:-	-0.47	-4.01	9.56E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs11766526	chr7:1101433	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs11767527	chr7:1097394	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs11768761	chr7:1069807	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs11770909	chr7:1086716	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.32	2.74E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs11782652	chr8:82653644	CHMP4C	chr8:82644688-82671746:+	-0.73	-5.92	2.0E-8	Epithelial ovarian cancer;Ovarian cancer	
PAAD	cis	1	rs117907570	chr6:86601283	SNHG5	chr6:86386726-86388451:-	-0.87	-12.29	1.4E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs118059236	chr7:1073202	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs11810993	chr1:46478793	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.99	1.46E-8	Body mass index	
PAAD	cis	1	rs118110670	chr10:81792242	LOC219347	chr10:81805991-81838949:-	0.9	8.2	8.98E-14	Chronic obstructive pulmonary disease-related biomarkers	
PAAD	cis	1	rs11816840	chr10:102309220	SEC31B	chr10:102246403-102289636:-	-0.34	-5.46	1.9E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs11845639	chr14:75570293	EIF2B2	chr14:75469612-75476292:+	0.36	4.09	7.0E-5	Height	
PAAD	cis	1	rs11856184	chr15:43919162	ADAL	chr15:43622872-43646094:+	-0.65	-5.01	1.46E-6	Tumor biomarkers	
PAAD	cis	1	rs11858714	chr15:40717447	C15orf23	chr15:40674922-40686488:+	0.72	8.66	6.14E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs11862744	chr16:31057800	MYST1	chr16:31128985-31142713:+	0.36	4.95	1.9E-6	Response to metformin (IC50)	
PAAD	cis	1	rs11870935	chr17:45732605	C17orf57	chr17:45401142-45518675:+	-0.43	-5.2	6.34E-7	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs11870935	chr17:45732605	TBKBP1	chr17:45772630-45789427:+	0.26	4.18	4.88E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs11880539	chr19:41918949	B3GNT8	chr19:41931265-41934635:-	0.29	4.54	1.14E-5	Height	
PAAD	cis	1	rs11882144	chr19:42072602	CEACAM21	chr19:42055886-42093196:+	0.59	8.49	1.68E-14	Schizophrenia	
PAAD	cis	1	rs11883104	chr19:41923799	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.73	4.97E-6	Height	
PAAD	cis	1	rs11919350	chr3:134235970	ANAPC13	chr3:134196547-134204865:-	-0.88	-11.96	1.1E-23	Height	
PAAD	cis	1	rs11921451	chr3:126787159	CHST13	chr3:126243176-126262133:+	0.48	4.58	9.68E-6	Amyotrophic lateral sclerosis (sporadic)	
PAAD	cis	1	rs11923562	chr3:41760331	ULK4	chr3:41288091-42003660:-	0.84	7.37	9.94E-12	Diastolic blood pressure	
PAAD	cis	1	rs11927068	chr3:134266321	ANAPC13	chr3:134196547-134204865:-	-0.88	-12	8.57E-24	Height	
PAAD	cis	1	rs11928499	chr3:134232350	ANAPC13	chr3:134196547-134204865:-	-0.88	-11.97	1.04E-23	Height	
PAAD	cis	1	rs11928580	chr3:41885722	ULK4	chr3:41288091-42003660:-	0.86	7.94	3.93E-13	Diastolic blood pressure	
PAAD	cis	1	rs11947857	chr4:17691047	MED28	chr4:17616273-17629791:+	-0.43	-4.68	6.21E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs11950957	chr5:150253914	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs11951694	chr5:150254338	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs11955172	chr5:150254378	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs11957134	chr5:150230950	LOC134466	chr5:150310000-150326146:-	-0.75	-6.27	3.56E-9	Crohn's disease	
PAAD	cis	1	rs11962024	chr6:25610203	HIST1H3D	chr6:26197013-26199464:-	-0.38	-4.19	4.67E-5	Uric acid levels	
PAAD	cis	1	rs11965538	chr6:28239915	ZSCAN23	chr6:28393287-28411279:-	0.42	4.21	4.33E-5	Depression	
PAAD	cis	1	rs11974702	chr7:99163951	ARPC1B	chr7:98972329-98992402:+	0.52	4.02	9.01E-5	Blood metabolite levels	
PAAD	cis	1	rs11975942	chr7:143740580	ARHGEF35	chr7:143883677-143892736:-	-0.41	-5.45	2.0E-7	Obesity-related traits	
PAAD	cis	1	rs11976020	chr7:72247800	TYW1B	chr7:72023729-72298813:-	1.12	14.88	1.54E-31	Educational attainment (years of education)	
PAAD	cis	1	rs11976037	chr7:143741024	ARHGEF35	chr7:143883677-143892736:-	-0.41	-5.54	1.29E-7	Obesity-related traits	
PAAD	cis	1	rs11976180	chr7:143741580	ARHGEF35	chr7:143883677-143892736:-	-0.41	-5.36	3.0E-7	Obesity-related traits	
PAAD	cis	1	rs12021587	chr1:46472759	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.99	1.46E-8	Body mass index	
PAAD	cis	1	rs12030612	chr1:113215637	ST7L	chr1:113066142-113162405:-	0.44	5.74	4.93E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs12030641	chr1:113215717	ST7L	chr1:113066142-113162405:-	0.44	5.74	4.93E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs12040988	chr1:113173804	ST7L	chr1:113066142-113162405:-	0.44	5.74	4.93E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs12049588	chr1:46472422	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.99	1.46E-8	Body mass index	
PAAD	cis	1	rs12054923	chr5:150249059	LOC134466	chr5:150310000-150326146:-	0.7	5.99	1.46E-8	Crohn's disease	
PAAD	cis	1	rs12083902	chr1:36275112	C1orf216	chr1:36179477-36184790:-	-0.32	-4.17	4.99E-5	Schizophrenia	
PAAD	cis	1	rs12091564	chr1:145395604	NOTCH2NL	chr1:145209111-145295525:+	-0.72	-4.48	1.46E-5	Coronary heart disease	
PAAD	cis	1	rs12120956	chr1:113202571	ST7L	chr1:113066142-113162405:-	0.44	5.74	4.93E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs12122290	chr1:247215810	ZNF670	chr1:247200087-247242069:-	-0.5	-5.54	1.3E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs12126971	chr1:113231286	ST7L	chr1:113066142-113162405:-	0.44	5.73	5.28E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs12127537	chr1:35780720	C1orf216	chr1:36179477-36184790:-	0.39	4	9.89E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs12130075	chr1:247218491	ZNF670	chr1:247200087-247242069:-	-0.47	-5.06	1.2E-6	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs12130219	chr1:152162106	FLG	chr1:152274651-152297679:-	0.4	4.96	1.88E-6	Inflammatory skin disease	
PAAD	cis	1	rs12130219	chr1:152162106	HRNR	chr1:152184558-152196669:-	-0.55	-6.53	9.37E-10	Inflammatory skin disease	
PAAD	cis	1	rs12130243	chr1:113169667	ST7L	chr1:113066142-113162405:-	0.44	5.74	4.93E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs12133583	chr1:113240790	ST7L	chr1:113066142-113162405:-	0.45	5.92	2.06E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs12139630	chr1:46350935	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.98	1.51E-8	Body mass index	
PAAD	cis	1	rs12143671	chr1:21875097	ALPL	chr1:21835858-21904904:+	-0.4	-4.7	5.8E-6	Response to TNF-alpha inhibitors in rheumatoid arthritis	
PAAD	cis	1	rs12144263	chr1:46352446	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.97	1.57E-8	Body mass index	
PAAD	cis	1	rs12147952	chr14:76624884	ESRRB	chr14:76837690-76968178:+	-0.49	-4	9.96E-5	Blood pressure	
PAAD	cis	1	rs12148786	chr15:76800362	SCAPER	chr15:76640529-77197744:-	-0.24	-4.45	1.64E-5	Blood metabolite levels	
PAAD	cis	1	rs12154056	chr6:86634094	SNHG5	chr6:86386726-86388451:-	-0.84	-11.44	2.8E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs12171333	chr4:129879711	C4orf33	chr4:130014829-130033842:+	0.5	5.91	2.19E-8	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs12190598	chr6:86686074	SNHG5	chr6:86386726-86388451:-	-0.82	-10.74	2.13E-20	Response to antipsychotic treatment	
PAAD	cis	1	rs12190604	chr6:86716215	SNHG5	chr6:86386726-86388451:-	-0.86	-11.97	1.0E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12192992	chr6:86609915	SNHG5	chr6:86386726-86388451:-	-0.87	-12.06	5.92E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs12196037	chr6:86694631	SNHG5	chr6:86386726-86388451:-	-0.86	-11.79	3.04E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12196411	chr6:86779762	SNHG5	chr6:86386726-86388451:-	-0.86	-11.94	1.19E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12196937	chr6:49382808	CENPQ	chr6:49431096-49460820:+	-0.34	-4.04	8.39E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs12196937	chr6:49382808	MUT	chr6:49398994-49431031:-	0.28	4	9.84E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs12199516	chr6:86726221	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12199784	chr6:86726808	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12200330	chr6:86656653	SNHG5	chr6:86386726-86388451:-	-0.86	-12.02	7.33E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs12201571	chr6:86609750	SNHG5	chr6:86386726-86388451:-	-0.87	-12.06	5.92E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs12201735	chr6:86656939	SNHG5	chr6:86386726-86388451:-	-0.84	-11.46	2.39E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs12201741	chr6:86602619	SNHG5	chr6:86386726-86388451:-	-0.85	-11.67	6.71E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12201880	chr6:86627007	SNHG5	chr6:86386726-86388451:-	-0.84	-11.44	2.8E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs12202075	chr6:49427655	CENPQ	chr6:49431096-49460820:+	-0.36	-4.13	6.02E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs12202075	chr6:49427655	MUT	chr6:49398994-49431031:-	0.29	4.18	4.87E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs12203493	chr6:86758642	SNHG5	chr6:86386726-86388451:-	-0.86	-12.02	7.33E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs12203924	chr6:86776412	SNHG5	chr6:86386726-86388451:-	-0.86	-12.02	7.33E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs12204015	chr6:86598334	SNHG5	chr6:86386726-86388451:-	-0.89	-12.9	3.07E-26	Response to antipsychotic treatment	
PAAD	cis	1	rs12204365	chr6:86700532	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs12205336	chr6:86722367	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12205548	chr6:86759770	SNHG5	chr6:86386726-86388451:-	-0.86	-12.08	5.17E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs12207305	chr6:86723502	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12207610	chr6:86688016	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs12208493	chr6:86662267	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12209127	chr6:86724427	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12212733	chr6:86726013	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12213149	chr6:86668644	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12213740	chr6:86656733	SNHG5	chr6:86386726-86388451:-	-0.84	-11.4	3.43E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs12215037	chr6:86727631	SNHG5	chr6:86386726-86388451:-	-0.86	-11.92	1.38E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12215903	chr6:86675028	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs12216203	chr6:86675301	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12216328	chr6:86703418	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12219158	chr10:102302923	SEC31B	chr10:102246403-102289636:-	-0.34	-5.46	1.9E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs12219789	chr10:102213778	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs12220777	chr10:81788104	LOC219347	chr10:81805991-81838949:-	-0.9	-8.95	1.14E-15	Chronic obstructive pulmonary disease-related biomarkers	
PAAD	cis	1	rs12232351	chr15:56140995	PRTG	chr15:55903748-56035177:-	0.32	5.09	1.05E-6	Keloid	
PAAD	cis	1	rs12273360	chr11:46889719	C11orf49	chr11:46958251-47185929:+	-0.46	-4.05	8.08E-5	Schizophrenia	
PAAD	cis	1	rs12287832	chr11:65553492	SNX32	chr11:65601410-65621170:+	0.68	5.73	5.12E-8	Systemic lupus erythematosus	
PAAD	cis	1	rs12326600	chr18:44596497	HDHD2	chr18:44633782-44676871:-	0.46	5.15	7.78E-7	Sitting height ratio	
PAAD	cis	1	rs1233491	chr6:29461730	ZFP57	chr6:29640171-29648887:-	0.95	4.8	3.8E-6	Cutaneous lupus erythematosus	
PAAD	cis	1	rs12354411	chr10:102294537	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs12355721	chr10:102244911	SEC31B	chr10:102246403-102289636:-	-0.34	-5.77	4.35E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs12355784	chr10:65121565	NRBF2	chr10:64893007-64914785:+	-0.39	-5.31	3.73E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs12358187	chr10:102284449	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs12377604	chr9:100697287	C9orf156	chr9:100666772-100684852:-	-0.33	-4.61	8.38E-6	Quantitative traits	
PAAD	cis	1	rs12405278	chr1:152282267	FLG	chr1:152274651-152297679:-	0.47	4.49	1.37E-5	Atopic dermatitis	
PAAD	cis	1	rs12405451	chr1:46384326	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs12409773	chr1:46358831	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.01	1.29E-8	Body mass index	
PAAD	cis	1	rs12410071	chr1:46358886	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.01	1.29E-8	Body mass index	
PAAD	cis	1	rs12411269	chr1:46271052	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.5	1.1E-9	Body mass index	
PAAD	cis	1	rs12416687	chr10:104629011	AS3MT	chr10:104613967-104661653:+	-0.53	-6.11	7.92E-9	Arsenic metabolism	
PAAD	cis	1	rs12416687	chr10:104629011	C10orf32	chr10:104613967-104624718:+	-0.6	-8.83	2.24E-15	Arsenic metabolism	
PAAD	cis	1	rs12422267	chr12:132601596	EP400NL	chr12:132568828-132600084:+;chr12	-0.53	-4.49	1.38E-5	Plasma amyloid beta peptide concentrations (ABx-40)	
PAAD	cis	1	rs12422771	chr12:6580273	ANO2	chr12:5671817-6055398:-	0.42	4.08	7.16E-5	Hip geometry	
PAAD	cis	1	rs12435391	chr14:75601737	EIF2B2	chr14:75469612-75476292:+	0.38	4.31	2.94E-5	Height	
PAAD	cis	1	rs12437310	chr14:76642757	ESRRB	chr14:76837690-76968178:+	0.47	4.15	5.4E-5	Blood pressure	
PAAD	cis	1	rs12441433	chr15:76816015	SCAPER	chr15:76640529-77197744:-	-0.24	-4.45	1.64E-5	Blood metabolite levels	
PAAD	cis	1	rs12443102	chr15:43932103	ADAL	chr15:43622872-43646094:+	-0.65	-4.92	2.23E-6	Tumor biomarkers	
PAAD	cis	1	rs12443137	chr15:76840832	SCAPER	chr15:76640529-77197744:-	-0.24	-4.45	1.64E-5	Blood metabolite levels	
PAAD	cis	1	rs12445650	chr16:31044897	MYST1	chr16:31128985-31142713:+	0.36	4.95	1.9E-6	Response to metformin (IC50)	
PAAD	cis	1	rs12487542	chr3:48426076	TREX1	chr3:48501186-48509043:+	-0.39	-5.64	7.81E-8	Longevity	
PAAD	cis	1	rs12490835	chr3:134223730	ANAPC13	chr3:134196547-134204865:-	0.89	12.08	5.22E-24	Height	
PAAD	cis	1	rs12495617	chr3:126797796	CHST13	chr3:126243176-126262133:+	0.44	4.17	5.12E-5	Amyotrophic lateral sclerosis (sporadic)	
PAAD	cis	1	rs12507142	chr4:17656103	MED28	chr4:17616273-17629791:+	0.45	5.39	2.65E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs12524768	chr6:33760478	LEMD2	chr6:33738991-33756906:-	0.33	4.05	8.24E-5	Body mass index	
PAAD	cis	1	rs12524835	chr6:33730843	LEMD2	chr6:33738991-33756906:-	0.37	4.34	2.6E-5	Body mass index	
PAAD	cis	1	rs12545109	chr8:57313906	PENK	chr8:57353513-57359282:-	-0.44	-5.14	8.35E-7	Obesity-related traits	
PAAD	cis	1	rs12561806	chr1:46396776	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs12564541	chr1:46380237	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs12567463	chr1:152180128	FLG	chr1:152274651-152297679:-	0.53	5.54	1.32E-7	Atopic dermatitis	
PAAD	cis	1	rs12577464	chr11:43662440	HSD17B12	chr11:43702143-43878160:+	-0.43	-5.79	3.78E-8	Forced vital capacity	
PAAD	cis	1	rs12588240	chr14:75612083	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs12589376	chr14:75561152	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs12589815	chr14:75544101	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs12589876	chr14:75544189	EIF2B2	chr14:75469612-75476292:+	0.36	4.09	7.0E-5	Height	
PAAD	cis	1	rs12590452	chr14:75548756	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs12594212	chr15:76802014	SCAPER	chr15:76640529-77197744:-	-0.24	-4.45	1.64E-5	Blood metabolite levels	
PAAD	cis	1	rs12594541	chr15:76834368	SCAPER	chr15:76640529-77197744:-	-0.24	-4.45	1.64E-5	Blood metabolite levels	
PAAD	cis	1	rs12600855	chr17:28279591	EFCAB5	chr17:28256874-28435469:+	0.36	4.16	5.3E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs12600993	chr17:28291222	EFCAB5	chr17:28256874-28435469:+	0.35	4.1	6.61E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs12621280	chr2:232132984	ARMC9	chr2:232063342-232238606:+	0.4	4.62	8.03E-6	Food antigen IgG levels	
PAAD	cis	1	rs12637751	chr3:134266124	ANAPC13	chr3:134196547-134204865:-	-0.88	-12	8.57E-24	Height	
PAAD	cis	1	rs12639255	chr3:41861738	ULK4	chr3:41288091-42003660:-	0.86	8.03	2.38E-13	Diastolic blood pressure	
PAAD	cis	1	rs12648232	chr4:17612537	MED28	chr4:17616273-17629791:+	-0.47	-5.57	1.14E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs12652003	chr5:150231945	LOC134466	chr5:150310000-150326146:-	0.75	6.27	3.56E-9	Crohn's disease	
PAAD	cis	1	rs12656538	chr5:150251380	LOC134466	chr5:150310000-150326146:-	0.88	6.75	2.84E-10	Crohn's disease	
PAAD	cis	1	rs12656600	chr5:150311872	LOC134466	chr5:150310000-150326146:-	0.84	7.01	7.22E-11	Crohn's disease	
PAAD	cis	1	rs12659118	chr5:150324622	LOC134466	chr5:150310000-150326146:-	0.87	7.17	2.97E-11	Crohn's disease	
PAAD	cis	1	rs12661204	chr6:86678586	SNHG5	chr6:86386726-86388451:-	-0.86	-11.79	3.04E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12663651	chr6:86701655	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs12663690	chr6:86640162	SNHG5	chr6:86386726-86388451:-	0.84	11.65	7.35E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs12664335	chr6:86597774	SNHG5	chr6:86386726-86388451:-	0.87	12.31	1.19E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs12665321	chr6:86769289	SNHG5	chr6:86386726-86388451:-	-0.86	-12.08	5.17E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs12698509	chr7:65418876	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs12760175	chr1:46447840	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.33	2.58E-9	Body mass index	
PAAD	cis	1	rs12800378	chr11:87865942	RAB38	chr11:87846431-87908599:-	0.4	4.57	9.87E-6	Frontotemporal dementia	
PAAD	cis	1	rs12806	chr10:101911142	CWF19L1	chr10:101992055-102027437:-	-0.5	-4.08	7.36E-5	Schizophrenia	
PAAD	cis	1	rs12879642	chr14:76682967	ESRRB	chr14:76837690-76968178:+	0.48	4	9.65E-5	Blood pressure	
PAAD	cis	1	rs12889309	chr14:75593902	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs12889472	chr14:75543979	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs12897094	chr14:75579416	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs12898430	chr15:76874923	SCAPER	chr15:76640529-77197744:-	-0.24	-4.45	1.64E-5	Blood metabolite levels	
PAAD	cis	1	rs12902672	chr15:84716986	LOC388152	chr15:84867600-84898920:-	-0.34	-4.14	5.81E-5	Schizophrenia	
PAAD	cis	1	rs12903820	chr15:84723820	LOC388152	chr15:84867600-84898920:-	-0.34	-4.14	5.81E-5	Schizophrenia	
PAAD	cis	1	rs12905057	chr15:85210765	LOC388152	chr15:84867600-84898920:-	-0.35	-4.24	3.89E-5	Schizophrenia	
PAAD	cis	1	rs12908161	chr15:85207825	LOC388152	chr15:84867600-84898920:-	-0.34	-4.11	6.55E-5	Schizophrenia	
PAAD	cis	1	rs12908549	chr15:85322351	LOC388152	chr15:84867600-84898920:-	-0.34	-4	9.86E-5	Schizophrenia	
PAAD	cis	1	rs12910992	chr15:90372465	AP3S2	chr15:90373832-90456222:-	-0.85	-10.02	1.8E-18	Type 2 diabetes	
PAAD	cis	1	rs12911736	chr15:85240008	LOC388152	chr15:84867600-84898920:-	-0.35	-4.21	4.28E-5	Schizophrenia	
PAAD	cis	1	rs12915234	chr15:84758301	LOC388152	chr15:84867600-84898920:-	-0.35	-4.2	4.54E-5	Schizophrenia	
PAAD	cis	1	rs12916348	chr15:84765527	LOC388152	chr15:84867600-84898920:-	-0.35	-4.2	4.54E-5	Schizophrenia	
PAAD	cis	1	rs12948099	chr17:79600799	TSPAN10	chr17:79609349-79615778:+	0.73	9.61	2.06E-17	Eye color traits	
PAAD	cis	1	rs13003464	chr2:61186829	C2orf74	chr2:61372243-61391964:+	0.45	4.78	4.11E-6	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
PAAD	cis	1	rs13006833	chr2:191205499	HIBCH	chr2:191069361-191184559:-	0.41	5.86	2.72E-8	Urinary metabolites	
PAAD	cis	1	rs13037759	chr20:43370692	WISP2	chr20:43343475-43356451:+	-0.37	-4.68	6.26E-6	Obesity-related traits	
PAAD	cis	1	rs13038016	chr20:43370497	WISP2	chr20:43343475-43356451:+	-0.37	-4.68	6.26E-6	Obesity-related traits	
PAAD	cis	1	rs13059720	chr3:134242021	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.75	3.95E-23	Height	
PAAD	cis	1	rs13069724	chr3:48478039	TREX1	chr3:48501186-48509043:+	-0.38	-5.59	1.0E-7	Longevity	
PAAD	cis	1	rs13071337	chr3:48438189	TREX1	chr3:48501186-48509043:+	-0.39	-5.65	7.76E-8	Longevity	
PAAD	cis	1	rs13071551	chr3:134310867	ANAPC13	chr3:134196547-134204865:-	-0.88	-11.62	9.09E-23	Height	
PAAD	cis	1	rs13076076	chr3:48479039	TREX1	chr3:48501186-48509043:+	-0.35	-5.22	5.71E-7	Longevity	
PAAD	cis	1	rs13081177	chr3:134289860	ANAPC13	chr3:134196547-134204865:-	-0.88	-11.62	9.09E-23	Height	
PAAD	cis	1	rs13081688	chr3:134259954	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.75	3.95E-23	Height	
PAAD	cis	1	rs13083794	chr3:121464928	IQCB1	chr3:121488610-121553926:-	0.57	5.99	1.46E-8	Cognitive performance	
PAAD	cis	1	rs13087578	chr3:121369207	IQCB1	chr3:121488610-121553926:-	0.59	6.17	5.82E-9	Cognitive performance	
PAAD	cis	1	rs13087719	chr3:41951576	ULK4	chr3:41288091-42003660:-	-0.89	-8.15	1.19E-13	Diastolic blood pressure	
PAAD	cis	1	rs13087875	chr3:134261123	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.87	1.92E-23	Height	
PAAD	cis	1	rs13089966	chr3:134279197	ANAPC13	chr3:134196547-134204865:-	-0.88	-12	8.57E-24	Height	
PAAD	cis	1	rs13090969	chr3:134307257	ANAPC13	chr3:134196547-134204865:-	-0.88	-11.62	9.09E-23	Height	
PAAD	cis	1	rs13091785	chr3:48494098	TREX1	chr3:48501186-48509043:+	-0.36	-5.24	5.32E-7	Longevity	
PAAD	cis	1	rs13096604	chr3:134250099	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.75	3.95E-23	Height	
PAAD	cis	1	rs13106338	chr4:17676871	MED28	chr4:17616273-17629791:+	-0.39	-4.43	1.82E-5	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs13109003	chr4:129975969	C4orf33	chr4:130014829-130033842:+	-0.5	-6.29	3.24E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs13119927	chr4:17691640	MED28	chr4:17616273-17629791:+	-0.43	-4.83	3.34E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs13120847	chr4:48030036	CNGA1	chr4:47937996-48018610:-	0.45	5.12	8.95E-7	Renal underexcretion gout;Gout	
PAAD	cis	1	rs13120847	chr4:48030036	NIPAL1	chr4:48018791-48039078:+	0.41	6.97	9.11E-11	Renal underexcretion gout;Gout	
PAAD	cis	1	rs13122400	chr4:39713743	RPL9	chr4:39455747-39460568:-	-0.4	-4.18	4.88E-5	Plasma amyloid beta peptide concentrations (ABx-40)	
PAAD	cis	1	rs13125949	chr4:48026560	CNGA1	chr4:47937996-48018610:-	0.46	5.23	5.38E-7	Renal underexcretion gout;Gout	
PAAD	cis	1	rs13125949	chr4:48026560	NIPAL1	chr4:48018791-48039078:+	0.4	6.96	9.56E-11	Renal underexcretion gout;Gout	
PAAD	cis	1	rs13130762	chr4:130022875	C4orf33	chr4:130014829-130033842:+	-0.54	-7.09	4.75E-11	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs13140968	chr4:48025095	CNGA1	chr4:47937996-48018610:-	0.46	5.26	4.8E-7	Renal underexcretion gout;Gout	
PAAD	cis	1	rs13140968	chr4:48025095	NIPAL1	chr4:48018791-48039078:+	0.4	7	7.57E-11	Renal underexcretion gout;Gout	
PAAD	cis	1	rs13142905	chr4:48025298	CNGA1	chr4:47937996-48018610:-	0.46	5.26	4.8E-7	Renal underexcretion gout;Gout	
PAAD	cis	1	rs13142905	chr4:48025298	NIPAL1	chr4:48018791-48039078:+	0.4	7	7.57E-11	Renal underexcretion gout;Gout	
PAAD	cis	1	rs13146880	chr4:48031499	CNGA1	chr4:47937996-48018610:-	0.45	5.1	1.01E-6	Renal underexcretion gout;Gout	
PAAD	cis	1	rs13146880	chr4:48031499	NIPAL1	chr4:48018791-48039078:+	0.41	7.05	5.71E-11	Renal underexcretion gout;Gout	
PAAD	cis	1	rs13194429	chr6:86646705	SNHG5	chr6:86386726-86388451:-	-0.87	-12.06	5.92E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs13195401	chr6:26463574	BTN3A2	chr6:26365398-26378546:+	-1.04	-8.31	4.68E-14	Schizophrenia	
PAAD	cis	1	rs13195402	chr6:26463575	BTN3A2	chr6:26365398-26378546:+	-1.04	-8.31	4.68E-14	Schizophrenia	
PAAD	cis	1	rs13196930	chr6:86652245	SNHG5	chr6:86386726-86388451:-	-0.87	-12.12	3.99E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs13199006	chr6:86608708	SNHG5	chr6:86386726-86388451:-	-0.88	-12.5	3.7E-25	Response to antipsychotic treatment	
PAAD	cis	1	rs1320893	chr7:143752112	ARHGEF35	chr7:143883677-143892736:-	-0.38	-5.02	1.4E-6	Obesity-related traits	
PAAD	cis	1	rs1320894	chr7:143751802	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.1	1.01E-6	Obesity-related traits	
PAAD	cis	1	rs1321252	chr6:25616232	HIST1H3D	chr6:26197013-26199464:-	-0.38	-4.03	8.75E-5	Uric acid levels	
PAAD	cis	1	rs13213582	chr6:151873896	C6orf97	chr6:151815175-151942327:+	0.45	4.05	8.14E-5	Bone mineral density (spine)	
PAAD	cis	1	rs13217384	chr6:86720000	SNHG5	chr6:86386726-86388451:-	-0.85	-11.52	1.66E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs13220495	chr6:26441640	BTN3A2	chr6:26365398-26378546:+	-1.07	-8.31	4.74E-14	Schizophrenia	
PAAD	cis	1	rs13220510	chr6:56779141	BEND6	chr6:56819773-56892138:+	-0.41	-5.1	9.73E-7	Menarche (age at onset)	
PAAD	cis	1	rs13220979	chr7:65363204	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs13226728	chr7:143746578	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.13	8.47E-7	Obesity-related traits	
PAAD	cis	1	rs13243677	chr7:143746572	ARHGEF35	chr7:143883677-143892736:-	-0.4	-5.24	5.32E-7	Obesity-related traits	
PAAD	cis	1	rs13247184	chr7:65358928	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs13252719	chr8:71734569	XKR9	chr8:71581600-71648176:+	0.5	8.1	1.65E-13	Bone mineral density	
PAAD	cis	1	rs13253842	chr8:71625503	XKR9	chr8:71581600-71648176:+	0.5	8.01	2.76E-13	Bone mineral density	
PAAD	cis	1	rs1331215	chr20:3376565	ITPA	chr20:3190056-3204504:+	-0.39	-5.62	8.84E-8	IFN-related cytopenia	
PAAD	cis	1	rs13314659	chr3:48449149	TREX1	chr3:48501186-48509043:+	0.37	5.52	1.42E-7	Longevity	
PAAD	cis	1	rs13322305	chr3:134310791	ANAPC13	chr3:134196547-134204865:-	0.86	11.36	4.41E-22	Height	
PAAD	cis	1	rs13325965	chr3:41914942	ULK4	chr3:41288091-42003660:-	0.91	8.21	8.7E-14	Diastolic blood pressure	
PAAD	cis	1	rs13344563	chr19:41945904	B3GNT8	chr19:41931265-41934635:-	0.32	4.96	1.82E-6	Height	
PAAD	cis	1	rs13358031	chr5:4477265	KIAA0947	chr5:5422807-5490337:+	0.22	4.26	3.6E-5	DNA methylation (variation)	
PAAD	cis	1	rs13361189	chr5:150223387	LOC134466	chr5:150310000-150326146:-	0.67	5.71	5.81E-8	Crohn's disease	
PAAD	cis	1	rs1337844	chr6:86677273	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs1337850	chr6:86729103	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs13385191	chr2:20888265	C2orf43	chr2:20883803-21022827:-	-0.5	-4.71	5.53E-6	Prostate cancer	
PAAD	cis	1	rs13408294	chr2:202171573	PPIL3	chr2:201735680-201753999:-	-0.68	-4.38	2.22E-5	Rheumatoid arthritis	
PAAD	cis	1	rs134869	chr22:42652074	CYP2D6	chr22:42522502-42526883:-	-0.42	-4.68	6.37E-6	Cognitive function	
PAAD	cis	1	rs134873	chr22:42657566	CYP2D6	chr22:42522502-42526883:-	-0.42	-4.69	6.08E-6	Cognitive function	
PAAD	cis	1	rs134900	chr22:42683343	CYP2D6	chr22:42522502-42526883:-	-0.41	-4.64	7.55E-6	Cognitive function	
PAAD	cis	1	rs134902	chr22:42683997	CYP2D6	chr22:42522502-42526883:-	-0.42	-4.88	2.62E-6	Cognitive function	
PAAD	cis	1	rs1351452	chr11:116943354	PCSK7	chr11:117075789-117102811:-	0.42	4.49	1.42E-5	Protein quantitative trait loci	
PAAD	cis	1	rs1357762	chr3:134264859	ANAPC13	chr3:134196547-134204865:-	0.87	11.75	3.95E-23	Height	
PAAD	cis	1	rs1359781	chr6:33762104	LEMD2	chr6:33738991-33756906:-	-0.29	-4.36	2.36E-5	Crohn's disease	
PAAD	cis	1	rs1360172	chr9:131907980	PPP2R4	chr9:131873244-131911223:+	0.43	4.29	3.12E-5	Blood metabolite ratios	
PAAD	cis	1	rs1371135	chr15:90391270	AP3S2	chr15:90373832-90456222:-	-0.83	-9.87	4.4E-18	Type 2 diabetes	
PAAD	cis	1	rs138209	chr22:50539413	MLC1	chr22:50497820-50524358:-	-0.43	-4.05	8.26E-5	Gestational age at birth in labor-initiated deliveries (child effect)	
PAAD	cis	1	rs1404147	chr7:65264524	CCT6P1	chr7:65216092-65228661:+	0.41	4.13	6.03E-5	Diabetic kidney disease	
PAAD	cis	1	rs1408916	chr1:92992627	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs1412444	chr10:91002927	LIPA	chr10:90973328-91174382:-	0.26	4.37	2.27E-5	Fibrinogen levels	
PAAD	cis	1	rs1412445	chr10:91002804	LIPA	chr10:90973328-91174382:-	0.26	4.32	2.77E-5	Fibrinogen levels	
PAAD	cis	1	rs1415753	chr6:86753074	SNHG5	chr6:86386726-86388451:-	-0.86	-12.03	6.85E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs1417823	chr10:102227886	SEC31B	chr10:102246403-102289636:-	0.33	5.6	9.52E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs1419183	chr6:28242794	ZSCAN23	chr6:28393287-28411279:-	0.41	4.06	7.8E-5	Depression	
PAAD	cis	1	rs1423620	chr5:56100996	C5orf35	chr5:56205103-56213010:+	1	9.25	1.9E-16	Type 2 diabetes	
PAAD	cis	1	rs1423621	chr5:56101035	C5orf35	chr5:56205103-56213010:+	1	9.07	5.48E-16	Type 2 diabetes	
PAAD	cis	1	rs1428551	chr5:150259832	LOC134466	chr5:150310000-150326146:-	0.67	5.78	4.03E-8	Crohn's disease	
PAAD	cis	1	rs1428552	chr5:150259831	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs1428554	chr5:150257616	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs1428555	chr5:150257391	LOC134466	chr5:150310000-150326146:-	-0.68	-5.84	3.03E-8	Crohn's disease	
PAAD	cis	1	rs144073979	chr22:18886814	DGCR6	chr22:18893541-18899600:+	-0.52	-4.66	6.85E-6	3-hydroxypropylmercapturic acid levels in smokers	
PAAD	cis	1	rs144447022	chr6:29244219	ZFP57	chr6:29640171-29648887:-	0.93	4.68	6.3E-6	Schizophrenia	
PAAD	cis	1	rs1451707	chr6:56801877	BEND6	chr6:56819773-56892138:+	-0.41	-5	1.55E-6	Menarche (age at onset)	
PAAD	cis	1	rs1451708	chr6:56802201	BEND6	chr6:56819773-56892138:+	-0.41	-5	1.55E-6	Menarche (age at onset)	
PAAD	cis	1	rs1459242	chr3:48413537	TREX1	chr3:48501186-48509043:+	0.35	5.07	1.16E-6	Longevity	
PAAD	cis	1	rs1460561	chr6:56797574	BEND6	chr6:56819773-56892138:+	-0.42	-5.24	5.2E-7	Menarche (age at onset)	
PAAD	cis	1	rs1466389	chr17:2096384	SRR	chr17:2207248-2228553:+	-0.49	-8.64	7.06E-15	Esophageal cancer (squamous cell)	
PAAD	cis	1	rs1467472	chr20:43371551	WISP2	chr20:43343475-43356451:+	-0.37	-4.68	6.26E-6	Obesity-related traits	
PAAD	cis	1	rs1473248	chr19:41923314	B3GNT8	chr19:41931265-41934635:-	0.3	4.73	4.97E-6	Height	
PAAD	cis	1	rs1475695	chr9:100691168	C9orf156	chr9:100666772-100684852:-	-0.33	-4.61	8.38E-6	Quantitative traits	
PAAD	cis	1	rs1475696	chr9:100691397	C9orf156	chr9:100666772-100684852:-	-0.33	-4.61	8.38E-6	Quantitative traits	
PAAD	cis	1	rs1497406	chr1:16505320	C1orf89	chr1:16558183-16563659:-	-0.36	-4.02	9.02E-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase)	
PAAD	cis	1	rs1498718	chr3:134205920	ANAPC13	chr3:134196547-134204865:-	0.87	11.86	2.04E-23	Height	
PAAD	cis	1	rs151222	chr16:20674492	ACSM1	chr16:20634559-20709066:-	-0.55	-4.17	5.11E-5	Schizophrenia	
PAAD	cis	1	rs151964	chr5:96123666	ERAP1	chr5:96096515-96149837:-	-0.62	-8.75	3.7E-15	Ankylosing spondylitis	
PAAD	cis	1	rs1533266	chr7:143766714	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.17	7.31E-7	Obesity-related traits	
PAAD	cis	1	rs1533267	chr7:143766440	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.17	7.31E-7	Obesity-related traits	
PAAD	cis	1	rs1533268	chr7:143766358	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.17	7.31E-7	Obesity-related traits	
PAAD	cis	1	rs1534025	chr3:134313304	ANAPC13	chr3:134196547-134204865:-	-0.88	-11.62	9.09E-23	Height	
PAAD	cis	1	rs1534026	chr3:134284767	ANAPC13	chr3:134196547-134204865:-	0.86	11.15	1.63E-21	Height	
PAAD	cis	1	rs1535500	chr6:39284050	KCNK17	chr6:39266778-39282237:-	0.24	4.53	1.18E-5	Type 2 diabetes	
PAAD	cis	1	rs1540894	chr7:143767676	ARHGEF35	chr7:143883677-143892736:-	-0.4	-5.34	3.25E-7	Obesity-related traits	
PAAD	cis	1	rs1540927	chr20:33931344	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs1555299	chr20:43370106	WISP2	chr20:43343475-43356451:+	-0.37	-4.68	6.26E-6	Obesity-related traits	
PAAD	cis	1	rs1555569	chr17:2149425	SRR	chr17:2207248-2228553:+	-0.52	-9.15	3.35E-16	Esophageal cancer (squamous cell)	
PAAD	cis	1	rs1556562	chr1:93034023	EVI5	chr1:92974255-93257961:-	0.37	4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs1558377	chr4:17650758	MED28	chr4:17616273-17629791:+	0.43	5.12	9.06E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs1558378	chr4:17650351	MED28	chr4:17616273-17629791:+	0.43	5.12	9.06E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs1559282	chr5:56099375	C5orf35	chr5:56205103-56213010:+	1	9.07	5.48E-16	Type 2 diabetes	
PAAD	cis	1	rs1563736	chr3:48436794	TREX1	chr3:48501186-48509043:+	-0.39	-5.64	7.81E-8	Longevity	
PAAD	cis	1	rs1564716	chr3:41862613	ULK4	chr3:41288091-42003660:-	0.86	8.03	2.38E-13	Diastolic blood pressure	
PAAD	cis	1	rs15676	chr9:131572027	ENDOG	chr9:131580779-131584954:+	-0.31	-5.02	1.4E-6	Blood metabolite levels	
PAAD	cis	1	rs1569483	chr6:25614595	HIST1H3D	chr6:26197013-26199464:-	-0.38	-4.03	8.75E-5	Uric acid levels	
PAAD	cis	1	rs1570004	chr20:33958253	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs1570063	chr6:49637027	CRISP2	chr6:49660072-49681299:-	-0.39	-4.07	7.49E-5	Prothrombin fragments F1+2 levels in ischemic stroke	
PAAD	cis	1	rs1570836	chr1:92972457	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs1570837	chr1:93006816	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs1571229	chr9:131913711	PPP2R4	chr9:131873244-131911223:+	0.43	4.35	2.47E-5	Blood metabolite ratios	
PAAD	cis	1	rs1573897	chr1:247215054	ZNF670	chr1:247200087-247242069:-	-0.49	-5.32	3.69E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs1577917	chr6:86691940	SNHG5	chr6:86386726-86388451:-	-0.86	-11.79	3.04E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs1577919	chr6:86757296	SNHG5	chr6:86386726-86388451:-	-0.86	-12.02	7.33E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs1599280	chr6:56792576	BEND6	chr6:56819773-56892138:+	-0.4	-5.02	1.42E-6	Menarche (age at onset)	
PAAD	cis	1	rs1599281	chr6:56789311	BEND6	chr6:56819773-56892138:+	0.39	5.1	9.83E-7	Menarche (age at onset)	
PAAD	cis	1	rs1599932	chr12:58177943	FAM119B	chr12:58166383-58176323:+	0.45	5.44	2.09E-7	Multiple sclerosis	
PAAD	cis	1	rs160633	chr7:65528228	CCT6P1	chr7:65216092-65228661:+	0.43	4.07	7.5E-5	Diabetic kidney disease	
PAAD	cis	1	rs160634	chr7:65528664	CCT6P1	chr7:65216092-65228661:+	-0.41	-4.03	8.66E-5	Diabetic kidney disease	
PAAD	cis	1	rs160643	chr7:65558222	CCT6P1	chr7:65216092-65228661:+	0.4	4.02	8.96E-5	Diabetic kidney disease	
PAAD	cis	1	rs160648	chr7:65543384	CCT6P1	chr7:65216092-65228661:+	0.43	4.34	2.53E-5	Diabetic kidney disease	
PAAD	cis	1	rs160652	chr7:65538431	CCT6P1	chr7:65216092-65228661:+	0.43	4.12	6.2E-5	Diabetic kidney disease	
PAAD	cis	1	rs160655	chr7:65533214	CCT6P1	chr7:65216092-65228661:+	0.43	4.34	2.53E-5	Diabetic kidney disease	
PAAD	cis	1	rs1607908	chr3:41905196	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs1609810	chr9:123642351	LOC253039	chr9:123605320-123616644:+	-0.58	-7.83	7.74E-13	Rheumatoid arthritis	
PAAD	cis	1	rs1612124	chr3:41967893	ULK4	chr3:41288091-42003660:-	-0.87	-7.75	1.21E-12	Diastolic blood pressure	
PAAD	cis	1	rs1613759	chr3:41906183	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs1615243	chr3:41965234	ULK4	chr3:41288091-42003660:-	-0.89	-8.07	1.88E-13	Diastolic blood pressure	
PAAD	cis	1	rs1615543	chr3:41906404	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs1628874	chr3:41955714	ULK4	chr3:41288091-42003660:-	-0.89	-8.15	1.19E-13	Diastolic blood pressure	
PAAD	cis	1	rs1629460	chr3:41927449	ULK4	chr3:41288091-42003660:-	-0.83	-7.34	1.17E-11	Diastolic blood pressure	
PAAD	cis	1	rs166925	chr19:41926098	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.89	2.49E-6	Height	
PAAD	cis	1	rs16837131	chr2:202173812	PPIL3	chr2:201735680-201753999:-	0.69	4.16	5.22E-5	Rheumatoid arthritis	
PAAD	cis	1	rs16876336	chr5:78323482	BHMT2	chr5:78365583-78385273:+	0.18	4.37	2.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs16876529	chr6:86591202	SNHG5	chr6:86386726-86388451:-	-0.89	-12.9	3.07E-26	Response to antipsychotic treatment	
PAAD	cis	1	rs16892796	chr4:16018216	FAM200B	chr4:15683352-15692062:+	0.59	4.25	3.67E-5	Smooth-surface caries	
PAAD	cis	1	rs16916041	chr10:63146547	C10orf107	chr10:63422719-63526089:+	-0.53	-4.03	8.68E-5	Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia	
PAAD	cis	1	rs16952009	chr17:2102437	SRR	chr17:2207248-2228553:+	-0.49	-8.6	8.96E-15	Esophageal cancer (squamous cell)	
PAAD	cis	1	rs16952848	chr18:44597829	HDHD2	chr18:44633782-44676871:-	0.46	5.15	7.78E-7	Sitting height ratio	
PAAD	cis	1	rs16958432	chr18:44631773	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs16958440	chr18:44632884	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs16958701	chr18:44655241	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs1699379	chr4:129992337	C4orf33	chr4:130014829-130033842:+	-0.51	-6.3	2.96E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1699389	chr4:130004079	C4orf33	chr4:130014829-130033842:+	-0.49	-6.11	7.93E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1699391	chr4:130005096	C4orf33	chr4:130014829-130033842:+	-0.49	-6.11	7.93E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1699392	chr4:130022347	C4orf33	chr4:130014829-130033842:+	-0.54	-7.09	4.75E-11	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1699393	chr4:130019352	C4orf33	chr4:130014829-130033842:+	-0.51	-6.51	1.0E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1699394	chr4:130019312	C4orf33	chr4:130014829-130033842:+	-0.53	-6.89	1.34E-10	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1701750	chr7:65467145	CCT6P1	chr7:65216092-65228661:+	0.44	4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs1701758	chr7:65470201	CCT6P1	chr7:65216092-65228661:+	0.44	4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs17030613	chr1:113190807	ST7L	chr1:113066142-113162405:-	0.44	5.74	4.93E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs17030651	chr1:113239382	ST7L	chr1:113066142-113162405:-	0.44	5.64	8.06E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs17061431	chr3:41792655	ULK4	chr3:41288091-42003660:-	0.8	7.18	2.91E-11	Diastolic blood pressure	
PAAD	cis	1	rs17062109	chr3:41810364	ULK4	chr3:41288091-42003660:-	0.86	8.02	2.54E-13	Diastolic blood pressure	
PAAD	cis	1	rs17063584	chr3:41861463	ULK4	chr3:41288091-42003660:-	0.86	7.99	2.98E-13	Diastolic blood pressure	
PAAD	cis	1	rs17063599	chr3:41861676	ULK4	chr3:41288091-42003660:-	0.86	8.03	2.38E-13	Diastolic blood pressure	
PAAD	cis	1	rs17063649	chr3:41863406	ULK4	chr3:41288091-42003660:-	0.86	8.03	2.38E-13	Diastolic blood pressure	
PAAD	cis	1	rs17064124	chr3:41890803	ULK4	chr3:41288091-42003660:-	0.85	7.66	1.98E-12	Diastolic blood pressure	
PAAD	cis	1	rs1707304	chr1:46598269	CCDC163P	chr1:45960581-45965646:-	-0.51	-6	1.35E-8	Body mass index	
PAAD	cis	1	rs1707321	chr1:46505309	CCDC163P	chr1:45960581-45965646:-	-0.52	-6.29	3.13E-9	Body mass index	
PAAD	cis	1	rs1707335	chr1:46571921	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.99	1.48E-8	Body mass index	
PAAD	cis	1	rs1707336	chr1:46493460	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.95	1.74E-8	Body mass index	
PAAD	cis	1	rs1707340	chr1:46514942	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.25	3.99E-9	Body mass index	
PAAD	cis	1	rs17096228	chr14:74558669	LIN52	chr14:74551656-74667117:+	0.44	7.8	8.75E-13	Common traits (Other)	
PAAD	cis	1	rs17111376	chr5:150226899	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs17113137	chr10:102241998	SEC31B	chr10:102246403-102289636:-	-0.35	-5.91	2.16E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs1715235	chr7:65488394	CCT6P1	chr7:65216092-65228661:+	0.44	4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs17161692	chr7:98953863	CYP3A5	chr7:99245818-99332821:-	-0.6	-5.59	1.04E-7	Blood metabolite levels	
PAAD	cis	1	rs17164851	chr7:130003487	CPA5	chr7:129984630-130008571:+	0.48	4.93	2.13E-6	Age-related hearing impairment (interaction)	
PAAD	cis	1	rs1716642	chr3:41965865	ULK4	chr3:41288091-42003660:-	-0.89	-8.07	1.88E-13	Diastolic blood pressure	
PAAD	cis	1	rs1716644	chr3:41968028	ULK4	chr3:41288091-42003660:-	-0.87	-7.75	1.21E-12	Diastolic blood pressure	
PAAD	cis	1	rs1716651	chr3:41975099	ULK4	chr3:41288091-42003660:-	-0.89	-8.22	8.19E-14	Diastolic blood pressure	
PAAD	cis	1	rs1716657	chr3:41918456	ULK4	chr3:41288091-42003660:-	-0.84	-7.48	5.46E-12	Diastolic blood pressure	
PAAD	cis	1	rs1716660	chr3:41929960	ULK4	chr3:41288091-42003660:-	-0.86	-7.82	8.15E-13	Diastolic blood pressure	
PAAD	cis	1	rs1716661	chr3:41962818	ULK4	chr3:41288091-42003660:-	-0.89	-8.07	1.88E-13	Diastolic blood pressure	
PAAD	cis	1	rs1716664	chr3:41948378	ULK4	chr3:41288091-42003660:-	-0.87	-7.83	7.46E-13	Diastolic blood pressure	
PAAD	cis	1	rs1716668	chr3:41907850	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs1716669	chr3:41908681	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs1716676	chr3:41903208	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs1716683	chr3:41923074	ULK4	chr3:41288091-42003660:-	-0.84	-7.48	5.46E-12	Diastolic blood pressure	
PAAD	cis	1	rs1716685	chr3:41925301	ULK4	chr3:41288091-42003660:-	0.84	7.76	1.15E-12	Diastolic blood pressure	
PAAD	cis	1	rs1716688	chr3:41926546	ULK4	chr3:41288091-42003660:-	-0.83	-7.34	1.17E-11	Diastolic blood pressure	
PAAD	cis	1	rs1716690	chr3:41922102	ULK4	chr3:41288091-42003660:-	-0.84	-7.48	5.46E-12	Diastolic blood pressure	
PAAD	cis	1	rs1716692	chr3:41983786	ULK4	chr3:41288091-42003660:-	-0.94	-8.5	1.54E-14	Diastolic blood pressure	
PAAD	cis	1	rs1716693	chr3:41985600	ULK4	chr3:41288091-42003660:-	-0.92	-8.85	2.05E-15	Diastolic blood pressure	
PAAD	cis	1	rs1716696	chr3:41935811	ULK4	chr3:41288091-42003660:-	-0.86	-7.82	8.15E-13	Diastolic blood pressure	
PAAD	cis	1	rs1716984	chr3:41965532	ULK4	chr3:41288091-42003660:-	-0.89	-8.23	7.85E-14	Diastolic blood pressure	
PAAD	cis	1	rs1716987	chr3:41970516	ULK4	chr3:41288091-42003660:-	-0.88	-7.84	7.26E-13	Diastolic blood pressure	
PAAD	cis	1	rs1716993	chr3:41974556	ULK4	chr3:41288091-42003660:-	-0.88	-7.84	7.26E-13	Diastolic blood pressure	
PAAD	cis	1	rs1716997	chr3:41924333	ULK4	chr3:41288091-42003660:-	-0.84	-7.48	5.46E-12	Diastolic blood pressure	
PAAD	cis	1	rs1716999	chr3:41930041	ULK4	chr3:41288091-42003660:-	-0.86	-7.82	8.15E-13	Diastolic blood pressure	
PAAD	cis	1	rs1717000	chr3:41930219	ULK4	chr3:41288091-42003660:-	-0.86	-7.82	8.15E-13	Diastolic blood pressure	
PAAD	cis	1	rs1717001	chr3:41934949	ULK4	chr3:41288091-42003660:-	-0.86	-7.68	1.78E-12	Diastolic blood pressure	
PAAD	cis	1	rs1717006	chr3:41940448	ULK4	chr3:41288091-42003660:-	0.91	8.5	1.55E-14	Diastolic blood pressure	
PAAD	cis	1	rs1717009	chr3:41946308	ULK4	chr3:41288091-42003660:-	-0.87	-7.97	3.43E-13	Diastolic blood pressure	
PAAD	cis	1	rs1717011	chr3:41980199	ULK4	chr3:41288091-42003660:-	-0.89	-8.07	1.88E-13	Diastolic blood pressure	
PAAD	cis	1	rs1717014	chr3:41917395	ULK4	chr3:41288091-42003660:-	0.84	7.48	5.46E-12	Diastolic blood pressure	
PAAD	cis	1	rs1717017	chr3:41915616	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs1717020	chr3:41981490	ULK4	chr3:41288091-42003660:-	0.9	8.31	4.93E-14	Diastolic blood pressure	
PAAD	cis	1	rs1717021	chr3:41983860	ULK4	chr3:41288091-42003660:-	-0.95	-8.64	6.9E-15	Diastolic blood pressure	
PAAD	cis	1	rs1717024	chr3:41984888	ULK4	chr3:41288091-42003660:-	-0.88	-8.27	6.12E-14	Diastolic blood pressure	
PAAD	cis	1	rs1717027	chr3:41987920	ULK4	chr3:41288091-42003660:-	-0.91	-8.68	5.67E-15	Diastolic blood pressure	
PAAD	cis	1	rs1717031	chr3:41905791	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs1717033	chr3:41910216	ULK4	chr3:41288091-42003660:-	0.85	7.66	1.98E-12	Diastolic blood pressure	
PAAD	cis	1	rs17172199	chr7:43377276	GCK	chr7:44183870-44229022:-	0.37	4.03	8.83E-5	Alzheimer's disease (cognitive decline)	
PAAD	cis	1	rs1723267	chr7:65473314	CCT6P1	chr7:65216092-65228661:+	0.46	4.52	1.21E-5	Diabetic kidney disease	
PAAD	cis	1	rs1723269	chr7:65472786	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs1723270	chr7:65469830	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs17311679	chr19:50521331	SIGLEC16	chr19:50472912-50479075:+	-0.89	-5.15	7.87E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs1731847	chr7:155655522	LOC100132707	chr7:154720227-154741194:+	-0.31	-4	9.82E-5	Triptolide cytotoxicity	
PAAD	cis	1	rs17318666	chr19:41940342	B3GNT8	chr19:41931265-41934635:-	0.32	4.92	2.21E-6	Height	
PAAD	cis	1	rs17431934	chr9:100695776	C9orf156	chr9:100666772-100684852:-	-0.33	-4.61	8.38E-6	Quantitative traits	
PAAD	cis	1	rs17433780	chr1:89474818	GBP3	chr1:89472367-89488549:-	0.96	22.4	3.65E-50	Carotid intima media thickness	
PAAD	cis	1	rs17450853	chr6:56788004	BEND6	chr6:56819773-56892138:+	-0.41	-5.38	2.73E-7	Menarche (age at onset)	
PAAD	cis	1	rs17455136	chr1:21862253	ALPL	chr1:21835858-21904904:+	-0.43	-5.04	1.33E-6	Response to TNF-alpha inhibitors in rheumatoid arthritis	
PAAD	cis	1	rs17507481	chr4:17620066	MED28	chr4:17616273-17629791:+	0.45	5.46	1.91E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs1757924	chr4:130019599	C4orf33	chr4:130014829-130033842:+	-0.52	-6.66	4.56E-10	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1757925	chr4:130020791	C4orf33	chr4:130014829-130033842:+	0.54	7.09	4.75E-11	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1757927	chr4:130022069	C4orf33	chr4:130014829-130033842:+	-0.54	-7.09	4.75E-11	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1757928	chr4:130022161	C4orf33	chr4:130014829-130033842:+	-0.54	-7.09	4.75E-11	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1757930	chr4:130022356	C4orf33	chr4:130014829-130033842:+	-0.53	-6.86	1.62E-10	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1757935	chr4:130023759	C4orf33	chr4:130014829-130033842:+	-0.54	-7.09	4.75E-11	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs17596617	chr11:43690717	HSD17B12	chr11:43702143-43878160:+	-0.45	-6.14	6.95E-9	Forced vital capacity	
PAAD	cis	1	rs17601029	chr15:85347709	LOC388152	chr15:84867600-84898920:-	-0.35	-4.12	6.3E-5	Schizophrenia	
PAAD	cis	1	rs17605685	chr19:50486741	SIGLEC16	chr19:50472912-50479075:+	1.01	5.52	1.42E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs17608059	chr17:13910549	CDRT15P	chr17:13927815-13928915:+	-0.61	-7.38	9.24E-12	Temperament	
PAAD	cis	1	rs17661933	chr19:50534520	SIGLEC16	chr19:50472912-50479075:+	-0.88	-5.42	2.29E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs17671194	chr15:40667539	C15orf23	chr15:40674922-40686488:+	0.76	8.95	1.09E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs17671250	chr15:40673124	C15orf23	chr15:40674922-40686488:+	-0.61	-7.36	1.07E-11	Heschl's gyrus morphology	
PAAD	cis	1	rs17685143	chr6:56774788	BEND6	chr6:56819773-56892138:+	-0.41	-5.1	9.73E-7	Menarche (age at onset)	
PAAD	cis	1	rs1768803	chr1:46546208	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs1768816	chr1:46528599	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.94	1.86E-8	Body mass index	
PAAD	cis	1	rs17691170	chr3:121357626	IQCB1	chr3:121488610-121553926:-	0.57	5.9	2.25E-8	Cognitive performance	
PAAD	cis	1	rs17694011	chr3:134213981	ANAPC13	chr3:134196547-134204865:-	0.87	11.61	9.26E-23	Height	
PAAD	cis	1	rs17713396	chr2:227201	SH3YL1	chr2:218138-264810:-	-0.47	-7.4	8.26E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs17713729	chr2:249092	SH3YL1	chr2:218138-264810:-	-0.46	-7.72	1.42E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs17714252	chr2:285471	SH3YL1	chr2:218138-264810:-	-0.47	-7.71	1.47E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs17727568	chr5:150244688	LOC134466	chr5:150310000-150326146:-	0.93	7.12	3.97E-11	Crohn's disease	
PAAD	cis	1	rs17746014	chr10:102315354	SEC31B	chr10:102246403-102289636:-	-0.32	-5.03	1.36E-6	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs1775148	chr1:205757824	PM20D1	chr1:205797154-205819245:-	-0.46	-5.61	9.22E-8	Prostate cancer	
PAAD	cis	1	rs17752459	chr6:56798755	BEND6	chr6:56819773-56892138:+	-0.4	-4.93	2.11E-6	Menarche (age at onset)	
PAAD	cis	1	rs17761723	chr17:2107090	SRR	chr17:2207248-2228553:+	0.48	9.15	3.37E-16	Esophageal cancer (squamous cell)	
PAAD	cis	1	rs17761864	chr17:2171637	SRR	chr17:2207248-2228553:+	-0.51	-9.12	4.02E-16	Esophageal cancer (squamous cell)	
PAAD	cis	1	rs1778508	chr6:28229881	HIST1H4J	chr6:27791903-27792257:+	0.43	4.12	6.15E-5	Depression	
PAAD	cis	1	rs17800886	chr5:150309539	LOC134466	chr5:150310000-150326146:-	0.78	6.79	2.37E-10	Crohn's disease	
PAAD	cis	1	rs17800987	chr5:150323428	LOC134466	chr5:150310000-150326146:-	0.71	6.31	2.89E-9	Crohn's disease	
PAAD	cis	1	rs17834627	chr17:2198892	SRR	chr17:2207248-2228553:+	-0.53	-9.19	2.61E-16	Esophageal cancer (squamous cell)	
PAAD	cis	1	rs17839567	chr16:31057945	MYST1	chr16:31128985-31142713:+	0.36	4.9	2.44E-6	Response to metformin (IC50)	
PAAD	cis	1	rs1800615	chr1:15832281	CASP9	chr1:15817324-15851384:-	0.37	4.31	2.91E-5	Glomerular filtration rate (creatinine)	
PAAD	cis	1	rs1800662	chr10:102289078	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs1805074	chr5:78324352	BHMT2	chr5:78365583-78385273:+	0.18	4.37	2.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs1814336	chr3:134200823	ANAPC13	chr3:134196547-134204865:-	0.9	12.22	2.1E-24	Height	
PAAD	cis	1	rs1814337	chr3:134200682	ANAPC13	chr3:134196547-134204865:-	0.87	11.61	9.26E-23	Height	
PAAD	cis	1	rs1815787	chr11:116921397	PCSK7	chr11:117075789-117102811:-	-0.4	-4.39	2.1E-5	Subjective well-being	
PAAD	cis	1	rs1816256	chr5:150272853	LOC134466	chr5:150310000-150326146:-	0.67	5.78	4.03E-8	Crohn's disease	
PAAD	cis	1	rs1818950	chr15:84722521	LOC388152	chr15:84867600-84898920:-	-0.33	-4	9.88E-5	Schizophrenia	
PAAD	cis	1	rs1820682	chr5:150262142	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs1830074	chr7:6718674	PMS2CL	chr7:6749757-6793492:+	-0.46	-4.72	5.36E-6	Body mass index	
PAAD	cis	1	rs1833896	chr5:56097669	C5orf35	chr5:56205103-56213010:+	1	9.07	5.48E-16	Type 2 diabetes	
PAAD	cis	1	rs1848093	chr15:84755527	LOC388152	chr15:84867600-84898920:-	-0.35	-4.2	4.54E-5	Schizophrenia	
PAAD	cis	1	rs1854774	chr4:129988405	C4orf33	chr4:130014829-130033842:+	-0.5	-6.23	4.41E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs1857964	chr6:86635994	SNHG5	chr6:86386726-86388451:-	-0.87	-12.06	5.92E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs1857965	chr6:86630776	SNHG5	chr6:86386726-86388451:-	-0.84	-11.44	2.8E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs1858482	chr1:152306921	FLG	chr1:152274651-152297679:-	-0.48	-5.34	3.33E-7	Atopic dermatitis	
PAAD	cis	1	rs1859690	chr7:99227172	CYP3A5	chr7:99245818-99332821:-	0.75	7.04	6.14E-11	Blood metabolite levels	
PAAD	cis	1	rs1860596	chr4:17660082	MED28	chr4:17616273-17629791:+	0.46	5.51	1.52E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs1860597	chr4:17657650	MED28	chr4:17616273-17629791:+	0.46	5.5	1.59E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs1862228	chr5:78314051	BHMT2	chr5:78365583-78385273:+	0.18	4.52	1.25E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs1862619	chr5:56098256	C5orf35	chr5:56205103-56213010:+	1	9.07	5.48E-16	Type 2 diabetes	
PAAD	cis	1	rs1863913	chr3:134200205	ANAPC13	chr3:134196547-134204865:-	0.87	11.86	2.04E-23	Height	
PAAD	cis	1	rs1863998	chr5:150271753	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs1864367	chr3:53111704	RFT1	chr3:53122503-53164470:-	-0.45	-5.21	5.94E-7	Height	
PAAD	cis	1	rs1874883	chr3:134205071	ANAPC13	chr3:134196547-134204865:-	0.89	11.95	1.15E-23	Height	
PAAD	cis	1	rs1875124	chr12:58196802	FAM119B	chr12:58166383-58176323:+	0.45	5.44	2.09E-7	Multiple sclerosis	
PAAD	cis	1	rs1880376	chr3:134270347	ANAPC13	chr3:134196547-134204865:-	-0.88	-12	8.57E-24	Height	
PAAD	cis	1	rs1880377	chr3:134270468	ANAPC13	chr3:134196547-134204865:-	-0.88	-12	8.57E-24	Height	
PAAD	cis	1	rs1881123	chr7:1084706	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.32	2.74E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs1882099	chr4:1352685	CRIPAK	chr4:1385340-1389782:+	0.48	6.62	5.63E-10	Systolic blood pressure	
PAAD	cis	1	rs1885986	chr17:2203175	SRR	chr17:2207248-2228553:+	-0.52	-9.06	5.87E-16	Esophageal cancer (squamous cell)	
PAAD	cis	1	rs1886682	chr1:92977275	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs1886683	chr1:92976023	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs1895320	chr5:159849586	SLU7	chr5:159828649-159846168:-	-0.35	-4.04	8.57E-5	Insulin-related traits	
PAAD	cis	1	rs1896707	chr5:150245129	LOC134466	chr5:150310000-150326146:-	0.68	5.81	3.49E-8	Crohn's disease	
PAAD	cis	1	rs1896708	chr5:150245076	LOC134466	chr5:150310000-150326146:-	0.73	6.25	3.89E-9	Crohn's disease	
PAAD	cis	1	rs1896709	chr5:150245032	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs1900120	chr14:76626516	ESRRB	chr14:76837690-76968178:+	0.47	4.15	5.4E-5	Blood pressure	
PAAD	cis	1	rs1900122	chr14:76629517	ESRRB	chr14:76837690-76968178:+	0.47	4.15	5.4E-5	Blood pressure	
PAAD	cis	1	rs1903330	chr6:56776985	BEND6	chr6:56819773-56892138:+	0.41	5.26	4.85E-7	Menarche (age at onset)	
PAAD	cis	1	rs190414	chr5:56116772	C5orf35	chr5:56205103-56213010:+	1.08	10.04	1.55E-18	Type 2 diabetes	
PAAD	cis	1	rs1911155	chr15:84787635	LOC388152	chr15:84867600-84898920:-	-0.35	-4.15	5.57E-5	Schizophrenia	
PAAD	cis	1	rs1911552	chr6:86638024	SNHG5	chr6:86386726-86388451:-	-0.87	-12.29	1.4E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs1911553	chr6:86630892	SNHG5	chr6:86386726-86388451:-	-0.84	-11.44	2.8E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs1917130	chr3:134313773	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.77	3.63E-23	Height	
PAAD	cis	1	rs1919948	chr7:143762843	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.17	7.31E-7	Obesity-related traits	
PAAD	cis	1	rs1919949	chr7:143767723	ARHGEF35	chr7:143883677-143892736:-	-0.4	-5.23	5.45E-7	Obesity-related traits	
PAAD	cis	1	rs1919950	chr7:143767898	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.16	7.65E-7	Obesity-related traits	
PAAD	cis	1	rs1919951	chr7:143768891	ARHGEF35	chr7:143883677-143892736:-	-0.41	-5.41	2.4E-7	Obesity-related traits	
PAAD	cis	1	rs1930961	chr22:25875265	CRYBB2	chr22:25615612-25627836:+	1.22	7.83	7.39E-13	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs1935	chr10:64927823	NRBF2	chr10:64893007-64914785:+	-0.38	-5.16	7.39E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs1936365	chr6:28268452	ZSCAN23	chr6:28393287-28411279:-	-0.45	-4.58	9.51E-6	Depression	
PAAD	cis	1	rs1953126	chr9:123640500	LOC253039	chr9:123605320-123616644:+	-0.58	-7.84	7.09E-13	Rheumatoid arthritis	
PAAD	cis	1	rs1962716	chr6:86648436	SNHG5	chr6:86386726-86388451:-	-0.87	-11.7	5.56E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs1964692	chr7:65454183	CCT6P1	chr7:65216092-65228661:+	0.44	4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs1974624	chr4:17650281	MED28	chr4:17616273-17629791:+	0.45	5.37	2.84E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs1975174	chr19:22515251	ZNF98	chr19:22573899-22605148:-	0.3	4.37	2.31E-5	Telomere length	
PAAD	cis	1	rs1975284	chr8:57314663	PENK	chr8:57353513-57359282:-	-0.4	-4.41	1.96E-5	Obesity-related traits	
PAAD	cis	1	rs1979	chr6:26377591	BTN3A2	chr6:26365398-26378546:+	-1.08	-9.38	8.43E-17	Schizophrenia	
PAAD	cis	1	rs198806	chr6:26133616	BTN3A2	chr6:26365398-26378546:+	0.34	4.2	4.58E-5	Schizophrenia	
PAAD	cis	1	rs1994157	chr3:41897482	ULK4	chr3:41288091-42003660:-	0.85	7.51	4.7E-12	Diastolic blood pressure	
PAAD	cis	1	rs1995688	chr6:86632319	SNHG5	chr6:86386726-86388451:-	-0.84	-11.44	2.8E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs1997243	chr7:1083777	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs1999852	chr6:86705738	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs2000614	chr11:116915742	PCSK7	chr11:117075789-117102811:-	-0.4	-4.39	2.1E-5	Protein quantitative trait loci	
PAAD	cis	1	rs2000615	chr11:116915819	PCSK7	chr11:117075789-117102811:-	-0.38	-4	0.0001	Protein quantitative trait loci	
PAAD	cis	1	rs2000616	chr11:116916529	PCSK7	chr11:117075789-117102811:-	-0.4	-4.39	2.1E-5	Protein quantitative trait loci	
PAAD	cis	1	rs2003284	chr10:102202338	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2004711	chr5:150225068	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs2006751	chr11:43670501	HSD17B12	chr11:43702143-43878160:+	-0.43	-5.87	2.58E-8	Forced vital capacity	
PAAD	cis	1	rs2010648	chr14:35604892	PPP2R3C	chr14:35554679-35591679:-	0.5	5.2	6.37E-7	Atopic dermatitis	
PAAD	cis	1	rs2011331	chr1:152286002	FLG	chr1:152274651-152297679:-	0.54	5.6	9.55E-8	Atopic dermatitis	
PAAD	cis	1	rs2017962	chr19:22208751	ZNF257	chr19:22235266-22273901:+	0.49	5.96	1.64E-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2019097	chr2:202193463	PPIL3	chr2:201735680-201753999:-	-0.65	-4.15	5.41E-5	Rheumatoid arthritis	
PAAD	cis	1	rs201983168	chr1:150314981	C1orf54	chr1:150244773-150253325:+	-0.38	-4.26	3.51E-5	Eye morphology	
PAAD	cis	1	rs2022068	chr22:37199806	LGALS2	chr22:37966254-37976024:-	-0.28	-4.12	6.25E-5	Pit-and-Fissure caries	
PAAD	cis	1	rs2028299	chr15:90374257	AP3S2	chr15:90373832-90456222:-	-0.83	-9.81	6.45E-18	Type 2 diabetes	
PAAD	cis	1	rs2029614	chr14:99547267	EVL	chr14:100438151-100610572:+	-0.27	-4.08	7.23E-5	Airway wall thickness	
PAAD	cis	1	rs2034899	chr5:78316188	BHMT2	chr5:78365583-78385273:+	0.19	4.52	1.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs2034900	chr5:78315964	BHMT2	chr5:78365583-78385273:+	-0.18	-4.52	1.25E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs2045554	chr3:48494542	TREX1	chr3:48501186-48509043:+	0.33	4.81	3.55E-6	Longevity	
PAAD	cis	1	rs2056544	chr15:76826003	SCAPER	chr15:76640529-77197744:-	-0.24	-4.45	1.64E-5	Blood metabolite levels	
PAAD	cis	1	rs2056603	chr3:134312749	ANAPC13	chr3:134196547-134204865:-	0.87	11.4	3.43E-22	Height	
PAAD	cis	1	rs2056604	chr3:134312648	ANAPC13	chr3:134196547-134204865:-	0.86	11.36	4.41E-22	Height	
PAAD	cis	1	rs2058059	chr7:72311817	TYW1B	chr7:72023729-72298813:-	-0.73	-6.99	8.14E-11	Subcutaneous adipose tissue	
PAAD	cis	1	rs2058337	chr4:17678649	MED28	chr4:17616273-17629791:+	0.44	5.17	7.22E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2058338	chr4:17678600	MED28	chr4:17616273-17629791:+	-0.45	-5.31	3.86E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2058339	chr4:17678456	MED28	chr4:17616273-17629791:+	0.45	5.23	5.6E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2058805	chr12:109998591	MYO1H	chr12:109826524-109886176:+	0.49	4.61	8.6E-6	HDL cholesterol	
PAAD	cis	1	rs2069502	chr12:58144665	FAM119B	chr12:58166383-58176323:+	-0.42	-4.99	1.62E-6	Multiple sclerosis	
PAAD	cis	1	rs2070180	chr3:121351338	IQCB1	chr3:121488610-121553926:-	-0.57	-5.9	2.25E-8	Cognitive performance	
PAAD	cis	1	rs2072052	chr12:58146719	FAM119B	chr12:58166383-58176323:+	0.42	4.95	1.92E-6	Multiple sclerosis	
PAAD	cis	1	rs2072052	chr12:58146719	TSFM	chr12:58176536-58191367:+	-0.34	-4	0.0001	Multiple sclerosis	
PAAD	cis	1	rs2072293	chr14:74537885	LIN52	chr14:74551656-74667117:+	0.43	7.66	2.01E-12	Common traits (Other)	
PAAD	cis	1	rs2072883	chr22:43435668	RRP7B	chr22:42951347-42978017:-	-0.33	-4.27	3.39E-5	Schizophrenia	
PAAD	cis	1	rs2074038	chr11:44087989	ACCS	chr11:44087475-44105569:+	0.92	8.98	9.06E-16	IgA nephropathy	
PAAD	cis	1	rs2074771	chr2:242350944	SEPT2	chr2:242254723-242293439:+	0.62	6.35	2.38E-9	Chronic lymphocytic leukemia	
PAAD	cis	1	rs2075555	chr17:48274291	SGCA	chr17:48243366-48253292:+	0.52	4.21	4.3E-5	Breast cancer	
PAAD	cis	1	rs2077808	chr1:45988115	CCDC163P	chr1:45960581-45965646:-	-0.96	-13.34	2.03E-27	Homocysteine levels	
PAAD	cis	1	rs2078089	chr19:22209753	ZNF257	chr19:22235266-22273901:+	0.49	5.96	1.64E-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2083634	chr4:129976478	C4orf33	chr4:130014829-130033842:+	-0.5	-6.29	3.24E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs2092990	chr20:3346338	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs2098297	chr14:75619118	EIF2B2	chr14:75469612-75476292:+	-0.37	-4.16	5.28E-5	Height	
PAAD	cis	1	rs2109522	chr4:17658645	MED28	chr4:17616273-17629791:+	0.46	5.5	1.59E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2113078	chr5:56087190	C5orf35	chr5:56205103-56213010:+	1.05	9.74	9.84E-18	Type 2 diabetes	
PAAD	cis	1	rs2113079	chr5:56157951	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs2115069	chr5:150252365	LOC134466	chr5:150310000-150326146:-	0.7	5.99	1.46E-8	Crohn's disease	
PAAD	cis	1	rs2120107	chr15:76869789	SCAPER	chr15:76640529-77197744:-	-0.23	-4.11	6.37E-5	Blood metabolite levels	
PAAD	cis	1	rs2121070	chr14:76650764	ESRRB	chr14:76837690-76968178:+	0.47	4.15	5.4E-5	Blood pressure	
PAAD	cis	1	rs2121071	chr14:76665477	ESRRB	chr14:76837690-76968178:+	0.46	4.03	8.74E-5	Blood pressure	
PAAD	cis	1	rs2121075	chr14:76675540	ESRRB	chr14:76837690-76968178:+	0.46	4.01	9.37E-5	Blood pressure	
PAAD	cis	1	rs2126129	chr2:212548	SH3YL1	chr2:218138-264810:-	-0.47	-7.49	5.15E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs2128834	chr3:41862645	ULK4	chr3:41288091-42003660:-	0.86	8.01	2.67E-13	Diastolic blood pressure	
PAAD	cis	1	rs2128835	chr3:41862873	ULK4	chr3:41288091-42003660:-	0.86	8.03	2.38E-13	Diastolic blood pressure	
PAAD	cis	1	rs2130392	chr4:185639169	MLF1IP	chr4:185615220-185655286:-	-0.44	-7.01	7.17E-11	Kawasaki disease	
PAAD	cis	1	rs2143950	chr14:35572357	PPP2R3C	chr14:35554679-35591679:-	0.54	5.42	2.29E-7	Atopic dermatitis	
PAAD	cis	1	rs2154536	chr21:38492147	PIGP	chr21:38437664-38445458:-	-0.49	-6.23	4.35E-9	Eye color traits	
PAAD	cis	1	rs2155583	chr11:116915217	PCSK7	chr11:117075789-117102811:-	-0.4	-4.17	5.04E-5	Protein quantitative trait loci	
PAAD	cis	1	rs2159583	chr4:17658838	MED28	chr4:17616273-17629791:+	0.46	5.5	1.59E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2159584	chr4:17620568	MED28	chr4:17616273-17629791:+	0.48	5.77	4.25E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2163167	chr3:53131772	RFT1	chr3:53122503-53164470:-	-0.44	-5.08	1.1E-6	Height	
PAAD	cis	1	rs2163846	chr19:22505844	ZNF98	chr19:22573899-22605148:-	0.29	4.2	4.59E-5	Telomere length	
PAAD	cis	1	rs2166663	chr6:86593896	SNHG5	chr6:86386726-86388451:-	-0.87	-12.29	1.4E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs2169748	chr2:28957753	TRMT61B	chr2:29072690-29093175:-	0.52	6.39	1.89E-9	Body mass index	
PAAD	cis	1	rs2169751	chr2:28966758	TRMT61B	chr2:29072690-29093175:-	-0.49	-5.93	1.97E-8	Body mass index	
PAAD	cis	1	rs2175366	chr19:22128279	ZNF257	chr19:22235266-22273901:+	0.5	5.97	1.58E-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2177601	chr3:134245434	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.87	1.92E-23	Height	
PAAD	cis	1	rs2177703	chr7:65391717	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs2182907	chr1:35801099	C1orf216	chr1:36179477-36184790:-	0.39	4	9.89E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs2198042	chr4:129885499	C4orf33	chr4:130014829-130033842:+	0.49	5.95	1.73E-8	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs2210913	chr1:157668993	FCRL3	chr1:157646278-157670775:-	0.23	4.17	5.05E-5	Type 1 diabetes autoantibodies	
PAAD	cis	1	rs2214047	chr22:30556101	CABP7	chr22:30116344-30127818:+	0.62	4.34	2.62E-5	LDL cholesterol	
PAAD	cis	1	rs2215450	chr4:17675394	MED28	chr4:17616273-17629791:+	0.45	5.19	6.49E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2217266	chr5:150272621	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs2217957	chr8:57313360	PENK	chr8:57353513-57359282:-	-0.44	-4.97	1.8E-6	Obesity-related traits	
PAAD	cis	1	rs2227336	chr17:38174855	GSDMA	chr17:38119226-38134019:+	-0.56	-6.21	4.72E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs2229384	chr6:49425521	CENPQ	chr6:49431096-49460820:+	0.6	8.42	2.5E-14	Homocysteine levels	
PAAD	cis	1	rs2231940	chr19:41944237	B3GNT8	chr19:41931265-41934635:-	0.32	4.92	2.22E-6	Height	
PAAD	cis	1	rs2236087	chr20:3255905	ITPA	chr20:3190056-3204504:+	-0.4	-5.71	5.63E-8	IFN-related cytopenia	
PAAD	cis	1	rs2236089	chr20:3257194	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs2236092	chr20:3258188	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs2236098	chr20:3267133	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs2236104	chr20:3277602	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs2236106	chr20:3278410	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs2236107	chr20:3285821	ITPA	chr20:3190056-3204504:+	-0.4	-5.71	5.63E-8	IFN-related cytopenia	
PAAD	cis	1	rs2236108	chr20:3286331	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs2236117	chr20:3302021	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs2236118	chr20:3302058	ITPA	chr20:3190056-3204504:+	-0.41	-5.88	2.5E-8	IFN-related cytopenia	
PAAD	cis	1	rs2236122	chr20:3305240	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs2236123	chr20:3305305	ITPA	chr20:3190056-3204504:+	0.38	5.61	9.18E-8	IFN-related cytopenia	
PAAD	cis	1	rs2239557	chr14:74551970	LIN52	chr14:74551656-74667117:+	0.44	7.8	8.75E-13	Common traits (Other)	
PAAD	cis	1	rs2241706	chr19:41912807	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.7	5.78E-6	Height	
PAAD	cis	1	rs2241708	chr19:41912270	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.84	3.18E-6	Height	
PAAD	cis	1	rs2241709	chr19:41912250	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.67	6.41E-6	Height	
PAAD	cis	1	rs2241710	chr19:41912092	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.7	5.78E-6	Height	
PAAD	cis	1	rs2241711	chr19:41911980	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.7	5.78E-6	Height	
PAAD	cis	1	rs2242150	chr3:48505964	TREX1	chr3:48501186-48509043:+	0.35	5.22	5.79E-7	Longevity	
PAAD	cis	1	rs2242471	chr4:76878716	NAAA	chr4:76831809-76862166:-	0.45	5.5	1.59E-7	Longevity	
PAAD	cis	1	rs2242473	chr4:76878956	NAAA	chr4:76831809-76862166:-	0.45	5.5	1.59E-7	Longevity	
PAAD	cis	1	rs2242474	chr4:76878982	NAAA	chr4:76831809-76862166:-	0.45	5.5	1.59E-7	Longevity	
PAAD	cis	1	rs2243480	chr7:65599196	CCT6P1	chr7:65216092-65228661:+	0.42	4.22	4.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs2245715	chr15:43818052	ADAL	chr15:43622872-43646094:+	-0.64	-4.61	8.32E-6	Tumor biomarkers	
PAAD	cis	1	rs2246833	chr10:91005854	LIPA	chr10:90973328-91174382:-	0.25	4.25	3.76E-5	Fibrinogen levels	
PAAD	cis	1	rs2246942	chr10:91004886	LIPA	chr10:90973328-91174382:-	0.26	4.27	3.4E-5	Fibrinogen levels	
PAAD	cis	1	rs2248393	chr20:33926103	UQCC	chr20:33890383-33999833:-	-0.36	-4.27	3.47E-5	Height	
PAAD	cis	1	rs2250402	chr15:40322552	SRP14	chr15:40327891-40331389:-	-0.76	-5.31	3.79E-7	Corneal curvature	
PAAD	cis	1	rs2250644	chr10:91008879	LIPA	chr10:90973328-91174382:-	0.28	4.59	9.23E-6	Fibrinogen levels	
PAAD	cis	1	rs2251115	chr6:49446509	CENPQ	chr6:49431096-49460820:+	-0.59	-8.3	5.21E-14	Homocysteine levels	
PAAD	cis	1	rs2251844	chr15:43836478	ADAL	chr15:43622872-43646094:+	-0.68	-4.95	1.91E-6	Tumor biomarkers	
PAAD	cis	1	rs2253209	chr3:53115160	RFT1	chr3:53122503-53164470:-	-0.49	-5.63	8.27E-8	Height	
PAAD	cis	1	rs2253656	chr3:53119099	RFT1	chr3:53122503-53164470:-	-0.49	-5.63	8.27E-8	Height	
PAAD	cis	1	rs2253685	chr3:53119703	RFT1	chr3:53122503-53164470:-	-0.49	-5.63	8.27E-8	Height	
PAAD	cis	1	rs2253796	chr3:53120098	RFT1	chr3:53122503-53164470:-	-0.49	-5.63	8.27E-8	Height	
PAAD	cis	1	rs2254230	chr9:131905177	PPP2R4	chr9:131873244-131911223:+	-0.42	-4.29	3.17E-5	Blood metabolite ratios	
PAAD	cis	1	rs2255042	chr15:43834318	ADAL	chr15:43622872-43646094:+	0.71	5.33	3.46E-7	Tumor biomarkers	
PAAD	cis	1	rs2255051	chr15:43846161	ADAL	chr15:43622872-43646094:+	-0.68	-4.95	1.91E-6	Tumor biomarkers	
PAAD	cis	1	rs2255440	chr15:43830467	ADAL	chr15:43622872-43646094:+	-0.65	-4.7	5.85E-6	Tumor biomarkers	
PAAD	cis	1	rs2260160	chr15:43895643	ADAL	chr15:43622872-43646094:+	-0.65	-4.96	1.89E-6	Tumor biomarkers	
PAAD	cis	1	rs2262909	chr19:22135270	ZNF257	chr19:22235266-22273901:+	0.48	5.85	2.83E-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2268617	chr14:75608728	EIF2B2	chr14:75469612-75476292:+	0.36	4.09	7.0E-5	Height	
PAAD	cis	1	rs2269558	chr16:682250	WFIKKN1	chr16:679239-684116:+	0.37	4.98	1.72E-6	Height	
PAAD	cis	1	rs2272006	chr3:41997059	ULK4	chr3:41288091-42003660:-	-0.92	-8.85	2.05E-15	Diastolic blood pressure	
PAAD	cis	1	rs2272007	chr3:41996136	ULK4	chr3:41288091-42003660:-	-0.9	-8.67	5.69E-15	Diastolic blood pressure	
PAAD	cis	1	rs2273694	chr10:102256496	SEC31B	chr10:102246403-102289636:-	-0.36	-5.91	2.11E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2273695	chr10:102259568	SEC31B	chr10:102246403-102289636:-	-0.34	-5.71	5.73E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2273	chr4:76889388	NAAA	chr4:76831809-76862166:-	0.45	5.46	1.89E-7	Longevity	
PAAD	cis	1	rs2275247	chr1:35908451	C1orf216	chr1:36179477-36184790:-	-0.38	-4.04	8.45E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs2275426	chr1:46487552	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.99	1.46E-8	Body mass index	
PAAD	cis	1	rs2276547	chr2:28975107	TRMT61B	chr2:29072690-29093175:-	-0.5	-6.05	1.05E-8	Body mass index	
PAAD	cis	1	rs2277862	chr20:34152782	CPNE1	chr20:34213968-34262539:-	-0.78	-7.17	3.02E-11	Cholesterol, total	
PAAD	cis	1	rs2279077	chr3:48474249	TREX1	chr3:48501186-48509043:+	-0.36	-5.33	3.45E-7	Longevity	
PAAD	cis	1	rs2281006	chr1:171110869	FMO3	chr1:171060018-171086957:+	-0.49	-5.58	1.04E-7	Blood metabolite levels	
PAAD	cis	1	rs2281494	chr20:3235494	ITPA	chr20:3190056-3204504:+	-0.39	-5.55	1.24E-7	IFN-related cytopenia	
PAAD	cis	1	rs2281497	chr20:3258874	ITPA	chr20:3190056-3204504:+	-0.39	-5.66	7.17E-8	IFN-related cytopenia	
PAAD	cis	1	rs2281500	chr20:3262824	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs2281503	chr20:3263636	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs2283873	chr22:31013296	PIK3IP1	chr22:31677580-31688520:-	0.76	4.05	8.05E-5	Wilms tumor	
PAAD	cis	1	rs2286457	chr4:16017960	FAM200B	chr4:15683352-15692062:+	-0.59	-4.25	3.67E-5	Smooth-surface caries	
PAAD	cis	1	rs2286458	chr4:16017898	FAM200B	chr4:15683352-15692062:+	0.59	4.25	3.67E-5	Smooth-surface caries	
PAAD	cis	1	rs2286771	chr4:17643848	MED28	chr4:17616273-17629791:+	0.46	5.49	1.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2287679	chr19:33600764	GPATCH1	chr19:33571786-33621318:+	0.45	4.01	9.34E-5	Bone properties (heel)	
PAAD	cis	1	rs2287680	chr19:33608566	GPATCH1	chr19:33571786-33621318:+	-0.47	-4.27	3.44E-5	Bone properties (heel)	
PAAD	cis	1	rs2288073	chr2:24413298	C2orf84	chr2:24397531-24414566:+	-0.57	-6.46	1.3E-9	Venous thromboembolism (SNP x SNP interaction)	
PAAD	cis	1	rs2288344	chr15:56122347	PRTG	chr15:55903748-56035177:-	0.3	4.69	5.91E-6	Keloid	
PAAD	cis	1	rs2288871	chr19:41917868	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.79	3.95E-6	Height	
PAAD	cis	1	rs2289130	chr18:44626630	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs2289131	chr18:44602864	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs2289132	chr18:44602292	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs2289836	chr14:76640125	ESRRB	chr14:76837690-76968178:+	-0.49	-4	9.96E-5	Blood pressure	
PAAD	cis	1	rs2290822	chr3:48473204	TREX1	chr3:48501186-48509043:+	-0.35	-5.22	5.71E-7	Longevity	
PAAD	cis	1	rs2290911	chr2:224919	SH3YL1	chr2:218138-264810:-	-0.46	-7.45	6.36E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs2292239	chr12:56482180	RPS26	chr12:56435686-56438005:+	0.51	5.99	1.43E-8	Cognitive function	
PAAD	cis	1	rs2292986	chr19:21776332	ZNF429	chr19:21688437-21739068:+	-0.4	-4.57	1.01E-5	Colorectal or endometrial cancer	
PAAD	cis	1	rs2295770	chr10:102239829	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.62E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2295772	chr10:102265183	SEC31B	chr10:102246403-102289636:-	-0.35	-5.8	3.65E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2295773	chr10:102265815	SEC31B	chr10:102246403-102289636:-	-0.35	-5.8	3.65E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2295774	chr10:102265847	SEC31B	chr10:102246403-102289636:-	-0.36	-5.9	2.2E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2295776	chr10:102295629	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2295779	chr10:102296061	SEC31B	chr10:102246403-102289636:-	-0.34	-5.66	7.09E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2295780	chr10:102305965	SEC31B	chr10:102246403-102289636:-	-0.35	-5.6	9.7E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2296747	chr6:33744882	LEMD2	chr6:33738991-33756906:-	-0.3	-4.45	1.68E-5	Crohn's disease	
PAAD	cis	1	rs2296748	chr6:33745071	LEMD2	chr6:33738991-33756906:-	-0.31	-4.58	9.7E-6	Crohn's disease	
PAAD	cis	1	rs2297112	chr9:131900180	PPP2R4	chr9:131873244-131911223:+	0.43	4.33	2.72E-5	Blood metabolite ratios	
PAAD	cis	1	rs2298074	chr10:102247526	SEC31B	chr10:102246403-102289636:-	-0.35	-5.86	2.73E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2298075	chr10:102247408	SEC31B	chr10:102246403-102289636:-	-0.34	-5.77	4.35E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2300601	chr14:75639571	EIF2B2	chr14:75469612-75476292:+	0.38	4.23	4.05E-5	Height	
PAAD	cis	1	rs2300601	chr14:75639571	MLH3	chr14:75480467-75518235:-	0.34	4.07	7.53E-5	Height	
PAAD	cis	1	rs2301889	chr7:98931105	CYP3A5	chr7:99245818-99332821:-	0.59	5.54	1.32E-7	Blood metabolite levels	
PAAD	cis	1	rs2303129	chr5:78324482	BHMT2	chr5:78365583-78385273:+	0.18	4.36	2.4E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs2304242	chr19:41944616	B3GNT8	chr19:41931265-41934635:-	0.32	4.92	2.21E-6	Height	
PAAD	cis	1	rs2306937	chr1:113246506	ST7L	chr1:113066142-113162405:-	0.44	5.69	6.37E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs2306940	chr1:113241052	ST7L	chr1:113066142-113162405:-	0.45	5.92	2.06E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs2310997	chr3:48678011	CCDC36	chr3:49235861-49295537:+	-0.49	-4.13	5.95E-5	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
PAAD	cis	1	rs2315556	chr4:17670861	MED28	chr4:17616273-17629791:+	0.45	5.21	6.11E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2315560	chr4:17677305	MED28	chr4:17616273-17629791:+	0.45	5.21	6.11E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2315561	chr4:17679695	MED28	chr4:17616273-17629791:+	0.45	5.18	6.83E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2324843	chr6:86617501	SNHG5	chr6:86386726-86388451:-	-0.88	-11.9	1.55E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs2326680	chr20:5942955	MCM8	chr20:5931298-5975829:+	-0.48	-5.47	1.79E-7	HIV-1 viral setpoint	
PAAD	cis	1	rs2336723	chr3:53106047	RFT1	chr3:53122503-53164470:-	-0.45	-5.09	1.03E-6	Height	
PAAD	cis	1	rs2338555	chr1:152309380	FLG	chr1:152274651-152297679:-	0.5	5.4	2.5E-7	Atopic dermatitis	
PAAD	cis	1	rs2338556	chr1:152309427	FLG	chr1:152274651-152297679:-	0.5	5.4	2.5E-7	Atopic dermatitis	
PAAD	cis	1	rs2344180	chr5:150267357	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs2344181	chr5:150262574	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs2345001	chr5:150266518	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs2351706	chr15:90384115	AP3S2	chr15:90373832-90456222:-	-0.82	-9.64	1.74E-17	Type 2 diabetes	
PAAD	cis	1	rs2351707	chr15:90384045	AP3S2	chr15:90373832-90456222:-	-0.83	-9.75	9.33E-18	Type 2 diabetes	
PAAD	cis	1	rs2356559	chr1:45981512	CCDC163P	chr1:45960581-45965646:-	-0.94	-12.8	5.99E-26	Homocysteine levels	
PAAD	cis	1	rs2356561	chr1:45980862	CCDC163P	chr1:45960581-45965646:-	-0.9	-12.01	8.04E-24	Homocysteine levels	
PAAD	cis	1	rs2358628	chr14:74631757	LIN52	chr14:74551656-74667117:+	-0.44	-7.65	2.08E-12	Common traits (Other)	
PAAD	cis	1	rs2358633	chr14:74647418	LIN52	chr14:74551656-74667117:+	-0.43	-7.66	2.01E-12	Common traits (Other)	
PAAD	cis	1	rs2359821	chr19:22208314	ZNF257	chr19:22235266-22273901:+	0.49	5.96	1.64E-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2360977	chr14:76654481	ESRRB	chr14:76837690-76968178:+	0.46	4.04	8.39E-5	Blood pressure	
PAAD	cis	1	rs236104	chr20:5958960	MCM8	chr20:5931298-5975829:+	-0.47	-5.38	2.74E-7	HIV-1 viral setpoint	
PAAD	cis	1	rs236121	chr20:5972594	MCM8	chr20:5931298-5975829:+	-0.47	-5.38	2.74E-7	HIV-1 viral setpoint	
PAAD	cis	1	rs2362450	chr3:48461313	TREX1	chr3:48501186-48509043:+	-0.33	-4.87	2.79E-6	Longevity	
PAAD	cis	1	rs2362452	chr3:48418214	TREX1	chr3:48501186-48509043:+	0.35	5.11	9.5E-7	Longevity	
PAAD	cis	1	rs2363286	chr7:1091625	ZFAND2A	chr7:1192544-1199855:-	-0.52	-4.54	1.13E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs2364143	chr5:78316227	BHMT2	chr5:78365583-78385273:+	0.19	4.52	1.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs2370578	chr3:134199612	ANAPC13	chr3:134196547-134204865:-	0.89	12.27	1.59E-24	Height	
PAAD	cis	1	rs2370641	chr3:134222161	ANAPC13	chr3:134196547-134204865:-	0.87	11.61	9.26E-23	Height	
PAAD	cis	1	rs2370642	chr3:134222136	ANAPC13	chr3:134196547-134204865:-	0.89	12.08	5.22E-24	Height	
PAAD	cis	1	rs2371244	chr7:143757611	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.06	1.17E-6	Obesity-related traits	
PAAD	cis	1	rs2371247	chr7:143764179	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.06	1.17E-6	Obesity-related traits	
PAAD	cis	1	rs2371248	chr7:143764189	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.17	7.31E-7	Obesity-related traits	
PAAD	cis	1	rs2371623	chr3:41761083	ULK4	chr3:41288091-42003660:-	0.83	7.26	1.79E-11	Diastolic blood pressure	
PAAD	cis	1	rs2371627	chr3:41839219	ULK4	chr3:41288091-42003660:-	0.85	7.98	3.25E-13	Diastolic blood pressure	
PAAD	cis	1	rs2373865	chr3:134291556	ANAPC13	chr3:134196547-134204865:-	-0.88	-11.62	9.09E-23	Height	
PAAD	cis	1	rs2391160	chr1:92992797	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs2393969	chr10:65140440	NRBF2	chr10:64893007-64914785:+	-0.36	-4.88	2.62E-6	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs2395400	chr6:33770076	LEMD2	chr6:33738991-33756906:-	0.35	4.27	3.42E-5	Body mass index	
PAAD	cis	1	rs2395449	chr6:33728755	LEMD2	chr6:33738991-33756906:-	-0.31	-4.58	9.57E-6	Crohn's disease	
PAAD	cis	1	rs2395909	chr7:107292663	COG5	chr7:106842189-107204959:-	-0.34	-4.25	3.67E-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers	
PAAD	cis	1	rs2404602	chr15:77030792	SCAPER	chr15:76640529-77197744:-	-0.26	-4.75	4.63E-6	Blood metabolite levels	
PAAD	cis	1	rs2404740	chr15:76852143	SCAPER	chr15:76640529-77197744:-	-0.25	-4.49	1.42E-5	Blood metabolite levels	
PAAD	cis	1	rs2404741	chr15:76851735	SCAPER	chr15:76640529-77197744:-	-0.25	-4.49	1.42E-5	Blood metabolite levels	
PAAD	cis	1	rs2417577	chr9:100701446	C9orf156	chr9:100666772-100684852:-	-0.34	-4.71	5.4E-6	Quantitative traits	
PAAD	cis	1	rs2425065	chr20:33926268	UQCC	chr20:33890383-33999833:-	-0.34	-4.04	8.31E-5	Height	
PAAD	cis	1	rs2425066	chr20:33927006	UQCC	chr20:33890383-33999833:-	-0.34	-4.04	8.31E-5	Height	
PAAD	cis	1	rs2432195	chr5:56120413	C5orf35	chr5:56205103-56213010:+	1.08	10.06	1.37E-18	Type 2 diabetes	
PAAD	cis	1	rs2447196	chr15:43893818	ADAL	chr15:43622872-43646094:+	0.71	5.39	2.61E-7	Tumor biomarkers	
PAAD	cis	1	rs2447208	chr15:43933895	ADAL	chr15:43622872-43646094:+	-0.71	-5.74	5.04E-8	Tumor biomarkers	
PAAD	cis	1	rs2447211	chr15:43936351	ADAL	chr15:43622872-43646094:+	-0.65	-5.01	1.46E-6	Tumor biomarkers	
PAAD	cis	1	rs2448704	chr6:49453672	CENPQ	chr6:49431096-49460820:+	0.57	7.88	5.82E-13	Homocysteine levels	
PAAD	cis	1	rs2448707	chr6:49446951	CENPQ	chr6:49431096-49460820:+	0.35	4.02	9.11E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs2448707	chr6:49446951	MUT	chr6:49398994-49431031:-	-0.3	-4.23	4.05E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs2458890	chr1:35745141	C1orf216	chr1:36179477-36184790:-	-0.39	-4	9.89E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs2462569	chr7:65474846	CCT6P1	chr7:65216092-65228661:+	-0.44	-4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs246454	chr5:96123264	ERAP1	chr5:96096515-96149837:-	-0.62	-8.75	3.7E-15	Ankylosing spondylitis	
PAAD	cis	1	rs2470134	chr15:43849886	ADAL	chr15:43622872-43646094:+	0.6	4.45	1.67E-5	Tumor biomarkers	
PAAD	cis	1	rs2470134	chr15:43849886	TUBGCP4	chr15:43663313-43698238:+	-0.42	-4	9.94E-5	Tumor biomarkers	
PAAD	cis	1	rs2471884	chr11:117010320	PCSK7	chr11:117075789-117102811:-	-0.38	-4.02	9.16E-5	Protein quantitative trait loci	
PAAD	cis	1	rs2479528	chr1:35757843	C1orf216	chr1:36179477-36184790:-	-0.39	-4	9.89E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs2486447	chr1:46545724	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.98	1.52E-8	Body mass index	
PAAD	cis	1	rs2489034	chr10:102319192	SEC31B	chr10:102246403-102289636:-	-0.32	-5.08	1.07E-6	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489035	chr10:102319395	SEC31B	chr10:102246403-102289636:-	-0.32	-5.08	1.07E-6	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489036	chr10:102319581	SEC31B	chr10:102246403-102289636:-	-0.32	-5.08	1.07E-6	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489037	chr10:102319918	SEC31B	chr10:102246403-102289636:-	0.35	5.65	7.52E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489039	chr10:102328036	SEC31B	chr10:102246403-102289636:-	-0.34	-5.6	9.79E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489040	chr10:102331298	SEC31B	chr10:102246403-102289636:-	-0.32	-5.42	2.27E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489043	chr10:102334327	SEC31B	chr10:102246403-102289636:-	-0.32	-5.37	2.93E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489045	chr10:102344754	SEC31B	chr10:102246403-102289636:-	-0.33	-5.45	1.98E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489046	chr10:102346282	SEC31B	chr10:102246403-102289636:-	-0.32	-5.35	3.15E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489047	chr10:102347028	SEC31B	chr10:102246403-102289636:-	-0.32	-5.24	5.13E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489048	chr10:102348497	SEC31B	chr10:102246403-102289636:-	-0.33	-5.43	2.13E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489049	chr10:102350732	SEC31B	chr10:102246403-102289636:-	-0.32	-5.35	3.15E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489050	chr10:102350898	SEC31B	chr10:102246403-102289636:-	-0.33	-5.45	1.98E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489051	chr10:102351785	SEC31B	chr10:102246403-102289636:-	0.31	5.3	4.05E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2489053	chr10:102353341	SEC31B	chr10:102246403-102289636:-	-0.31	-4.95	1.94E-6	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495732	chr10:102357780	SEC31B	chr10:102246403-102289636:-	-0.34	-5.61	9.25E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495734	chr10:102338686	SEC31B	chr10:102246403-102289636:-	-0.33	-5.46	1.86E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495736	chr10:102338410	SEC31B	chr10:102246403-102289636:-	-0.33	-5.46	1.86E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495737	chr10:102338344	SEC31B	chr10:102246403-102289636:-	-0.32	-5.23	5.61E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495739	chr10:102335507	SEC31B	chr10:102246403-102289636:-	-0.32	-5.42	2.27E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495741	chr10:102331795	SEC31B	chr10:102246403-102289636:-	-0.33	-5.57	1.14E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495742	chr10:102331364	SEC31B	chr10:102246403-102289636:-	-0.33	-5.46	1.86E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495743	chr10:102329739	SEC31B	chr10:102246403-102289636:-	-0.35	-5.52	1.42E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495745	chr10:102329075	SEC31B	chr10:102246403-102289636:-	-0.34	-5.8	3.71E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495747	chr10:102328247	SEC31B	chr10:102246403-102289636:-	-0.34	-5.58	1.07E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495750	chr10:102327708	SEC31B	chr10:102246403-102289636:-	-0.34	-5.51	1.51E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495751	chr10:102327260	SEC31B	chr10:102246403-102289636:-	-0.34	-5.6	9.79E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495752	chr10:102326115	SEC31B	chr10:102246403-102289636:-	-0.34	-5.34	3.29E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495753	chr10:102325640	SEC31B	chr10:102246403-102289636:-	-0.35	-5.56	1.18E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495754	chr10:102324812	SEC31B	chr10:102246403-102289636:-	-0.34	-5.34	3.29E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495755	chr10:102324649	SEC31B	chr10:102246403-102289636:-	-0.35	-5.56	1.18E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495758	chr10:102321900	SEC31B	chr10:102246403-102289636:-	-0.35	-5.6	9.7E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495759	chr10:102320363	SEC31B	chr10:102246403-102289636:-	-0.31	-4.91	2.32E-6	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2495760	chr10:102318771	SEC31B	chr10:102246403-102289636:-	-0.34	-5.27	4.65E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs2501962	chr6:49453636	MUT	chr6:49398994-49431031:-	-0.3	-4.22	4.18E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs2501963	chr6:49454281	MUT	chr6:49398994-49431031:-	-0.3	-4.22	4.18E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs2502757	chr9:136586954	SARDH	chr9:136528686-136605077:-	-0.46	-5.81	3.59E-8	Asthma	
PAAD	cis	1	rs2524005	chr6:29899677	HCG4	chr6:29758809-29760850:-	-0.66	-6.36	2.19E-9	Bipolar disorder and schizophrenia	
PAAD	cis	1	rs2524005	chr6:29899677	ZFP57	chr6:29640171-29648887:-	0.81	6.7	3.78E-10	Bipolar disorder and schizophrenia	
PAAD	cis	1	rs2524276	chr6:31408265	ATP6V1G2	chr6:31512242-31514627:-	0.48	4.57	9.83E-6	Capecitabine sensitivity	
PAAD	cis	1	rs2524276	chr6:31408265	MICB	chr6:31462658-31478898:+	0.63	4.31	2.85E-5	Capecitabine sensitivity	
PAAD	cis	1	rs252887	chr5:56166188	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs252898	chr5:56188931	C5orf35	chr5:56205103-56213010:+	1.11	10.63	4.06E-20	Type 2 diabetes	
PAAD	cis	1	rs252902	chr5:56116085	C5orf35	chr5:56205103-56213010:+	1.06	10.17	6.93E-19	Type 2 diabetes	
PAAD	cis	1	rs252904	chr5:56118733	C5orf35	chr5:56205103-56213010:+	1.06	9.89	3.79E-18	Type 2 diabetes	
PAAD	cis	1	rs252909	chr5:56121131	C5orf35	chr5:56205103-56213010:+	1.08	10.09	1.16E-18	Type 2 diabetes	
PAAD	cis	1	rs252910	chr5:56192983	C5orf35	chr5:56205103-56213010:+	1.18	11.07	2.68E-21	Type 2 diabetes	
PAAD	cis	1	rs252915	chr5:56121754	C5orf35	chr5:56205103-56213010:+	-1.07	-9.87	4.32E-18	Type 2 diabetes	
PAAD	cis	1	rs252916	chr5:56121788	C5orf35	chr5:56205103-56213010:+	1.08	10.06	1.37E-18	Type 2 diabetes	
PAAD	cis	1	rs252919	chr5:56124111	C5orf35	chr5:56205103-56213010:+	1.08	10.09	1.16E-18	Type 2 diabetes	
PAAD	cis	1	rs252921	chr5:56137787	C5orf35	chr5:56205103-56213010:+	1.1	10.39	1.78E-19	Type 2 diabetes	
PAAD	cis	1	rs252922	chr5:56136343	C5orf35	chr5:56205103-56213010:+	1.1	10.39	1.78E-19	Type 2 diabetes	
PAAD	cis	1	rs2531152	chr4:16018534	FAM200B	chr4:15683352-15692062:+	-0.59	-4.25	3.67E-5	Smooth-surface caries	
PAAD	cis	1	rs2531154	chr4:16018324	FAM200B	chr4:15683352-15692062:+	-0.59	-4.25	3.67E-5	Smooth-surface caries	
PAAD	cis	1	rs2541161	chr9:131884802	PPP2R4	chr9:131873244-131911223:+	-0.5	-5.13	8.58E-7	Blood metabolite ratios	
PAAD	cis	1	rs2541164	chr9:131876908	PPP2R4	chr9:131873244-131911223:+	0.44	4.42	1.87E-5	Blood metabolite ratios	
PAAD	cis	1	rs2543376	chr14:76609923	ESRRB	chr14:76837690-76968178:+	0.46	4.15	5.51E-5	Blood pressure	
PAAD	cis	1	rs2543382	chr14:76624887	ESRRB	chr14:76837690-76968178:+	0.47	4.15	5.4E-5	Blood pressure	
PAAD	cis	1	rs2543383	chr14:76626703	ESRRB	chr14:76837690-76968178:+	0.47	4.15	5.4E-5	Blood pressure	
PAAD	cis	1	rs2543384	chr14:76627301	ESRRB	chr14:76837690-76968178:+	0.47	4.15	5.4E-5	Blood pressure	
PAAD	cis	1	rs2543387	chr14:76629046	ESRRB	chr14:76837690-76968178:+	0.47	4.15	5.4E-5	Blood pressure	
PAAD	cis	1	rs2548664	chr5:56133555	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs2548665	chr5:56131805	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs2564921	chr3:53125585	RFT1	chr3:53122503-53164470:-	0.45	5.27	4.58E-7	Height	
PAAD	cis	1	rs2564940	chr3:53107569	RFT1	chr3:53122503-53164470:-	-0.47	-5.37	2.91E-7	Height	
PAAD	cis	1	rs2569754	chr19:41936734	B3GNT8	chr19:41931265-41934635:-	-0.32	-4.91	2.29E-6	Height	
PAAD	cis	1	rs2581782	chr3:53122257	RFT1	chr3:53122503-53164470:-	-0.49	-5.69	6.25E-8	Height	
PAAD	cis	1	rs2581783	chr3:53122258	RFT1	chr3:53122503-53164470:-	-0.49	-5.69	6.25E-8	Height	
PAAD	cis	1	rs2581786	chr3:53126143	RFT1	chr3:53122503-53164470:-	-0.45	-5.27	4.58E-7	Height	
PAAD	cis	1	rs2581787	chr3:53127677	RFT1	chr3:53122503-53164470:-	-0.43	-4.91	2.33E-6	Height	
PAAD	cis	1	rs2581800	chr3:53109352	RFT1	chr3:53122503-53164470:-	-0.44	-4.95	1.92E-6	Height	
PAAD	cis	1	rs2591092	chr14:76630133	ESRRB	chr14:76837690-76968178:+	0.47	4.15	5.4E-5	Blood pressure	
PAAD	cis	1	rs2591094	chr14:76632335	ESRRB	chr14:76837690-76968178:+	0.47	4.15	5.4E-5	Blood pressure	
PAAD	cis	1	rs2614811	chr15:43913487	ADAL	chr15:43622872-43646094:+	-0.66	-4.92	2.17E-6	Tumor biomarkers	
PAAD	cis	1	rs2617170	chr12:10560957	KLRC2	chr12:10579193-10588592:-	-0.52	-5.37	2.84E-7	Behcet's disease	
PAAD	cis	1	rs2625667	chr3:41900951	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs2625668	chr3:41905930	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs2629540	chr10:126426148	METTL10	chr10:126447406-126480439:-	0.48	4.39	2.09E-5	Cocaine dependence	
PAAD	cis	1	rs26510	chr5:96125910	ERAP1	chr5:96096515-96149837:-	-0.62	-8.89	1.57E-15	Ankylosing spondylitis	
PAAD	cis	1	rs2655310	chr4:130017919	C4orf33	chr4:130014829-130033842:+	-0.53	-6.89	1.34E-10	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs2677780	chr4:16022540	FAM200B	chr4:15683352-15692062:+	0.59	4.25	3.67E-5	Smooth-surface caries	
PAAD	cis	1	rs2677786	chr4:16018920	FAM200B	chr4:15683352-15692062:+	-0.52	-4.1	6.8E-5	Smooth-surface caries	
PAAD	cis	1	rs2677787	chr4:16018623	FAM200B	chr4:15683352-15692062:+	-0.58	-4.27	3.36E-5	Smooth-surface caries	
PAAD	cis	1	rs2683695	chr3:41914928	ULK4	chr3:41288091-42003660:-	0.85	7.66	1.98E-12	Diastolic blood pressure	
PAAD	cis	1	rs2683696	chr3:41914898	ULK4	chr3:41288091-42003660:-	0.85	7.67	1.86E-12	Diastolic blood pressure	
PAAD	cis	1	rs2734839	chr11:113286490	TTC12	chr11:113185251-113244016:+	-0.38	-4.17	5.06E-5	Information processing speed	
PAAD	cis	1	rs27529	chr5:96126308	ERAP1	chr5:96096515-96149837:-	-0.62	-8.89	1.57E-15	Ankylosing spondylitis	
PAAD	cis	1	rs27710	chr5:96126197	ERAP1	chr5:96096515-96149837:-	0.56	7.9	4.97E-13	Ankylosing spondylitis	
PAAD	cis	1	rs2794521	chr1:159685096	CADM3	chr1:159141377-159172932:+	-0.31	-4.05	8.15E-5	C-reactive protein	
PAAD	cis	1	rs2799079	chr6:28235176	HIST1H4J	chr6:27791903-27792257:+	-0.43	-4	9.83E-5	Depression	
PAAD	cis	1	rs2799079	chr6:28235176	ZSCAN23	chr6:28393287-28411279:-	0.41	4.22	4.12E-5	Depression	
PAAD	cis	1	rs280603	chr4:129915063	C4orf33	chr4:130014829-130033842:+	-0.49	-6.13	7.17E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs280604	chr4:129921170	C4orf33	chr4:130014829-130033842:+	-0.5	-6.27	3.59E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs2806561	chr1:23504795	HTR1D	chr1:23518389-23521222:-	0.38	4	0.0001	Height	
PAAD	cis	1	rs2808630	chr1:159680868	CADM3	chr1:159141377-159172932:+	-0.31	-4.14	5.79E-5	C-reactive protein	
PAAD	cis	1	rs2808632	chr1:159687373	CADM3	chr1:159141377-159172932:+	-0.31	-4.05	8.15E-5	C-reactive protein	
PAAD	cis	1	rs2808633	chr1:159688475	CADM3	chr1:159141377-159172932:+	-0.31	-4.05	8.15E-5	C-reactive protein	
PAAD	cis	1	rs2812972	chr6:86669880	SNHG5	chr6:86386726-86388451:-	-0.86	-12.07	5.3E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs2816815	chr6:86691656	SNHG5	chr6:86386726-86388451:-	-0.86	-11.77	3.44E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs2816821	chr6:86657084	SNHG5	chr6:86386726-86388451:-	-0.87	-12.26	1.72E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs2832183	chr21:30482150	NCRNA00189	chr21:30565801-30660525:+	0.48	5.15	7.88E-7	Dental caries	
PAAD	cis	1	rs2832184	chr21:30483265	NCRNA00189	chr21:30565801-30660525:+	0.47	5.16	7.55E-7	Dental caries	
PAAD	cis	1	rs2832185	chr21:30483761	NCRNA00189	chr21:30565801-30660525:+	0.47	5.16	7.55E-7	Dental caries	
PAAD	cis	1	rs2832189	chr21:30487414	NCRNA00189	chr21:30565801-30660525:+	0.47	5.16	7.45E-7	Dental caries	
PAAD	cis	1	rs2832190	chr21:30488226	NCRNA00189	chr21:30565801-30660525:+	0.47	5.2	6.24E-7	Dental caries	
PAAD	cis	1	rs2832191	chr21:30489300	NCRNA00189	chr21:30565801-30660525:+	0.48	5.22	5.83E-7	Dental caries	
PAAD	cis	1	rs2835607	chr21:38491973	PIGP	chr21:38437664-38445458:-	-0.49	-6.23	4.35E-9	Eye color traits	
PAAD	cis	1	rs2835608	chr21:38493455	PIGP	chr21:38437664-38445458:-	-0.49	-6.23	4.35E-9	Eye color traits	
PAAD	cis	1	rs28365850	chr14:35591316	PPP2R3C	chr14:35554679-35591679:-	0.56	5.74	4.83E-8	Atopic dermatitis	
PAAD	cis	1	rs28379681	chr7:1070539	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs2839181	chr21:47685939	C21orf57	chr21:47706267-47717664:+	-0.47	-6.82	1.96E-10	Testicular germ cell tumor	
PAAD	cis	1	rs2839186	chr21:47690068	C21orf57	chr21:47706267-47717664:+	-0.49	-7.11	4.06E-11	Testicular germ cell tumor	
PAAD	cis	1	rs28399702	chr14:35625217	PPP2R3C	chr14:35554679-35591679:-	0.44	4.78	4.15E-6	Atopic dermatitis	
PAAD	cis	1	rs28399710	chr7:1070631	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.34	2.54E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs2840331	chr1:21861656	ALPL	chr1:21835858-21904904:+	0.43	5.01	1.5E-6	Response to TNF-alpha inhibitors in rheumatoid arthritis	
PAAD	cis	1	rs28409322	chr3:134252385	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.87	1.92E-23	Height	
PAAD	cis	1	rs284648	chr19:41926790	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.89	2.49E-6	Height	
PAAD	cis	1	rs284649	chr19:41926838	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.89	2.49E-6	Height	
PAAD	cis	1	rs284650	chr19:41927129	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.89	2.49E-6	Height	
PAAD	cis	1	rs284651	chr19:41928336	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.87	2.76E-6	Height	
PAAD	cis	1	rs284652	chr19:41928652	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.89	2.49E-6	Height	
PAAD	cis	1	rs284654	chr19:41928724	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.9	2.43E-6	Height	
PAAD	cis	1	rs284655	chr19:41928765	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.89	2.49E-6	Height	
PAAD	cis	1	rs284656	chr19:41929251	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.89	2.49E-6	Height	
PAAD	cis	1	rs284657	chr19:41929915	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.96	1.83E-6	Height	
PAAD	cis	1	rs284658	chr19:41929988	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.96	1.83E-6	Height	
PAAD	cis	1	rs284663	chr19:41932612	B3GNT8	chr19:41931265-41934635:-	-0.33	-5.14	8.32E-7	Height	
PAAD	cis	1	rs28468623	chr7:98922812	CYP3A5	chr7:99245818-99332821:-	0.6	5.7	6.09E-8	Blood metabolite levels	
PAAD	cis	1	rs28480159	chr4:17685707	MED28	chr4:17616273-17629791:+	0.46	5.45	1.98E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs28485881	chr17:80690014	FN3KRP	chr17:80674582-80685889:+	-0.46	-4.39	2.07E-5	Glycated hemoglobin levels	
PAAD	cis	1	rs28497813	chr4:17685503	MED28	chr4:17616273-17629791:+	0.46	5.45	1.98E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs28501187	chr4:17643620	MED28	chr4:17616273-17629791:+	0.45	5.36	2.96E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs28517362	chr6:151876387	C6orf97	chr6:151815175-151942327:+	0.47	4.11	6.43E-5	Bone mineral density (spine)	
PAAD	cis	1	rs28528096	chr7:1070912	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs28545485	chr4:17645376	MED28	chr4:17616273-17629791:+	0.46	5.49	1.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs28552744	chr4:17620165	MED28	chr4:17616273-17629791:+	0.48	5.77	4.25E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs28626045	chr14:75589195	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs2862961	chr11:43656535	HSD17B12	chr11:43702143-43878160:+	0.43	5.83	3.14E-8	Forced vital capacity	
PAAD	cis	1	rs2862963	chr11:43640115	HSD17B12	chr11:43702143-43878160:+	0.43	5.83	3.14E-8	Forced vital capacity	
PAAD	cis	1	rs2862996	chr11:43653833	HSD17B12	chr11:43702143-43878160:+	-0.43	-5.83	3.14E-8	Forced vital capacity	
PAAD	cis	1	rs28660477	chr15:56145267	PRTG	chr15:55903748-56035177:-	0.32	5.06	1.18E-6	Keloid	
PAAD	cis	1	rs28693609	chr4:17645233	MED28	chr4:17616273-17629791:+	0.45	5.4	2.44E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs28702390	chr3:41889920	ULK4	chr3:41288091-42003660:-	0.85	7.51	4.7E-12	Diastolic blood pressure	
PAAD	cis	1	rs2872958	chr4:17665032	MED28	chr4:17616273-17629791:+	0.45	5.28	4.33E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs2872959	chr4:17677163	MED28	chr4:17616273-17629791:+	-0.39	-4.43	1.82E-5	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs28733681	chr3:41863444	ULK4	chr3:41288091-42003660:-	0.86	8.03	2.38E-13	Diastolic blood pressure	
PAAD	cis	1	rs28755797	chr3:41774446	ULK4	chr3:41288091-42003660:-	0.84	7.1	4.31E-11	Diastolic blood pressure	
PAAD	cis	1	rs2880791	chr5:150267376	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs28824259	chr3:48425675	TREX1	chr3:48501186-48509043:+	-0.39	-5.64	7.81E-8	Longevity	
PAAD	cis	1	rs2885510	chr3:48418226	TREX1	chr3:48501186-48509043:+	0.36	5.23	5.39E-7	Longevity	
PAAD	cis	1	rs2887797	chr3:134202506	ANAPC13	chr3:134196547-134204865:-	0.9	12.22	2.1E-24	Height	
PAAD	cis	1	rs2896954	chr15:76851692	SCAPER	chr15:76640529-77197744:-	-0.25	-4.49	1.42E-5	Blood metabolite levels	
PAAD	cis	1	rs2920781	chr15:43924682	ADAL	chr15:43622872-43646094:+	-0.68	-5.26	4.86E-7	Tumor biomarkers	
PAAD	cis	1	rs2924584	chr4:99988208	ADH4	chr4:100044835-100065449:-	-0.35	-4.11	6.55E-5	HDL cholesterol	
PAAD	cis	1	rs2927072	chr15:43922398	ADAL	chr15:43622872-43646094:+	-0.65	-5.01	1.46E-6	Tumor biomarkers	
PAAD	cis	1	rs2935183	chr17:45607572	C17orf57	chr17:45401142-45518675:+	-0.44	-5.15	7.98E-7	Multiple sclerosis or amyotrophic lateral sclerosis	
PAAD	cis	1	rs2945232	chr8:8098038	FLJ10661	chr8:8086092-8102386:+	0.41	4.99	1.6E-6	Schizophrenia	
PAAD	cis	1	rs2951308	chr7:143767149	ARHGEF35	chr7:143883677-143892736:-	0.39	5.17	7.31E-7	Obesity-related traits	
PAAD	cis	1	rs2951353	chr7:143761116	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.06	1.17E-6	Obesity-related traits	
PAAD	cis	1	rs2951354	chr7:143761001	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.17	7.31E-7	Obesity-related traits	
PAAD	cis	1	rs2951360	chr7:143757349	ARHGEF35	chr7:143883677-143892736:-	-0.4	-5.35	3.19E-7	Obesity-related traits	
PAAD	cis	1	rs2951363	chr7:143754724	ARHGEF35	chr7:143883677-143892736:-	-0.38	-4.98	1.67E-6	Obesity-related traits	
PAAD	cis	1	rs2951364	chr7:143754483	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.07	1.14E-6	Obesity-related traits	
PAAD	cis	1	rs2951368	chr7:143752821	ARHGEF35	chr7:143883677-143892736:-	-0.38	-5.01	1.51E-6	Obesity-related traits	
PAAD	cis	1	rs2951369	chr7:143752638	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.1	1.01E-6	Obesity-related traits	
PAAD	cis	1	rs2951372	chr7:143749503	ARHGEF35	chr7:143883677-143892736:-	-0.38	-5.01	1.51E-6	Obesity-related traits	
PAAD	cis	1	rs2961102	chr7:65424658	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs2961115	chr7:143753371	ARHGEF35	chr7:143883677-143892736:-	-0.38	-5.01	1.51E-6	Obesity-related traits	
PAAD	cis	1	rs2961117	chr7:143755253	ARHGEF35	chr7:143883677-143892736:-	-0.42	-5.48	1.72E-7	Obesity-related traits	
PAAD	cis	1	rs2961118	chr7:143755443	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.06	1.17E-6	Obesity-related traits	
PAAD	cis	1	rs2961119	chr7:143755852	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.17	7.31E-7	Obesity-related traits	
PAAD	cis	1	rs2961120	chr7:143756585	ARHGEF35	chr7:143883677-143892736:-	-0.4	-5.35	3.19E-7	Obesity-related traits	
PAAD	cis	1	rs2961125	chr7:143761770	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.17	7.31E-7	Obesity-related traits	
PAAD	cis	1	rs2961126	chr7:143762736	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.17	7.31E-7	Obesity-related traits	
PAAD	cis	1	rs2961128	chr7:143763483	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.17	7.31E-7	Obesity-related traits	
PAAD	cis	1	rs2961132	chr7:143768128	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.16	7.65E-7	Obesity-related traits	
PAAD	cis	1	rs2961134	chr7:143771062	ARHGEF35	chr7:143883677-143892736:-	-0.42	-5.77	4.33E-8	Obesity-related traits	
PAAD	cis	1	rs2961144	chr7:143747870	ARHGEF35	chr7:143883677-143892736:-	0.4	5.2	6.31E-7	Obesity-related traits	
PAAD	cis	1	rs2985697	chr14:50092902	RPL36AL	chr14:50085407-50087349:-	0.34	4	9.75E-5	Carotid intima media thickness	
PAAD	cis	1	rs2993259	chr1:46001550	CCDC163P	chr1:45960581-45965646:-	-0.95	-13.18	5.44E-27	Homocysteine levels	
PAAD	cis	1	rs30187	chr5:96124330	ERAP1	chr5:96096515-96149837:-	-0.62	-8.75	3.7E-15	Ankylosing spondylitis	
PAAD	cis	1	rs302660	chr11:87885448	RAB38	chr11:87846431-87908599:-	0.36	4.16	5.19E-5	Frontotemporal dementia	
PAAD	cis	1	rs302662	chr11:87881236	RAB38	chr11:87846431-87908599:-	0.36	4.19	4.73E-5	Frontotemporal dementia	
PAAD	cis	1	rs302663	chr11:87880759	RAB38	chr11:87846431-87908599:-	0.36	4.19	4.73E-5	Frontotemporal dementia	
PAAD	cis	1	rs302668	chr11:87876911	RAB38	chr11:87846431-87908599:-	0.36	4.19	4.73E-5	Frontotemporal dementia	
PAAD	cis	1	rs30378	chr5:96121994	ERAP1	chr5:96096515-96149837:-	-0.62	-8.75	3.7E-15	Ankylosing spondylitis	
PAAD	cis	1	rs30379	chr5:96122260	ERAP1	chr5:96096515-96149837:-	-0.62	-8.75	3.7E-15	Ankylosing spondylitis	
PAAD	cis	1	rs30380	chr5:96122281	ERAP1	chr5:96096515-96149837:-	-0.62	-8.75	3.7E-15	Ankylosing spondylitis	
PAAD	cis	1	rs3091242	chr1:25674785	RHCE	chr1:25688741-25756683:-	0.54	6.41	1.75E-9	Erythrocyte sedimentation rate	
PAAD	cis	1	rs3091242	chr1:25674785	RHD	chr1:25598981-25656935:+	-0.64	-6.67	4.34E-10	Erythrocyte sedimentation rate	
PAAD	cis	1	rs3099459	chr5:56137170	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs3099899	chr4:129917368	C4orf33	chr4:130014829-130033842:+	-0.5	-6.27	3.59E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs310124	chr1:153020275	SPRR1A	chr1:152956557-152958289:+	0.43	4.9	2.42E-6	Inflammatory skin disease	
PAAD	cis	1	rs3101443	chr15:43912372	ADAL	chr15:43622872-43646094:+	-0.67	-5.09	1.06E-6	Tumor biomarkers	
PAAD	cis	1	rs3105369	chr4:130022448	C4orf33	chr4:130014829-130033842:+	-0.54	-7.09	4.75E-11	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs3113489	chr4:129961179	C4orf33	chr4:130014829-130033842:+	-0.5	-6.23	4.41E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs3118632	chr9:131901284	PPP2R4	chr9:131873244-131911223:+	-0.49	-5	1.57E-6	Blood metabolite ratios	
PAAD	cis	1	rs3120662	chr1:152302865	FLG	chr1:152274651-152297679:-	0.5	5.4	2.5E-7	Atopic dermatitis	
PAAD	cis	1	rs3124510	chr9:131899690	CRAT	chr9:131857075-131873070:-	-0.36	-4.1	6.79E-5	Blood metabolite ratios	
PAAD	cis	1	rs3124510	chr9:131899690	PPP2R4	chr9:131873244-131911223:+	-0.53	-5.44	2.1E-7	Blood metabolite ratios	
PAAD	cis	1	rs3124511	chr9:131901458	PPP2R4	chr9:131873244-131911223:+	-0.42	-4.29	3.17E-5	Blood metabolite ratios	
PAAD	cis	1	rs3124513	chr9:131904593	PPP2R4	chr9:131873244-131911223:+	-0.5	-5.05	1.22E-6	Blood metabolite ratios	
PAAD	cis	1	rs3124514	chr9:131904608	PPP2R4	chr9:131873244-131911223:+	-0.5	-5.05	1.22E-6	Blood metabolite ratios	
PAAD	cis	1	rs3126085	chr1:152300817	FLG	chr1:152274651-152297679:-	0.5	5.4	2.5E-7	Atopic dermatitis	
PAAD	cis	1	rs3126092	chr1:152307955	FLG	chr1:152274651-152297679:-	0.49	5.39	2.56E-7	Atopic dermatitis	
PAAD	cis	1	rs3126095	chr1:152309683	FLG	chr1:152274651-152297679:-	0.49	5.39	2.56E-7	Atopic dermatitis	
PAAD	cis	1	rs3126098	chr1:152311923	FLG	chr1:152274651-152297679:-	0.49	5.21	5.88E-7	Atopic dermatitis	
PAAD	cis	1	rs313798	chr7:65493031	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs313799	chr7:65494330	CCT6P1	chr7:65216092-65228661:+	0.44	4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs313802	chr7:65516373	CCT6P1	chr7:65216092-65228661:+	0.43	4.13	5.87E-5	Diabetic kidney disease	
PAAD	cis	1	rs313803	chr7:65514731	CCT6P1	chr7:65216092-65228661:+	0.43	4.13	5.87E-5	Diabetic kidney disease	
PAAD	cis	1	rs313807	chr7:65499481	CCT6P1	chr7:65216092-65228661:+	0.44	4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs313809	chr7:65499983	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs313813	chr7:65503500	CCT6P1	chr7:65216092-65228661:+	0.44	4.32	2.84E-5	Diabetic kidney disease	
PAAD	cis	1	rs313814	chr7:65503293	CCT6P1	chr7:65216092-65228661:+	0.43	4.13	5.87E-5	Diabetic kidney disease	
PAAD	cis	1	rs316330	chr7:65605372	CCT6P1	chr7:65216092-65228661:+	0.42	4.17	4.99E-5	Diabetic kidney disease	
PAAD	cis	1	rs3183928	chr9:100684719	C9orf156	chr9:100666772-100684852:-	-0.35	-4.77	4.3E-6	Quantitative traits	
PAAD	cis	1	rs3204270	chr17:79682051	ARL16	chr17:79648234-79650954:-	-0.68	-5.45	1.98E-7	Dental caries	
PAAD	cis	1	rs3213762	chr17:38178627	GSDMA	chr17:38119226-38134019:+	-0.57	-6.3	2.99E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs3213861	chr19:41919944	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.72	5.24E-6	Height	
PAAD	cis	1	rs3214041	chr3:48454468	TREX1	chr3:48501186-48509043:+	-0.38	-5.45	1.93E-7	Longevity	
PAAD	cis	1	rs321622	chr4:48024380	CNGA1	chr4:47937996-48018610:-	0.46	5.26	4.8E-7	Renal underexcretion gout;Gout	
PAAD	cis	1	rs321622	chr4:48024380	NIPAL1	chr4:48018791-48039078:+	0.4	7	7.57E-11	Renal underexcretion gout;Gout	
PAAD	cis	1	rs3310	chr20:3237232	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs331463	chr11:36501787	C11orf74	chr11:36616066-36696390:+	0.4	4	9.66E-5	Rheumatoid arthritis	
PAAD	cis	1	rs33322	chr5:56175226	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs33325	chr5:56142547	C5orf35	chr5:56205103-56213010:+	1.1	10.39	1.78E-19	Type 2 diabetes	
PAAD	cis	1	rs33326	chr5:56142601	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs33988592	chr3:121415610	IQCB1	chr3:121488610-121553926:-	0.57	5.99	1.46E-8	Cognitive performance	
PAAD	cis	1	rs34055941	chr9:131895076	PPP2R4	chr9:131873244-131911223:+	0.49	5.04	1.29E-6	Blood metabolite ratios	
PAAD	cis	1	rs34086988	chr3:121352745	IQCB1	chr3:121488610-121553926:-	0.55	5.58	1.06E-7	Cognitive performance	
PAAD	cis	1	rs34088794	chr15:40665420	C15orf23	chr15:40674922-40686488:+	0.76	8.95	1.09E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs34102169	chr1:46424864	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.98	1.5E-8	Body mass index	
PAAD	cis	1	rs34106666	chr6:86676258	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs34136756	chr7:65381256	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs34156253	chr5:150226230	LOC134466	chr5:150310000-150326146:-	0.68	5.71	5.76E-8	Crohn's disease	
PAAD	cis	1	rs34193460	chr7:65393110	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs34281561	chr6:86701872	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs34292685	chr11:64049021	C11orf20	chr11:64067863-64072238:+	-0.53	-4.1	6.74E-5	Mean platelet volume	
PAAD	cis	1	rs34344888	chr14:23387585	HAUS4	chr14:23415438-23426335:-	-0.43	-4.83	3.29E-6	Educational attainment (years of education)	
PAAD	cis	1	rs34409160	chr2:28943865	TRMT61B	chr2:29072690-29093175:-	0.5	6.13	7.01E-9	Body mass index	
PAAD	cis	1	rs34428306	chr1:152184316	FLG	chr1:152274651-152297679:-	0.4	5.01	1.46E-6	Inflammatory skin disease	
PAAD	cis	1	rs34428306	chr1:152184316	HRNR	chr1:152184558-152196669:-	-0.55	-6.51	9.96E-10	Inflammatory skin disease	
PAAD	cis	1	rs34453673	chr5:434722	EXOC3	chr5:443334-467407:+	-0.36	-4.05	8.17E-5	Cystic fibrosis severity	
PAAD	cis	1	rs34529418	chr7:65403209	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs34530577	chr3:53103796	RFT1	chr3:53122503-53164470:-	-0.46	-5.26	4.72E-7	Height	
PAAD	cis	1	rs34560516	chr7:65404092	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs34570071	chr15:85280212	LOC388152	chr15:84867600-84898920:-	-0.34	-4.1	6.57E-5	Schizophrenia	
PAAD	cis	1	rs34577383	chr7:65385726	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs34581302	chr6:86705948	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs34622557	chr6:86630852	SNHG5	chr6:86386726-86388451:-	-0.84	-11.44	2.8E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs34637256	chr7:65360131	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs34638686	chr3:48682658	CCDC36	chr3:49235861-49295537:+	-0.5	-4.14	5.66E-5	Educational attainment (years of education)	
PAAD	cis	1	rs34702770	chr7:65344823	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs34703416	chr7:65300642	CCT6P1	chr7:65216092-65228661:+	0.44	4.31	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs34751999	chr15:84758419	LOC388152	chr15:84867600-84898920:-	-0.35	-4.2	4.54E-5	Schizophrenia	
PAAD	cis	1	rs34812189	chr6:56806727	BEND6	chr6:56819773-56892138:+	-0.42	-5.09	1.05E-6	Menarche (age at onset)	
PAAD	cis	1	rs34815098	chr7:65292254	CCT6P1	chr7:65216092-65228661:+	0.45	4.38	2.23E-5	Diabetic kidney disease	
PAAD	cis	1	rs34847072	chr5:437862	EXOC3	chr5:443334-467407:+	-0.36	-4.05	8.17E-5	Cystic fibrosis severity	
PAAD	cis	1	rs34848593	chr1:113240106	ST7L	chr1:113066142-113162405:-	0.45	5.92	2.06E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs34852683	chr6:86702330	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs34900908	chr15:85257599	LOC388152	chr15:84867600-84898920:-	-0.35	-4.25	3.75E-5	Schizophrenia	
PAAD	cis	1	rs34933526	chr7:65383199	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs34970380	chr7:65431493	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs34974928	chr7:65364006	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs35006492	chr4:129878342	C4orf33	chr4:130014829-130033842:+	0.51	6.08	9.14E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs35025342	chr6:151876661	C6orf97	chr6:151815175-151942327:+	0.47	4.11	6.43E-5	Bone mineral density (spine)	
PAAD	cis	1	rs35046236	chr7:65408613	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs35058610	chr7:65390925	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs35060985	chr11:43693110	HSD17B12	chr11:43702143-43878160:+	-0.43	-5.89	2.34E-8	Forced vital capacity	
PAAD	cis	1	rs35099099	chr6:39284857	KCNK17	chr6:39266778-39282237:-	0.24	4.54	1.14E-5	Type 2 diabetes	
PAAD	cis	1	rs35106985	chr10:102307542	SEC31B	chr10:102246403-102289636:-	-0.34	-5.4	2.54E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs35146655	chr22:24605938	SUSD2	chr22:24577444-24585074:+	0.68	5.56	1.18E-7	Amyotrophic lateral sclerosis	
PAAD	cis	1	rs35202312	chr6:56788937	BEND6	chr6:56819773-56892138:+	-0.41	-5.41	2.36E-7	Menarche (age at onset)	
PAAD	cis	1	rs35283677	chr7:65359233	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs35297609	chr15:84772896	LOC388152	chr15:84867600-84898920:-	-0.35	-4.2	4.54E-5	Schizophrenia	
PAAD	cis	1	rs35316992	chr15:85248133	LOC388152	chr15:84867600-84898920:-	-0.35	-4.25	3.75E-5	Schizophrenia	
PAAD	cis	1	rs35385043	chr6:86648546	SNHG5	chr6:86386726-86388451:-	-0.87	-12.29	1.4E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs35391607	chr7:65360829	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs35396113	chr7:65495461	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs35419329	chr6:86702291	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs35421653	chr7:65363429	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs35432774	chr7:65393019	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs35435780	chr17:79579602	TSPAN10	chr17:79609349-79615778:+	0.74	9.99	2.09E-18	Eye color traits	
PAAD	cis	1	rs35468353	chr16:31056433	MYST1	chr16:31128985-31142713:+	0.36	4.95	1.9E-6	Response to metformin (IC50)	
PAAD	cis	1	rs35524990	chr15:85258203	LOC388152	chr15:84867600-84898920:-	-0.35	-4.25	3.75E-5	Schizophrenia	
PAAD	cis	1	rs35527216	chr6:56791278	BEND6	chr6:56819773-56892138:+	-0.42	-5.32	3.63E-7	Menarche (age at onset)	
PAAD	cis	1	rs35542501	chr7:65431215	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs35648189	chr15:84740748	LOC388152	chr15:84867600-84898920:-	-0.35	-4.2	4.54E-5	Schizophrenia	
PAAD	cis	1	rs35658069	chr15:84780146	LOC388152	chr15:84867600-84898920:-	-0.35	-4.19	4.68E-5	Schizophrenia	
PAAD	cis	1	rs35718987	chr3:134272783	ANAPC13	chr3:134196547-134204865:-	-0.88	-12	8.57E-24	Height	
PAAD	cis	1	rs35735127	chr7:65300423	CCT6P1	chr7:65216092-65228661:+	0.45	4.37	2.25E-5	Diabetic kidney disease	
PAAD	cis	1	rs35760725	chr6:86648985	SNHG5	chr6:86386726-86388451:-	-0.87	-12.29	1.4E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs35761942	chr6:86629504	SNHG5	chr6:86386726-86388451:-	-0.87	-11.99	9.11E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs35797755	chr6:86706554	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs35820085	chr7:65442758	CCT6P1	chr7:65216092-65228661:+	0.42	4.09	7.03E-5	Diabetic kidney disease	
PAAD	cis	1	rs35825738	chr7:65318027	CCT6P1	chr7:65216092-65228661:+	0.45	4.46	1.58E-5	Diabetic kidney disease	
PAAD	cis	1	rs35835884	chr10:127708468	UROS	chr10:127477148-127511837:-	-0.33	-4.15	5.49E-5	Visceral fat	
PAAD	cis	1	rs35934224	chr22:19872645	TXNRD2	chr22:19863040-19929359:-	-0.45	-4.62	8.04E-6	Glaucoma (primary open-angle)	
PAAD	cis	1	rs35988617	chr3:121432902	IQCB1	chr3:121488610-121553926:-	0.57	5.99	1.46E-8	Cognitive performance	
PAAD	cis	1	rs36033484	chr7:65390558	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs36033486	chr15:85319692	LOC388152	chr15:84867600-84898920:-	-0.34	-4	9.86E-5	Schizophrenia	
PAAD	cis	1	rs36068983	chr7:65408991	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs36096931	chr6:86693134	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs36216559	chr2:262335	SH3YL1	chr2:218138-264810:-	-0.47	-7.75	1.2E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs3732276	chr2:242343404	SEPT2	chr2:242254723-242293439:+	0.63	6.41	1.67E-9	Chronic lymphocytic leukemia	
PAAD	cis	1	rs3732408	chr3:121421179	IQCB1	chr3:121488610-121553926:-	0.57	5.99	1.46E-8	Cognitive performance	
PAAD	cis	1	rs3733579	chr4:17694943	MED28	chr4:17616273-17629791:+	0.42	4.85	3.02E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs3734618	chr6:39284184	KCNK17	chr6:39266778-39282237:-	0.25	4.7	5.85E-6	Type 2 diabetes	
PAAD	cis	1	rs3738814	chr1:17331676	ATP13A2	chr1:17312453-17338423:-	-0.32	-4.14	5.8E-5	Height	
PAAD	cis	1	rs3739843	chr9:131882961	PPP2R4	chr9:131873244-131911223:+	0.44	4.41	1.9E-5	Blood metabolite ratios	
PAAD	cis	1	rs3739847	chr9:131911574	PPP2R4	chr9:131873244-131911223:+	-0.5	-5.05	1.22E-6	Blood metabolite ratios	
PAAD	cis	1	rs3742500	chr14:24611978	FAM158A	chr14:24608175-24610797:-	-0.37	-6.12	7.43E-9	IgG glycosylation	
PAAD	cis	1	rs3742773	chr14:75579643	EIF2B2	chr14:75469612-75476292:+	0.36	4.09	7.0E-5	Height	
PAAD	cis	1	rs3742778	chr14:75538217	EIF2B2	chr14:75469612-75476292:+	-0.37	-4.16	5.28E-5	Height	
PAAD	cis	1	rs3745937	chr19:42071289	CEACAM21	chr19:42055886-42093196:+	0.55	8.07	1.95E-13	Schizophrenia	
PAAD	cis	1	rs3748656	chr1:113236681	ST7L	chr1:113066142-113162405:-	0.45	5.92	2.06E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs3750626	chr10:102266316	SEC31B	chr10:102246403-102289636:-	-0.35	-5.8	3.65E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs3750627	chr10:102275642	SEC31B	chr10:102246403-102289636:-	-0.35	-5.8	3.65E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs3750629	chr10:102275727	SEC31B	chr10:102246403-102289636:-	-0.35	-5.8	3.65E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs3750630	chr10:102275780	SEC31B	chr10:102246403-102289636:-	-0.35	-5.75	4.74E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs3750633	chr10:102308214	SEC31B	chr10:102246403-102289636:-	-0.35	-5.6	9.7E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs3750719	chr10:102248950	SEC31B	chr10:102246403-102289636:-	-0.35	-5.85	2.95E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs3750720	chr10:102248884	SEC31B	chr10:102246403-102289636:-	-0.31	-5.3	4.03E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs3758253	chr9:100700654	C9orf156	chr9:100666772-100684852:-	-0.34	-4.71	5.4E-6	Quantitative traits	
PAAD	cis	1	rs3758254	chr9:100701001	C9orf156	chr9:100666772-100684852:-	-0.34	-4.71	5.4E-6	Quantitative traits	
PAAD	cis	1	rs3760891	chr19:33599708	GPATCH1	chr19:33571786-33621318:+	0.45	4.01	9.34E-5	Bone properties (heel)	
PAAD	cis	1	rs3763695	chr10:102269206	SEC31B	chr10:102246403-102289636:-	-0.35	-5.8	3.65E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs3772128	chr3:121345094	IQCB1	chr3:121488610-121553926:-	0.57	5.9	2.25E-8	Cognitive performance	
PAAD	cis	1	rs3772130	chr3:121344140	IQCB1	chr3:121488610-121553926:-	0.57	5.9	2.25E-8	Cognitive performance	
PAAD	cis	1	rs3774372	chr3:41877414	ULK4	chr3:41288091-42003660:-	0.86	7.96	3.64E-13	Diastolic blood pressure	
PAAD	cis	1	rs3774808	chr3:48481647	TREX1	chr3:48501186-48509043:+	-0.36	-5.33	3.45E-7	Longevity	
PAAD	cis	1	rs3781001	chr10:127706028	UROS	chr10:127477148-127511837:-	-0.34	-4.18	4.84E-5	Visceral fat	
PAAD	cis	1	rs3782130	chr12:58161898	FAM119B	chr12:58166383-58176323:+	0.44	5.42	2.24E-7	Multiple sclerosis	
PAAD	cis	1	rs3782894	chr12:110026024	MYO1H	chr12:109826524-109886176:+	0.46	4.32	2.79E-5	HDL cholesterol	
PAAD	cis	1	rs3786933	chr19:33602881	GPATCH1	chr19:33571786-33621318:+	0.45	4.01	9.34E-5	Bone properties (heel)	
PAAD	cis	1	rs3791220	chr2:227066	SH3YL1	chr2:218138-264810:-	-0.47	-7.59	2.88E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs3791221	chr2:226933	SH3YL1	chr2:218138-264810:-	-0.47	-7.59	2.88E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs3791223	chr2:222336	SH3YL1	chr2:218138-264810:-	-0.47	-7.57	3.24E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs3791224	chr2:221981	SH3YL1	chr2:218138-264810:-	-0.47	-7.59	2.86E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs3793079	chr6:33767788	LEMD2	chr6:33738991-33756906:-	-0.29	-4.32	2.79E-5	Crohn's disease	
PAAD	cis	1	rs3793706	chr10:102269085	SEC31B	chr10:102246403-102289636:-	0.35	5.8	3.65E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs3793771	chr10:102222957	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs3793772	chr10:102222825	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs3795819	chr1:113234179	ST7L	chr1:113066142-113162405:-	-0.42	-5.77	4.37E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs3796689	chr4:185649866	MLF1IP	chr4:185615220-185655286:-	-0.43	-6.76	2.73E-10	Kawasaki disease	
PAAD	cis	1	rs3797537	chr5:78322650	BHMT2	chr5:78365583-78385273:+	0.18	4.37	2.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs3797538	chr5:78322671	BHMT2	chr5:78365583-78385273:+	0.18	4.37	2.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs3803358	chr15:40662773	C15orf23	chr15:40674922-40686488:+	0.73	8.24	7.12E-14	Heschl's gyrus morphology	
PAAD	cis	1	rs3804105	chr6:25612683	HIST1H3D	chr6:26197013-26199464:-	-0.38	-4.03	8.75E-5	Uric acid levels	
PAAD	cis	1	rs3804118	chr6:25592651	HIST1H3D	chr6:26197013-26199464:-	-0.39	-4.17	5.02E-5	Uric acid levels	
PAAD	cis	1	rs3806108	chr6:33767579	LEMD2	chr6:33738991-33756906:-	-0.29	-4.32	2.79E-5	Crohn's disease	
PAAD	cis	1	rs3806988	chr6:49431569	MUT	chr6:49398994-49431031:-	0.32	4.59	9.12E-6	Folate pathway vitamin levels	
PAAD	cis	1	rs3808894	chr9:100686129	C9orf156	chr9:100666772-100684852:-	-0.34	-4.66	6.76E-6	Quantitative traits	
PAAD	cis	1	rs3809868	chr17:45750596	C17orf57	chr17:45401142-45518675:+	-0.44	-5.22	5.88E-7	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs3809868	chr17:45750596	TBKBP1	chr17:45772630-45789427:+	0.27	4.24	3.88E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs3810174	chr19:41904165	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.61	8.44E-6	Height	
PAAD	cis	1	rs3810175	chr19:41904396	B3GNT8	chr19:41931265-41934635:-	0.3	4.6	8.82E-6	Height	
PAAD	cis	1	rs3815413	chr4:17654648	MED28	chr4:17616273-17629791:+	0.43	5.13	8.77E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs3815414	chr4:17606659	MED28	chr4:17616273-17629791:+	-0.45	-5.35	3.15E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs3816037	chr19:41918009	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.79	3.95E-6	Height	
PAAD	cis	1	rs3816587	chr4:25417244	ANAPC4	chr4:25378848-25420119:+	-0.3	-4.14	5.73E-5	Rheumatoid arthritis	
PAAD	cis	1	rs3823114	chr6:49431720	CENPQ	chr6:49431096-49460820:+	-0.36	-4.13	5.84E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs3823114	chr6:49431720	MUT	chr6:49398994-49431031:-	0.29	4.14	5.66E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs3824496	chr9:100684645	C9orf156	chr9:100666772-100684852:-	-0.34	-4.66	6.76E-6	Quantitative traits	
PAAD	cis	1	rs3825079	chr12:58203354	FAM119B	chr12:58166383-58176323:+	0.46	5.57	1.14E-7	Multiple sclerosis	
PAAD	cis	1	rs3826061	chr16:88927221	TRAPPC2L	chr16:88922628-88927591:+	-0.26	-4	9.96E-5	Parkinson disease and lewy body pathology	
PAAD	cis	1	rs3826331	chr17:38150492	GSDMA	chr17:38119226-38134019:+	0.59	6.5	1.08E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs3828165	chr2:220889	SH3YL1	chr2:218138-264810:-	-0.47	-7.46	6.01E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs3846055	chr3:134203973	ANAPC13	chr3:134196547-134204865:-	0.9	12.22	2.1E-24	Height	
PAAD	cis	1	rs3846056	chr3:134227292	ANAPC13	chr3:134196547-134204865:-	0.87	11.61	9.26E-23	Height	
PAAD	cis	1	rs3846357	chr4:17635887	MED28	chr4:17616273-17629791:+	0.46	5.47	1.83E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs3846926	chr6:56092186	COL21A1	chr6:55921389-56258892:-	0.28	3.99	0.000101	Pulse pressure	
PAAD	cis	1	rs3857422	chr5:150268609	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs3861882	chr9:132465304	TOR1A	chr9:132575222-132586441:-	-0.41	-4	9.88E-5	Response to exercise (triglyceride levels)	
PAAD	cis	1	rs3862260	chr1:120160789	ZNF697	chr1:120162000-120190390:-	-0.3	-4.52	1.23E-5	Systemic lupus erythematosus	
PAAD	cis	1	rs3885839	chr7:65290403	CCT6P1	chr7:65216092-65228661:+	0.42	4.06	7.72E-5	Diabetic kidney disease	
PAAD	cis	1	rs3890604	chr3:41760625	ULK4	chr3:41288091-42003660:-	0.83	7.26	1.79E-11	Diastolic blood pressure	
PAAD	cis	1	rs3900064	chr5:150264414	LOC134466	chr5:150310000-150326146:-	-0.63	-5.54	1.27E-7	Crohn's disease	
PAAD	cis	1	rs3906527	chr5:150266392	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs3906528	chr5:150266718	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs391396	chr4:130037653	C4orf33	chr4:130014829-130033842:+	-0.53	-6.62	5.66E-10	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs3932818	chr3:134206069	ANAPC13	chr3:134196547-134204865:-	0.87	11.86	2.04E-23	Height	
PAAD	cis	1	rs3933453	chr4:17636319	MED28	chr4:17616273-17629791:+	0.45	5.36	3.05E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs3934103	chr3:41977214	ULK4	chr3:41288091-42003660:-	-0.88	-7.84	7.26E-13	Diastolic blood pressure	
PAAD	cis	1	rs3935358	chr6:3295190	SERPINB1	chr6:2833736-2842081:-	0.48	4.07	7.53E-5	Obesity-related traits	
PAAD	cis	1	rs3935543	chr17:79579874	TSPAN10	chr17:79609349-79615778:+	0.74	9.99	2.09E-18	Eye color traits	
PAAD	cis	1	rs3960018	chr15:90383307	AP3S2	chr15:90373832-90456222:-	-0.82	-9.64	1.74E-17	Type 2 diabetes	
PAAD	cis	1	rs396508	chr16:20682354	ACSM1	chr16:20634559-20709066:-	-0.48	-5.15	7.88E-7	Schizophrenia	
PAAD	cis	1	rs3981351	chr10:115515120	CASP7	chr10:115438935-115490662:+	0.37	4.48	1.48E-5	Obesity-related traits	
PAAD	cis	1	rs39841	chr5:96120170	ERAP1	chr5:96096515-96149837:-	-0.5	-6.13	7.25E-9	Inflammatory skin disease	
PAAD	cis	1	rs402418	chr7:65509469	CCT6P1	chr7:65216092-65228661:+	0.43	4.13	5.87E-5	Diabetic kidney disease	
PAAD	cis	1	rs4073846	chr1:46462881	CCDC163P	chr1:45960581-45965646:-	0.5	6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs4074170	chr17:28381141	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.93E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs4074915	chr17:79579230	TSPAN10	chr17:79609349-79615778:+	-0.74	-9.99	2.09E-18	Eye color traits	
PAAD	cis	1	rs4074916	chr17:79579248	TSPAN10	chr17:79609349-79615778:+	-0.74	-10.03	1.69E-18	Eye color traits	
PAAD	cis	1	rs4075623	chr17:28386526	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.93E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs4076006	chr1:46438076	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs4077468	chr1:205914757	SLC26A9	chr1:205882179-205912588:-	0.31	4.13	5.98E-5	Cystic fibrosis-related diabetes	
PAAD	cis	1	rs4078160	chr10:52565940	ASAH2B	chr10:52499696-52514567:+	-0.46	-4.03	8.92E-5	Urate levels in lean individuals	
PAAD	cis	1	rs409035	chr20:5943649	MCM8	chr20:5931298-5975829:+	-0.48	-5.47	1.79E-7	HIV-1 viral setpoint	
PAAD	cis	1	rs41266839	chr6:26409890	BTN3A2	chr6:26365398-26378546:+	-1.07	-8.31	4.74E-14	Schizophrenia	
PAAD	cis	1	rs4130590	chr9:130107964	ZNF79	chr9:130186653-130207650:+	0.36	4.75	4.57E-6	Bipolar disorder	
PAAD	cis	1	rs4134386	chr1:46395089	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs4140574	chr6:56099424	COL21A1	chr6:55921389-56258892:-	0.28	4.01	9.3E-5	Pulse pressure	
PAAD	cis	1	rs4150161	chr16:84214236	ADAD2	chr16:84224723-84230772:+	-0.59	-4.08	7.18E-5	Systolic blood pressure response to hydrochlorothiazide in hypertension	
PAAD	cis	1	rs4235388	chr4:17682030	MED28	chr4:17616273-17629791:+	0.45	5.18	6.83E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs4237643	chr11:43648368	HSD17B12	chr11:43702143-43878160:+	0.43	5.83	3.14E-8	Forced vital capacity	
PAAD	cis	1	rs4239227	chr17:28389103	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.93E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs4244338	chr10:102272802	SEC31B	chr10:102246403-102289636:-	-0.35	-5.8	3.65E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs4256922	chr10:52568616	ASAH2B	chr10:52499696-52514567:+	-0.48	-4.15	5.46E-5	Urate levels in lean individuals	
PAAD	cis	1	rs4263408	chr4:39785276	RPL9	chr4:39455747-39460568:-	-0.42	-4.55	1.06E-5	Plasma amyloid beta peptide concentrations (ABx-40)	
PAAD	cis	1	rs4267943	chr6:49439805	MUT	chr6:49398994-49431031:-	-0.3	-4.26	3.59E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs427044	chr7:65508545	CCT6P1	chr7:65216092-65228661:+	0.44	4.32	2.84E-5	Diabetic kidney disease	
PAAD	cis	1	rs4282209	chr4:76919536	NAAA	chr4:76831809-76862166:-	-0.45	-5.52	1.45E-7	Longevity	
PAAD	cis	1	rs4285028	chr3:121660664	IQCB1	chr3:121488610-121553926:-	-0.43	-4.06	7.81E-5	Multiple sclerosis	
PAAD	cis	1	rs4294134	chr7:135293128	PL-5283	chr7:135347221-135378160:+	0.84	9.08	5.29E-16	Paget's disease	
PAAD	cis	1	rs4294134	chr7:135293128	SLC13A4	chr7:135365993-135412933:-	-0.47	-4.2	4.45E-5	Paget's disease	
PAAD	cis	1	rs4296773	chr5:4486970	KIAA0947	chr5:5422807-5490337:+	-0.22	-4.27	3.42E-5	DNA methylation (variation)	
PAAD	cis	1	rs4304957	chr14:76647572	ESRRB	chr14:76837690-76968178:+	0.47	4.15	5.4E-5	Blood pressure	
PAAD	cis	1	rs4309773	chr3:134277301	ANAPC13	chr3:134196547-134204865:-	0.87	11.51	1.83E-22	Height	
PAAD	cis	1	rs4310508	chr10:65138573	NRBF2	chr10:64893007-64914785:+	-0.38	-5.16	7.4E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs431318	chr7:65511597	CCT6P1	chr7:65216092-65228661:+	0.43	4.13	5.87E-5	Diabetic kidney disease	
PAAD	cis	1	rs431328	chr19:22222236	ZNF257	chr19:22235266-22273901:+	0.44	5.51	1.47E-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs43184	chr5:56141777	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs4322591	chr14:75600697	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs4323544	chr9:123647377	LOC253039	chr9:123605320-123616644:+	-0.57	-7.62	2.46E-12	Rheumatoid arthritis	
PAAD	cis	1	rs4324798	chr6:28776117	ZFP57	chr6:29640171-29648887:-	0.89	4.54	1.14E-5	Lung adenocarcinoma	
PAAD	cis	1	rs4328498	chr17:28344276	EFCAB5	chr17:28256874-28435469:+	-0.36	-4.16	5.3E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs4334685	chr3:134304335	ANAPC13	chr3:134196547-134204865:-	0.86	11.36	4.41E-22	Height	
PAAD	cis	1	rs433598	chr16:20680206	ACSM1	chr16:20634559-20709066:-	0.45	4.84	3.21E-6	Schizophrenia	
PAAD	cis	1	rs4342423	chr6:33732679	LEMD2	chr6:33738991-33756906:-	-0.32	-4.66	6.76E-6	Crohn's disease	
PAAD	cis	1	rs4350617	chr17:28423088	EFCAB5	chr17:28256874-28435469:+	0.36	4.13	5.97E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs436039	chr19:22214873	ZNF257	chr19:22235266-22273901:+	0.49	5.96	1.64E-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs4363385	chr1:152989321	SPRR1A	chr1:152956557-152958289:+	0.37	4.47	1.5E-5	Inflammatory skin disease	
PAAD	cis	1	rs4367113	chr3:134287975	ANAPC13	chr3:134196547-134204865:-	0.86	11.15	1.63E-21	Height	
PAAD	cis	1	rs4368544	chr3:134300014	ANAPC13	chr3:134196547-134204865:-	-0.88	-11.62	9.09E-23	Height	
PAAD	cis	1	rs4372836	chr2:28973883	TRMT61B	chr2:29072690-29093175:-	-0.49	-5.93	1.97E-8	Body mass index	
PAAD	cis	1	rs4375281	chr1:92987575	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs4375701	chr17:45712218	C17orf57	chr17:45401142-45518675:+	0.42	4.84	3.11E-6	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs4375701	chr17:45712218	TBKBP1	chr17:45772630-45789427:+	-0.26	-4.02	9.12E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs4376778	chr1:46288846	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.49	1.11E-9	Body mass index	
PAAD	cis	1	rs437889	chr7:65509234	CCT6P1	chr7:65216092-65228661:+	0.42	4.08	7.11E-5	Diabetic kidney disease	
PAAD	cis	1	rs4379723	chr10:64963449	NRBF2	chr10:64893007-64914785:+	-0.38	-5.16	7.4E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs4394010	chr4:129894649	C4orf33	chr4:130014829-130033842:+	0.49	6.07	9.69E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs4399232	chr10:64999490	NRBF2	chr10:64893007-64914785:+	-0.38	-5.17	7.37E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs4399664	chr19:21778026	ZNF429	chr19:21688437-21739068:+	0.4	4.68	6.24E-6	Colorectal or endometrial cancer	
PAAD	cis	1	rs4400684	chr10:65012687	NRBF2	chr10:64893007-64914785:+	-0.38	-5.17	7.37E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs4408846	chr3:41753679	ULK4	chr3:41288091-42003660:-	0.83	7.23	2.18E-11	Diastolic blood pressure	
PAAD	cis	1	rs4409059	chr5:4486962	KIAA0947	chr5:5422807-5490337:+	-0.22	-4.25	3.68E-5	DNA methylation (variation)	
PAAD	cis	1	rs4417907	chr3:134291363	ANAPC13	chr3:134196547-134204865:-	0.88	11.58	1.13E-22	Height	
PAAD	cis	1	rs4423809	chr3:134300107	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.77	3.63E-23	Height	
PAAD	cis	1	rs4442739	chr14:76647645	ESRRB	chr14:76837690-76968178:+	0.47	4.13	6.05E-5	Blood pressure	
PAAD	cis	1	rs4465649	chr17:28394747	EFCAB5	chr17:28256874-28435469:+	-0.36	-4.16	5.3E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs4465650	chr17:28396721	EFCAB5	chr17:28256874-28435469:+	0.36	4.16	5.3E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs4466058	chr4:129923879	C4orf33	chr4:130014829-130033842:+	-0.48	-6	1.36E-8	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs4469291	chr6:49440614	CENPQ	chr6:49431096-49460820:+	-0.35	-4.02	9.11E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs4469291	chr6:49440614	MUT	chr6:49398994-49431031:-	0.3	4.23	4.05E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs4479813	chr5:4486842	KIAA0947	chr5:5422807-5490337:+	-0.22	-4.25	3.68E-5	DNA methylation (variation)	
PAAD	cis	1	rs4490383	chr3:48484683	TREX1	chr3:48501186-48509043:+	-0.35	-5.22	5.71E-7	Longevity	
PAAD	cis	1	rs4490669	chr6:56789465	BEND6	chr6:56819773-56892138:+	-0.41	-5.38	2.73E-7	Menarche (age at onset)	
PAAD	cis	1	rs4497901	chr2:239969	SH3YL1	chr2:218138-264810:-	-0.47	-7.55	3.72E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs4498009	chr3:134198008	ANAPC13	chr3:134196547-134204865:-	0.89	12.19	2.56E-24	Height	
PAAD	cis	1	rs451396	chr7:65484074	CCT6P1	chr7:65216092-65228661:+	0.44	4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs4533340	chr17:28277951	EFCAB5	chr17:28256874-28435469:+	0.36	4.11	6.34E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs4535272	chr3:134299916	ANAPC13	chr3:134196547-134204865:-	-0.86	-11.19	1.31E-21	Height	
PAAD	cis	1	rs454422	chr20:5943693	MCM8	chr20:5931298-5975829:+	-0.47	-5.41	2.4E-7	HIV-1 viral setpoint	
PAAD	cis	1	rs4545281	chr1:46360054	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.14	6.64E-9	Body mass index	
PAAD	cis	1	rs4548056	chr7:65298873	CCT6P1	chr7:65216092-65228661:+	0.45	4.34	2.55E-5	Diabetic kidney disease	
PAAD	cis	1	rs4549034	chr2:28972579	TRMT61B	chr2:29072690-29093175:-	-0.49	-5.93	1.97E-8	Body mass index	
PAAD	cis	1	rs4560537	chr5:150262586	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs4572812	chr3:134291177	ANAPC13	chr3:134196547-134204865:-	-0.88	-11.62	9.09E-23	Height	
PAAD	cis	1	rs4575590	chr17:28361969	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.93E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs4579248	chr5:150268151	LOC134466	chr5:150310000-150326146:-	0.9	6.96	9.27E-11	Crohn's disease	
PAAD	cis	1	rs458291	chr7:65520479	CCT6P1	chr7:65216092-65228661:+	0.43	4.13	5.87E-5	Diabetic kidney disease	
PAAD	cis	1	rs4594164	chr14:35509571	PPP2R3C	chr14:35554679-35591679:-	0.55	5.74	4.84E-8	Atopic dermatitis	
PAAD	cis	1	rs4595427	chr10:65012944	NRBF2	chr10:64893007-64914785:+	-0.38	-5.17	7.37E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs4604805	chr10:102261409	SEC31B	chr10:102246403-102289636:-	-0.35	-5.88	2.44E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs4609941	chr18:44645491	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs4631576	chr9:100705210	C9orf156	chr9:100666772-100684852:-	-0.31	-4.22	4.15E-5	Quantitative traits	
PAAD	cis	1	rs4631830	chr10:51543344	MSMB	chr10:51549553-51562590:+	0.43	4.43	1.77E-5	Prostate-specific antigen levels	
PAAD	cis	1	rs4640348	chr2:28965479	TRMT61B	chr2:29072690-29093175:-	-0.5	-6.14	6.74E-9	Body mass index	
PAAD	cis	1	rs4642241	chr4:17617111	MED28	chr4:17616273-17629791:+	0.48	5.76	4.56E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs4643294	chr15:85250253	LOC388152	chr15:84867600-84898920:-	-0.35	-4.25	3.75E-5	Schizophrenia	
PAAD	cis	1	rs4646457	chr7:99245080	CYP3A5	chr7:99245818-99332821:-	0.69	6.47	1.23E-9	Blood metabolite levels	
PAAD	cis	1	rs4646536	chr12:58157988	FAM119B	chr12:58166383-58176323:+	0.47	5.87	2.62E-8	Multiple sclerosis	
PAAD	cis	1	rs464895	chr7:65527106	CCT6P1	chr7:65216092-65228661:+	0.43	4.07	7.5E-5	Diabetic kidney disease	
PAAD	cis	1	rs4653129	chr1:35802949	C1orf216	chr1:36179477-36184790:-	0.39	4	9.89E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs4653130	chr1:35804141	C1orf216	chr1:36179477-36184790:-	0.39	4	9.89E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs4658552	chr1:243412936	SDCCAG8	chr1:243419320-243663392:+	0.48	4.78	4.08E-6	Educational attainment	
PAAD	cis	1	rs4660306	chr1:45978675	CCDC163P	chr1:45960581-45965646:-	0.96	13.34	2.03E-27	Homocysteine levels	
PAAD	cis	1	rs4660317	chr1:46326226	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.87E-9	Body mass index	
PAAD	cis	1	rs4660319	chr1:46341623	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.87E-9	Body mass index	
PAAD	cis	1	rs4660321	chr1:46366760	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs4660870	chr1:45995231	CCDC163P	chr1:45960581-45965646:-	-0.9	-11.81	2.75E-23	Homocysteine levels	
PAAD	cis	1	rs4660898	chr1:46402171	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs4660910	chr1:46548402	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs4666118	chr2:28951698	TRMT61B	chr2:29072690-29093175:-	-0.49	-5.93	1.97E-8	Body mass index	
PAAD	cis	1	rs4666119	chr2:28975690	TRMT61B	chr2:29072690-29093175:-	-0.49	-5.81	3.46E-8	Body mass index	
PAAD	cis	1	rs466983	chr7:65520496	CCT6P1	chr7:65216092-65228661:+	0.43	4.13	5.87E-5	Diabetic kidney disease	
PAAD	cis	1	rs4674	chr19:41930396	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.89	2.49E-6	Height	
PAAD	cis	1	rs4687701	chr3:53121276	RFT1	chr3:53122503-53164470:-	0.47	5.39	2.63E-7	Height	
PAAD	cis	1	rs4690909	chr4:159629151	C4orf46	chr4:159587831-159593407:-	0.33	4.15	5.6E-5	Blood metabolite levels;Metabolite levels;Metabolic traits;Acylcarnitine levels	
PAAD	cis	1	rs469758	chr5:96121715	ERAP1	chr5:96096515-96149837:-	-0.62	-8.81	2.62E-15	Ankylosing spondylitis	
PAAD	cis	1	rs4698198	chr4:17656536	MED28	chr4:17616273-17629791:+	0.46	5.5	1.59E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs4698199	chr4:17656738	MED28	chr4:17616273-17629791:+	0.46	5.5	1.59E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs4698200	chr4:17657051	MED28	chr4:17616273-17629791:+	0.45	5.42	2.28E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs4698634	chr4:17630192	MED28	chr4:17616273-17629791:+	-0.48	-5.76	4.43E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs4698635	chr4:17630242	MED28	chr4:17616273-17629791:+	0.48	5.77	4.25E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs4698641	chr4:17642630	MED28	chr4:17616273-17629791:+	0.45	5.37	2.84E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs4698648	chr4:17692715	MED28	chr4:17616273-17629791:+	0.41	4.68	6.2E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs4698649	chr4:17692782	MED28	chr4:17616273-17629791:+	0.41	4.68	6.2E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs4698651	chr4:17694223	MED28	chr4:17616273-17629791:+	0.41	4.68	6.2E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs4706254	chr6:86602813	SNHG5	chr6:86386726-86388451:-	-0.88	-12.5	3.7E-25	Response to antipsychotic treatment	
PAAD	cis	1	rs4707239	chr6:86610717	SNHG5	chr6:86386726-86388451:-	-0.88	-12.5	3.7E-25	Response to antipsychotic treatment	
PAAD	cis	1	rs4711346	chr6:33730996	LEMD2	chr6:33738991-33756906:-	0.36	4.27	3.37E-5	Body mass index	
PAAD	cis	1	rs4711351	chr6:33754592	LEMD2	chr6:33738991-33756906:-	-0.31	-4.49	1.37E-5	Crohn's disease	
PAAD	cis	1	rs4712120	chr6:56092916	COL21A1	chr6:55921389-56258892:-	0.28	4.01	9.52E-5	Pulse pressure	
PAAD	cis	1	rs4713682	chr6:33757047	LEMD2	chr6:33738991-33756906:-	-0.31	-4.54	1.15E-5	Crohn's disease	
PAAD	cis	1	rs4713684	chr6:33766488	LEMD2	chr6:33738991-33756906:-	-0.29	-4.32	2.79E-5	Crohn's disease	
PAAD	cis	1	rs4713	chr9:131910805	PPP2R4	chr9:131873244-131911223:+	-0.5	-5.08	1.09E-6	Blood metabolite ratios	
PAAD	cis	1	rs4715129	chr6:49415043	CENPQ	chr6:49431096-49460820:+	-0.35	-4.03	8.85E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs4715129	chr6:49415043	MUT	chr6:49398994-49431031:-	0.29	4.09	7.06E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs4718269	chr7:65200778	CCT6P1	chr7:65216092-65228661:+	-0.42	-4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs4718270	chr7:65202407	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs4726669	chr7:143758191	ARHGEF35	chr7:143883677-143892736:-	-0.39	-5.06	1.17E-6	Obesity-related traits	
PAAD	cis	1	rs4727443	chr7:99593346	CYP3A5	chr7:99245818-99332821:-	-0.25	-4.05	8.06E-5	Interstitial lung disease	
PAAD	cis	1	rs4727443	chr7:99593346	TRIM4	chr7:99488037-99517154:-	-0.4	-5.31	3.74E-7	Interstitial lung disease	
PAAD	cis	1	rs473073	chr10:131429646	MGMT	chr10:131265454-131565783:+	0.39	5.88	2.5E-8	Response to temozolomide	
PAAD	cis	1	rs473188	chr11:116812029	PCSK7	chr11:117075789-117102811:-	-0.39	-4.1	6.66E-5	Protein quantitative trait loci	
PAAD	cis	1	rs473771	chr10:131408155	MGMT	chr10:131265454-131565783:+	0.38	5.76	4.47E-8	Response to temozolomide	
PAAD	cis	1	rs4750759	chr10:131436603	MGMT	chr10:131265454-131565783:+	-0.37	-5.5	1.58E-7	Response to temozolomide	
PAAD	cis	1	rs4755726	chr11:43642130	HSD17B12	chr11:43702143-43878160:+	-0.44	-5.93	1.95E-8	Forced vital capacity	
PAAD	cis	1	rs4759229	chr12:56474480	RPS26	chr12:56435686-56438005:+	-0.53	-6.12	7.51E-9	Cognitive function	
PAAD	cis	1	rs477692	chr10:131426022	MGMT	chr10:131265454-131565783:+	0.41	6.28	3.35E-9	Response to temozolomide	
PAAD	cis	1	rs4789400	chr17:74997897	FOXJ1	chr17:74132417-74137371:-	-0.7	-4.04	8.53E-5	Cannabis use (initiation)	
PAAD	cis	1	rs4794016	chr17:45725931	C17orf57	chr17:45401142-45518675:+	-0.43	-5.15	7.86E-7	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs4794016	chr17:45725931	TBKBP1	chr17:45772630-45789427:+	0.25	4	9.95E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs4794048	chr17:45763073	C17orf57	chr17:45401142-45518675:+	0.41	4.87	2.79E-6	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs4794048	chr17:45763073	TBKBP1	chr17:45772630-45789427:+	-0.26	-4.17	5.1E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs4794202	chr17:45930539	SCRN2	chr17:45915049-45918699:-	-0.51	-7.21	2.36E-11	Alzheimer's disease (cognitive decline)	
PAAD	cis	1	rs479478	chr10:131428959	MGMT	chr10:131265454-131565783:+	0.39	5.88	2.5E-8	Response to temozolomide	
PAAD	cis	1	rs4794823	chr17:38166265	GSDMA	chr17:38119226-38134019:+	-0.57	-6.29	3.12E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs4794824	chr17:38179290	GSDMA	chr17:38119226-38134019:+	-0.58	-6.37	2.13E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs4795412	chr17:38150604	GSDMA	chr17:38119226-38134019:+	-0.58	-6.33	2.54E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs4795415	chr17:38157995	GSDMA	chr17:38119226-38134019:+	-0.57	-6.35	2.34E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs4795416	chr17:38158133	GSDMA	chr17:38119226-38134019:+	-0.57	-6.35	2.34E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs4795418	chr17:38164851	GSDMA	chr17:38119226-38134019:+	-0.57	-6.29	3.12E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs4795525	chr17:28388487	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.93E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs4803463	chr19:41911040	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.62	8.21E-6	Height	
PAAD	cis	1	rs4803465	chr19:41918158	B3GNT8	chr19:41931265-41934635:-	0.3	4.78	4.13E-6	Height	
PAAD	cis	1	rs4803468	chr19:41922352	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.73	4.97E-6	Height	
PAAD	cis	1	rs4803469	chr19:41922775	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.73	4.97E-6	Height	
PAAD	cis	1	rs4803480	chr19:42066279	CEACAM21	chr19:42055886-42093196:+	0.54	8.27	6.01E-14	Schizophrenia	
PAAD	cis	1	rs480643	chr10:131400308	MGMT	chr10:131265454-131565783:+	0.38	5.69	6.43E-8	Response to temozolomide	
PAAD	cis	1	rs4836668	chr9:132465807	TOR1A	chr9:132575222-132586441:-	-0.41	-4	9.88E-5	Response to exercise (triglyceride levels)	
PAAD	cis	1	rs4845756	chr1:152254919	FLG	chr1:152274651-152297679:-	-0.55	-5.88	2.48E-8	Atopic dermatitis	
PAAD	cis	1	rs4847181	chr1:93028792	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs485576	chr10:131425496	MGMT	chr10:131265454-131565783:+	0.41	6.28	3.35E-9	Response to temozolomide	
PAAD	cis	1	rs4858793	chr3:48415007	TREX1	chr3:48501186-48509043:+	0.37	5.19	6.66E-7	Longevity	
PAAD	cis	1	rs4858817	chr3:48416756	TREX1	chr3:48501186-48509043:+	0.35	5.09	1.05E-6	Longevity	
PAAD	cis	1	rs4859413	chr4:76898250	NAAA	chr4:76831809-76862166:-	0.45	5.5	1.53E-7	Longevity	
PAAD	cis	1	rs4859581	chr4:76906974	NAAA	chr4:76831809-76862166:-	-0.44	-5.42	2.26E-7	Longevity	
PAAD	cis	1	rs4859582	chr4:76907213	NAAA	chr4:76831809-76862166:-	-0.45	-5.5	1.53E-7	Longevity	
PAAD	cis	1	rs4862406	chr4:185629339	MLF1IP	chr4:185615220-185655286:-	0.46	7.3	1.44E-11	Kawasaki disease	
PAAD	cis	1	rs486301	chr15:43836949	ADAL	chr15:43622872-43646094:+	-0.68	-4.95	1.91E-6	Tumor biomarkers	
PAAD	cis	1	rs4869313	chr5:96223880	ERAP2	chr5:96211644-96255398:+	-1.11	-17.64	1.06E-38	Pediatric autoimmune diseases	
PAAD	cis	1	rs4870040	chr6:151872090	C6orf97	chr6:151815175-151942327:+	0.45	4.05	8.14E-5	Bone mineral density (spine)	
PAAD	cis	1	rs4870041	chr6:151872324	C6orf97	chr6:151815175-151942327:+	0.45	4.05	8.14E-5	Bone mineral density (spine)	
PAAD	cis	1	rs4886018	chr13:52990717	CKAP2	chr13:53029495-53050763:+	-0.35	-5.75	4.79E-8	Lewy body disease	
PAAD	cis	1	rs488676	chr1:35753755	C1orf216	chr1:36179477-36184790:-	-0.39	-4	9.89E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs4886818	chr15:76880939	SCAPER	chr15:76640529-77197744:-	-0.24	-4.45	1.64E-5	Blood metabolite levels	
PAAD	cis	1	rs4887783	chr16:74700743	RFWD3	chr16:74655298-74700779:-	-0.32	-4.74	4.83E-6	Testicular germ cell tumor	
PAAD	cis	1	rs4888262	chr16:74670458	RFWD3	chr16:74655298-74700779:-	-0.29	-4.31	2.96E-5	Testicular germ cell tumor	
PAAD	cis	1	rs4888264	chr16:74681632	RFWD3	chr16:74655298-74700779:-	-0.3	-4.39	2.09E-5	Testicular germ cell tumor	
PAAD	cis	1	rs4888265	chr16:74683737	RFWD3	chr16:74655298-74700779:-	-0.3	-4.38	2.18E-5	Testicular germ cell tumor	
PAAD	cis	1	rs4889609	chr16:31026427	MYST1	chr16:31128985-31142713:+	0.36	4.87	2.77E-6	Response to metformin (IC50)	
PAAD	cis	1	rs4899148	chr14:65303778	CHURC1	chr14:65381140-65411309:+	0.57	4.27	3.46E-5	Daytime sleep phenotypes	
PAAD	cis	1	rs4899544	chr14:75546556	EIF2B2	chr14:75469612-75476292:+	0.37	4.17	5.09E-5	Height	
PAAD	cis	1	rs4899546	chr14:75594946	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs4899586	chr14:76660856	ESRRB	chr14:76837690-76968178:+	0.46	4.04	8.39E-5	Blood pressure	
PAAD	cis	1	rs4903201	chr14:74659690	LIN52	chr14:74551656-74667117:+	-0.42	-7.21	2.4E-11	Common traits (Other)	
PAAD	cis	1	rs4903202	chr14:74660302	LIN52	chr14:74551656-74667117:+	-0.42	-7.21	2.4E-11	Common traits (Other)	
PAAD	cis	1	rs4903203	chr14:74660508	LIN52	chr14:74551656-74667117:+	-0.42	-7.21	2.4E-11	Common traits (Other)	
PAAD	cis	1	rs4903279	chr14:75546583	EIF2B2	chr14:75469612-75476292:+	0.37	4.17	5.09E-5	Height	
PAAD	cis	1	rs4903281	chr14:75554361	EIF2B2	chr14:75469612-75476292:+	0.36	4.09	7.0E-5	Height	
PAAD	cis	1	rs4903284	chr14:75592483	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs4903289	chr14:75623988	EIF2B2	chr14:75469612-75476292:+	-0.37	-4.16	5.28E-5	Height	
PAAD	cis	1	rs4903386	chr14:76669658	ESRRB	chr14:76837690-76968178:+	0.46	4.01	9.37E-5	Blood pressure	
PAAD	cis	1	rs4911178	chr20:33952620	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs4911180	chr20:33972948	UQCC	chr20:33890383-33999833:-	0.35	4.06	7.69E-5	Height	
PAAD	cis	1	rs4911491	chr20:33947285	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs4911492	chr20:33951799	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs4911494	chr20:33971914	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs4911496	chr20:33972053	UQCC	chr20:33890383-33999833:-	-0.36	-4.31	2.92E-5	Height	
PAAD	cis	1	rs4917901	chr10:102201773	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs4919431	chr10:101944325	CWF19L1	chr10:101992055-102027437:-	-0.48	-4.13	5.91E-5	Schizophrenia	
PAAD	cis	1	rs4919464	chr10:102221195	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs4919465	chr10:102221703	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs4919466	chr10:102241213	SEC31B	chr10:102246403-102289636:-	-0.33	-5.6	9.56E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs4919468	chr10:102288343	SEC31B	chr10:102246403-102289636:-	-0.36	-5.9	2.2E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs4919469	chr10:102298855	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs4919470	chr10:102298920	SEC31B	chr10:102246403-102289636:-	-0.36	-5.84	3.06E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs4919471	chr10:102299239	SEC31B	chr10:102246403-102289636:-	-0.36	-5.76	4.41E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs4919472	chr10:102315864	SEC31B	chr10:102246403-102289636:-	-0.32	-5.03	1.36E-6	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs4919690	chr10:104616500	AS3MT	chr10:104613967-104661653:+	0.54	6.44	1.47E-9	Arsenic metabolism	
PAAD	cis	1	rs4919690	chr10:104616500	C10orf32	chr10:104613967-104624718:+	0.55	8.27	6.02E-14	Arsenic metabolism	
PAAD	cis	1	rs4925540	chr1:247214878	ZNF670	chr1:247200087-247242069:-	-0.5	-5.5	1.54E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs4932143	chr15:90372067	AP3S2	chr15:90373832-90456222:-	-0.82	-9.65	1.69E-17	Type 2 diabetes	
PAAD	cis	1	rs4932148	chr15:90394356	AP3S2	chr15:90373832-90456222:-	-0.83	-9.78	7.63E-18	Type 2 diabetes	
PAAD	cis	1	rs4936444	chr11:118743338	TREH	chr11:118528942-118550381:-	0.49	4.96	1.83E-6	Primary biliary cirrhosis	
PAAD	cis	1	rs494003	chr11:65542298	SNX32	chr11:65601410-65621170:+	0.68	5.78	4.11E-8	Systemic lupus erythematosus	
PAAD	cis	1	rs4951261	chr1:205717823	PM20D1	chr1:205797154-205819245:-	0.38	4.46	1.57E-5	Menarche (age at onset)	
PAAD	cis	1	rs4951261	chr1:205717823	RAB7L1	chr1:205737115-205744610:-	-0.33	-4.02	9.26E-5	Menarche (age at onset)	
PAAD	cis	1	rs4955485	chr3:134295843	ANAPC13	chr3:134196547-134204865:-	0.86	11.36	4.41E-22	Height	
PAAD	cis	1	rs4955555	chr3:134286427	ANAPC13	chr3:134196547-134204865:-	0.86	11.15	1.63E-21	Height	
PAAD	cis	1	rs4958422	chr5:150186734	LOC134466	chr5:150310000-150326146:-	0.85	6.85	1.72E-10	Crohn's disease	
PAAD	cis	1	rs4958424	chr5:150225036	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs4958426	chr5:150278346	LOC134466	chr5:150310000-150326146:-	0.93	7.16	3.22E-11	Crohn's disease	
PAAD	cis	1	rs4958842	chr5:150224877	LOC134466	chr5:150310000-150326146:-	0.76	6.38	1.95E-9	Crohn's disease	
PAAD	cis	1	rs4958843	chr5:150224924	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs4958848	chr5:150271122	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs4958852	chr5:150330631	LOC134466	chr5:150310000-150326146:-	0.76	5.8	3.77E-8	Crohn's disease	
PAAD	cis	1	rs496547	chr11:118576463	TREH	chr11:118528942-118550381:-	0.39	4.8	3.69E-6	Hip minimal joint space width	
PAAD	cis	1	rs496584	chr15:43831923	ADAL	chr15:43622872-43646094:+	-0.69	-5.23	5.39E-7	Tumor biomarkers	
PAAD	cis	1	rs4970698	chr1:92972933	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs4970705	chr1:92971828	EVI5	chr1:92974255-93257961:-	0.37	4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs4970708	chr1:92986514	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs4970709	chr1:92988592	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs4970710	chr1:92988717	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs4970712	chr1:92993547	EVI5	chr1:92974255-93257961:-	0.37	4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs4971316	chr1:247210903	ZNF670	chr1:247200087-247242069:-	-0.5	-5.5	1.54E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs4971319	chr1:247211565	ZNF670	chr1:247200087-247242069:-	-0.5	-5.5	1.54E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs4973991	chr3:41927273	ULK4	chr3:41288091-42003660:-	-0.83	-7.34	1.17E-11	Diastolic blood pressure	
PAAD	cis	1	rs4974483	chr3:134219001	ANAPC13	chr3:134196547-134204865:-	0.87	11.86	2.04E-23	Height	
PAAD	cis	1	rs4974484	chr3:134219019	ANAPC13	chr3:134196547-134204865:-	0.88	11.99	9.11E-24	Height	
PAAD	cis	1	rs4974493	chr3:134219993	ANAPC13	chr3:134196547-134204865:-	0.89	12.08	5.22E-24	Height	
PAAD	cis	1	rs4974559	chr4:1380848	CRIPAK	chr4:1385340-1389782:+	-0.45	-6.29	3.23E-9	Systolic blood pressure	
PAAD	cis	1	rs4975193	chr4:129980630	C4orf33	chr4:130014829-130033842:+	-0.5	-6.36	2.22E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs4975194	chr4:129982377	C4orf33	chr4:130014829-130033842:+	-0.5	-6.36	2.22E-9	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs498872	chr11:118477367	TREH	chr11:118528942-118550381:-	0.52	6.57	7.26E-10	Glioma	
PAAD	cis	1	rs501220	chr6:25873025	BTN3A2	chr6:26365398-26378546:+	-0.58	-4.95	1.9E-6	Homocysteine levels	
PAAD	cis	1	rs503660	chr10:131418999	MGMT	chr10:131265454-131565783:+	0.4	6.04	1.12E-8	Response to temozolomide	
PAAD	cis	1	rs506274	chr10:131409392	MGMT	chr10:131265454-131565783:+	0.38	5.79	3.87E-8	Response to temozolomide	
PAAD	cis	1	rs508303	chr10:131424996	MGMT	chr10:131265454-131565783:+	-0.38	-5.65	7.66E-8	Response to temozolomide	
PAAD	cis	1	rs513736	chr10:131406489	MGMT	chr10:131265454-131565783:+	0.38	5.79	3.87E-8	Response to temozolomide	
PAAD	cis	1	rs516704	chr10:131419879	MGMT	chr10:131265454-131565783:+	0.38	5.73	5.06E-8	Response to temozolomide	
PAAD	cis	1	rs522821	chr1:35741663	C1orf216	chr1:36179477-36184790:-	-0.39	-4	9.89E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs522891	chr10:131430916	MGMT	chr10:131265454-131565783:+	-0.39	-5.88	2.5E-8	Response to temozolomide	
PAAD	cis	1	rs530466	chr10:131427717	MGMT	chr10:131265454-131565783:+	0.41	6.28	3.35E-9	Response to temozolomide	
PAAD	cis	1	rs531572	chr10:131427569	MGMT	chr10:131265454-131565783:+	-0.41	-6.28	3.35E-9	Response to temozolomide	
PAAD	cis	1	rs538969	chr10:131410608	MGMT	chr10:131265454-131565783:+	0.38	5.79	3.87E-8	Response to temozolomide	
PAAD	cis	1	rs548390	chr10:131417427	MGMT	chr10:131265454-131565783:+	0.38	5.79	3.87E-8	Response to temozolomide	
PAAD	cis	1	rs553371	chr10:131413676	MGMT	chr10:131265454-131565783:+	0.38	5.79	3.87E-8	Response to temozolomide	
PAAD	cis	1	rs554792	chr10:131423181	MGMT	chr10:131265454-131565783:+	0.38	5.73	5.06E-8	Response to temozolomide	
PAAD	cis	1	rs555	chr4:17625658	MED28	chr4:17616273-17629791:+	0.48	5.76	4.43E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs55737216	chr9:100695901	C9orf156	chr9:100666772-100684852:-	-0.34	-4.71	5.4E-6	Quantitative traits	
PAAD	cis	1	rs55753056	chr2:243929	SH3YL1	chr2:218138-264810:-	-0.46	-7.52	4.3E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs55762838	chr19:50727179	SIGLEC16	chr19:50472912-50479075:+	-0.48	-4.29	3.15E-5	Disc degeneration (lumbar)	
PAAD	cis	1	rs55775340	chr6:33751784	LEMD2	chr6:33738991-33756906:-	0.36	4.35	2.47E-5	Body mass index	
PAAD	cis	1	rs55786720	chr6:56783647	BEND6	chr6:56819773-56892138:+	-0.41	-5.41	2.36E-7	Menarche (age at onset)	
PAAD	cis	1	rs55788133	chr15:40664239	C15orf23	chr15:40674922-40686488:+	0.75	8.69	5.34E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs55835850	chr2:28949296	TRMT61B	chr2:29072690-29093175:-	0.49	5.93	1.97E-8	Body mass index	
PAAD	cis	1	rs55842567	chr5:437586	EXOC3	chr5:443334-467407:+	-0.36	-4.05	8.17E-5	Cystic fibrosis severity	
PAAD	cis	1	rs558764	chr10:131426957	MGMT	chr10:131265454-131565783:+	-0.38	-5.89	2.4E-8	Response to temozolomide	
PAAD	cis	1	rs55876615	chr14:99545932	EVL	chr14:100438151-100610572:+	-0.27	-4.08	7.23E-5	Airway wall thickness	
PAAD	cis	1	rs55879323	chr1:152168740	FLG	chr1:152274651-152297679:-	-0.61	-10.78	1.59E-20	Inflammatory skin disease	
PAAD	cis	1	rs55879323	chr1:152168740	HRNR	chr1:152184558-152196669:-	0.55	7.87	6.03E-13	Inflammatory skin disease	
PAAD	cis	1	rs55895244	chr7:65387678	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs55913793	chr3:134285968	ANAPC13	chr3:134196547-134204865:-	0.86	11.15	1.63E-21	Height	
PAAD	cis	1	rs55914901	chr19:50528346	SIGLEC16	chr19:50472912-50479075:+	0.93	5.14	8.39E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs55936726	chr2:258210	SH3YL1	chr2:218138-264810:-	-0.47	-7.71	1.48E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs55939327	chr4:17642937	MED28	chr4:17616273-17629791:+	0.46	5.49	1.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs55946380	chr2:268293	SH3YL1	chr2:218138-264810:-	-0.47	-7.75	1.2E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs55957623	chr1:152223196	FLG	chr1:152274651-152297679:-	0.47	4.97	1.79E-6	Atopic dermatitis	
PAAD	cis	1	rs55971458	chr17:28427016	EFCAB5	chr17:28256874-28435469:+	0.36	4.13	5.97E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs55979739	chr16:31049155	MYST1	chr16:31128985-31142713:+	0.38	4.84	3.11E-6	Response to metformin (IC50)	
PAAD	cis	1	rs55986560	chr19:41939835	B3GNT8	chr19:41931265-41934635:-	0.32	4.96	1.82E-6	Height	
PAAD	cis	1	rs56016656	chr7:65383481	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs56030203	chr6:56783857	BEND6	chr6:56819773-56892138:+	-0.41	-5.41	2.36E-7	Menarche (age at onset)	
PAAD	cis	1	rs56040780	chr16:28861881	EIF3CL	chr16:28699879-28747052:+;chr16	0.49	6.38	2.0E-9	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
PAAD	cis	1	rs56040780	chr16:28861881	TUFM	chr16:28853732-28857729:-	0.31	5.71	5.81E-8	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
PAAD	cis	1	rs56042615	chr5:437667	EXOC3	chr5:443334-467407:+	-0.36	-4.05	8.17E-5	Cystic fibrosis severity	
PAAD	cis	1	rs56043407	chr17:2166078	SRR	chr17:2207248-2228553:+	-0.52	-9.08	5.08E-16	Esophageal cancer (squamous cell)	
PAAD	cis	1	rs56104584	chr5:437542	EXOC3	chr5:443334-467407:+	-0.36	-4.05	8.17E-5	Cystic fibrosis severity	
PAAD	cis	1	rs56121764	chr3:41883975	ULK4	chr3:41288091-42003660:-	0.86	7.96	3.64E-13	Diastolic blood pressure	
PAAD	cis	1	rs56158380	chr3:41885588	ULK4	chr3:41288091-42003660:-	0.86	7.96	3.64E-13	Diastolic blood pressure	
PAAD	cis	1	rs56167434	chr2:282137	SH3YL1	chr2:218138-264810:-	-0.47	-7.65	2.14E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs56207540	chr3:41976627	ULK4	chr3:41288091-42003660:-	0.92	7.94	4.13E-13	Diastolic blood pressure	
PAAD	cis	1	rs56291018	chr7:65390339	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs56306402	chr20:33937704	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs56308330	chr4:17643050	MED28	chr4:17616273-17629791:+	0.45	5.4	2.44E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs56314138	chr3:121356656	IQCB1	chr3:121488610-121553926:-	0.57	5.9	2.25E-8	Cognitive performance	
PAAD	cis	1	rs56321614	chr2:268191	SH3YL1	chr2:218138-264810:-	-0.44	-7.03	6.54E-11	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs56331152	chr11:46885016	C11orf49	chr11:46958251-47185929:+	-0.46	-4.05	8.08E-5	Schizophrenia	
PAAD	cis	1	rs56354891	chr19:50727510	SIGLEC16	chr19:50472912-50479075:+	-0.49	-4.35	2.47E-5	Disc degeneration (lumbar)	
PAAD	cis	1	rs565974	chr10:131423274	MGMT	chr10:131265454-131565783:+	0.38	5.73	5.06E-8	Response to temozolomide	
PAAD	cis	1	rs567700	chr10:131423126	MGMT	chr10:131265454-131565783:+	0.38	5.73	5.06E-8	Response to temozolomide	
PAAD	cis	1	rs56776628	chr3:41866856	ULK4	chr3:41288091-42003660:-	0.86	8.03	2.38E-13	Diastolic blood pressure	
PAAD	cis	1	rs568617	chr11:65653242	CTSW	chr11:65647284-65651212:+	-0.75	-10.33	2.59E-19	Crohn's disease	
PAAD	cis	1	rs568617	chr11:65653242	SNX32	chr11:65601410-65621170:+	0.63	6.02	1.22E-8	Crohn's disease	
PAAD	cis	1	rs56884994	chr1:247211057	ZNF670	chr1:247200087-247242069:-	-0.5	-5.54	1.3E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs56922390	chr17:38157021	GSDMA	chr17:38119226-38134019:+	-0.57	-6.35	2.34E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs569235	chr10:131411620	MGMT	chr10:131265454-131565783:+	0.38	5.79	3.87E-8	Response to temozolomide	
PAAD	cis	1	rs56974987	chr4:17627856	MED28	chr4:17616273-17629791:+	0.48	5.77	4.25E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs56985706	chr7:65394562	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs57001853	chr5:150272452	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs57025426	chr10:102205868	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs57057549	chr7:65405738	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs57075379	chr14:35577801	PPP2R3C	chr14:35554679-35591679:-	0.54	5.39	2.65E-7	Atopic dermatitis	
PAAD	cis	1	rs574045	chr1:35756171	C1orf216	chr1:36179477-36184790:-	-0.39	-4	9.89E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs57406211	chr5:150170966	LOC134466	chr5:150310000-150326146:-	0.85	6.75	2.9E-10	Crohn's disease	
PAAD	cis	1	rs57411618	chr17:28273052	EFCAB5	chr17:28256874-28435469:+	0.36	4.12	6.28E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs57479675	chr3:41798038	ULK4	chr3:41288091-42003660:-	0.83	7.51	4.66E-12	Diastolic blood pressure	
PAAD	cis	1	rs5751255	chr22:42648408	CYP2D6	chr22:42522502-42526883:-	-0.42	-4.68	6.37E-6	Cognitive function	
PAAD	cis	1	rs5751901	chr22:24992266	GGT1	chr22:24979718-25024972:+	-0.36	-5.8	3.62E-8	Protein quantitative trait loci	
PAAD	cis	1	rs57542652	chr2:228088	SH3YL1	chr2:218138-264810:-	-0.47	-7.56	3.43E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs57576577	chr16:31036367	MYST1	chr16:31128985-31142713:+	0.36	4.87	2.77E-6	Response to metformin (IC50)	
PAAD	cis	1	rs5758659	chr22:42622003	CYP2D6	chr22:42522502-42526883:-	-0.41	-4.47	1.49E-5	Cognitive function	
PAAD	cis	1	rs5758660	chr22:42623718	CYP2D6	chr22:42522502-42526883:-	-0.42	-4.71	5.62E-6	Cognitive function	
PAAD	cis	1	rs5758677	chr22:42643039	CYP2D6	chr22:42522502-42526883:-	-0.42	-4.68	6.37E-6	Cognitive function	
PAAD	cis	1	rs5760216	chr22:24539734	SUSD2	chr22:24577444-24585074:+	0.85	6.51	1.04E-9	Amyotrophic lateral sclerosis	
PAAD	cis	1	rs5760220	chr22:24542480	SUSD2	chr22:24577444-24585074:+	0.9	6.4	1.84E-9	Amyotrophic lateral sclerosis	
PAAD	cis	1	rs5760229	chr22:24560254	SUSD2	chr22:24577444-24585074:+	0.85	6.51	1.04E-9	Amyotrophic lateral sclerosis	
PAAD	cis	1	rs577227	chr10:131404528	MGMT	chr10:131265454-131565783:+	0.38	5.79	3.87E-8	Response to temozolomide	
PAAD	cis	1	rs578056	chr11:65514874	SNX32	chr11:65601410-65621170:+	0.68	5.78	4.11E-8	Systemic lupus erythematosus	
PAAD	cis	1	rs57928699	chr18:44645593	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs58062456	chr7:65394852	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs580745	chr10:131414401	MGMT	chr10:131265454-131565783:+	0.38	5.79	3.87E-8	Response to temozolomide	
PAAD	cis	1	rs58189451	chr6:149921388	NUP43	chr6:150045453-150067688:-	-0.45	-6.31	2.83E-9	Lung cancer	
PAAD	cis	1	rs583583	chr1:147083114	ACP6	chr1:147119168-147142634:-	0.32	4.24	3.9E-5	Schizophrenia (negative symptoms)	
PAAD	cis	1	rs58416181	chr15:85264461	LOC388152	chr15:84867600-84898920:-	-0.35	-4.17	5.04E-5	Schizophrenia	
PAAD	cis	1	rs58461606	chr2:267367	SH3YL1	chr2:218138-264810:-	-0.47	-7.75	1.2E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs58717741	chr5:150284936	LOC134466	chr5:150310000-150326146:-	0.84	6.87	1.54E-10	Crohn's disease	
PAAD	cis	1	rs588918	chr11:116856642	PCSK7	chr11:117075789-117102811:-	-0.41	-4.16	5.24E-5	Protein quantitative trait loci	
PAAD	cis	1	rs59043558	chr5:150334662	LOC134466	chr5:150310000-150326146:-	0.61	5.3	3.89E-7	Crohn's disease	
PAAD	cis	1	rs59226697	chr22:25870037	CRYBB2	chr22:25615612-25627836:+	1.34	7.18	2.79E-11	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs59321715	chr5:150313480	LOC134466	chr5:150310000-150326146:-	0.96	7.32	1.33E-11	Crohn's disease	
PAAD	cis	1	rs59531858	chr5:150247063	LOC134466	chr5:150310000-150326146:-	0.88	6.75	2.84E-10	Crohn's disease	
PAAD	cis	1	rs59715748	chr5:150189287	LOC134466	chr5:150310000-150326146:-	0.85	6.85	1.72E-10	Crohn's disease	
PAAD	cis	1	rs59794892	chr7:65415873	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs59925331	chr17:38169273	GSDMA	chr17:38119226-38134019:+	-0.57	-6.29	3.12E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs59937473	chr2:271797	SH3YL1	chr2:218138-264810:-	-0.47	-7.78	1.0E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs5995448	chr22:37925702	SSTR3	chr22:37602246-37608353:-	0.41	4.29	3.2E-5	Autoimmune hepatitis type-1	
PAAD	cis	1	rs5995450	chr22:37925852	SSTR3	chr22:37602246-37608353:-	0.41	4.29	3.2E-5	Autoimmune hepatitis type-1	
PAAD	cis	1	rs5996946	chr22:25875988	CRYBB2	chr22:25615612-25627836:+	1.21	7.7	1.57E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs59980321	chr5:150241813	LOC134466	chr5:150310000-150326146:-	0.71	6.06	1.02E-8	Crohn's disease	
PAAD	cis	1	rs6000778	chr22:37925723	SSTR3	chr22:37602246-37608353:-	0.41	4.29	3.2E-5	Autoimmune hepatitis type-1	
PAAD	cis	1	rs6004654	chr22:25855204	CRYBB2	chr22:25615612-25627836:+	1.21	7.66	2.02E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6004655	chr22:25855629	CRYBB2	chr22:25615612-25627836:+	1.23	8.12	1.45E-13	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6004657	chr22:25855714	CRYBB2	chr22:25615612-25627836:+	1.16	7.19	2.74E-11	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6004658	chr22:25856231	CRYBB2	chr22:25615612-25627836:+	1.22	7.76	1.14E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6004659	chr22:25856411	CRYBB2	chr22:25615612-25627836:+	1.19	7.71	1.46E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6004662	chr22:25862124	CRYBB2	chr22:25615612-25627836:+	1.19	7.71	1.46E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6004667	chr22:25874464	CRYBB2	chr22:25615612-25627836:+	-1.18	-7.81	8.46E-13	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6004668	chr22:25874502	CRYBB2	chr22:25615612-25627836:+	-1.18	-7.81	8.46E-13	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6004669	chr22:25875803	CRYBB2	chr22:25615612-25627836:+	1.21	7.7	1.57E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6004671	chr22:25879474	CRYBB2	chr22:25615612-25627836:+	1.21	7.7	1.57E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6004672	chr22:25881013	CRYBB2	chr22:25615612-25627836:+	1.21	7.7	1.57E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6004673	chr22:25885353	CRYBB2	chr22:25615612-25627836:+	1.2	7.47	5.84E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6004675	chr22:25889385	CRYBB2	chr22:25615612-25627836:+	1.25	7.95	3.83E-13	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs601338	chr19:49206674	FUT2	chr19:49199228-49209190:+	-0.27	-4.88	2.65E-6	Blood metabolite levels;Blood metabolite ratios	
PAAD	cis	1	rs60134818	chr5:150261043	LOC134466	chr5:150310000-150326146:-	0.64	5.66	7.41E-8	Crohn's disease	
PAAD	cis	1	rs60149603	chr2:285421	SH3YL1	chr2:218138-264810:-	-0.47	-7.68	1.76E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs60178264	chr4:17685308	MED28	chr4:17616273-17629791:+	0.46	5.45	1.98E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs60228288	chr18:44640412	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs6037526	chr20:3251248	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6037532	chr20:3267911	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6037533	chr20:3268817	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6037535	chr20:3270621	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6037538	chr20:3282978	ITPA	chr20:3190056-3204504:+	-0.39	-5.56	1.16E-7	IFN-related cytopenia	
PAAD	cis	1	rs6037547	chr20:3299228	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6037551	chr20:3306690	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6037553	chr20:3313884	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6037554	chr20:3315613	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6037556	chr20:3317890	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6037560	chr20:3323055	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6037562	chr20:3326141	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6037567	chr20:3332160	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6037579	chr20:3347980	ITPA	chr20:3190056-3204504:+	-0.41	-5.88	2.53E-8	IFN-related cytopenia	
PAAD	cis	1	rs6037583	chr20:3360632	ITPA	chr20:3190056-3204504:+	-0.39	-5.6	9.65E-8	IFN-related cytopenia	
PAAD	cis	1	rs6037590	chr20:3374085	ITPA	chr20:3190056-3204504:+	-0.41	-5.8	3.65E-8	IFN-related cytopenia	
PAAD	cis	1	rs60422392	chr18:44621473	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs60482539	chr15:56180297	PRTG	chr15:55903748-56035177:-	0.32	5	1.53E-6	Keloid	
PAAD	cis	1	rs60484953	chr2:221560	SH3YL1	chr2:218138-264810:-	-0.47	-7.45	6.3E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs6051080	chr20:25975674	FAM182A	chr20:26035250-26067552:+	0.44	4.47	1.49E-5	Colorectal or endometrial cancer	
PAAD	cis	1	rs6051080	chr20:25975674	FAM182B	chr20:25744102-25848786:-	0.55	5.78	4.08E-8	Colorectal or endometrial cancer	
PAAD	cis	1	rs60512868	chr3:48483445	TREX1	chr3:48501186-48509043:+	-0.33	-4.78	4.12E-6	Longevity	
PAAD	cis	1	rs6051672	chr20:3224819	ITPA	chr20:3190056-3204504:+	-0.4	-5.78	4.0E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051702	chr20:3251924	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051703	chr20:3252347	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051705	chr20:3253143	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051708	chr20:3262493	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051709	chr20:3263685	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051712	chr20:3265029	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051713	chr20:3265779	ITPA	chr20:3190056-3204504:+	0.39	5.58	1.07E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051715	chr20:3266548	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051716	chr20:3267736	ITPA	chr20:3190056-3204504:+	-0.4	-5.71	5.63E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051718	chr20:3270370	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051722	chr20:3274435	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051723	chr20:3278512	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051724	chr20:3279338	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051732	chr20:3294182	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051736	chr20:3296898	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051737	chr20:3296992	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051745	chr20:3307243	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051747	chr20:3307945	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051751	chr20:3310049	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051753	chr20:3315513	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051762	chr20:3321590	ITPA	chr20:3190056-3204504:+	-0.4	-5.71	5.63E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051763	chr20:3321616	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051764	chr20:3321807	ITPA	chr20:3190056-3204504:+	0.37	5.31	3.79E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051779	chr20:3333449	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051790	chr20:3342994	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051792	chr20:3343519	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051806	chr20:3350319	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051807	chr20:3350485	ITPA	chr20:3190056-3204504:+	-0.4	-5.71	5.63E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051808	chr20:3350697	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051809	chr20:3352551	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051810	chr20:3355384	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051827	chr20:3372007	ITPA	chr20:3190056-3204504:+	-0.39	-5.62	8.84E-8	IFN-related cytopenia	
PAAD	cis	1	rs6051831	chr20:3373712	ITPA	chr20:3190056-3204504:+	0.39	5.59	1.01E-7	IFN-related cytopenia	
PAAD	cis	1	rs6051838	chr20:3389012	ITPA	chr20:3190056-3204504:+	-0.37	-5.16	7.52E-7	IFN-related cytopenia	
PAAD	cis	1	rs6053815	chr20:5970438	MCM8	chr20:5931298-5975829:+	-0.45	-5.07	1.12E-6	HIV-1 viral setpoint	
PAAD	cis	1	rs6053816	chr20:5970750	MCM8	chr20:5931298-5975829:+	-0.47	-5.38	2.74E-7	HIV-1 viral setpoint	
PAAD	cis	1	rs60563713	chr5:78313516	BHMT2	chr5:78365583-78385273:+	0.19	4.51	1.31E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs6060401	chr20:34005214	UQCC	chr20:33890383-33999833:-	0.34	4.02	9.01E-5	Height	
PAAD	cis	1	rs6060402	chr20:34005240	UQCC	chr20:33890383-33999833:-	0.35	4.09	6.83E-5	Height	
PAAD	cis	1	rs60683927	chr7:65394768	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs60693825	chr14:35514456	PPP2R3C	chr14:35554679-35591679:-	0.56	5.79	3.87E-8	Atopic dermatitis	
PAAD	cis	1	rs607003	chr1:35833291	C1orf216	chr1:36179477-36184790:-	-0.4	-4.07	7.59E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs6073534	chr20:43365504	WISP2	chr20:43343475-43356451:+	-0.37	-4.68	6.26E-6	Obesity-related traits	
PAAD	cis	1	rs60843830	chr2:286756	SH3YL1	chr2:218138-264810:-	-0.48	-7.83	7.67E-13	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs60854219	chr18:44646664	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs6087698	chr20:33948919	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6087702	chr20:33995945	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6087703	chr20:33996433	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6087704	chr20:34001058	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6087705	chr20:34001250	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6088799	chr20:33934301	UQCC	chr20:33890383-33999833:-	0.34	4.03	8.84E-5	Height	
PAAD	cis	1	rs6088812	chr20:33974163	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6088813	chr20:33975181	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6088815	chr20:33976474	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6088816	chr20:33982435	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6088820	chr20:33987298	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6088821	chr20:33987576	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6088823	chr20:33994265	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6088825	chr20:33995972	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs60957376	chr15:85280792	LOC388152	chr15:84867600-84898920:-	-0.34	-4.06	7.75E-5	Schizophrenia	
PAAD	cis	1	rs60967688	chr17:28437052	EFCAB5	chr17:28256874-28435469:+	0.37	4.34	2.53E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs60982898	chr6:49385806	CENPQ	chr6:49431096-49460820:+	-0.34	-4.04	8.39E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs60982898	chr6:49385806	MUT	chr6:49398994-49431031:-	0.28	4	9.84E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs6099851	chr20:56505232	PPP4R1L	chr20:56806189-56884495:-	-0.37	-4.07	7.4E-5	Obesity-related traits	
PAAD	cis	1	rs61004609	chr20:56504175	PPP4R1L	chr20:56806189-56884495:-	-0.37	-4	0.0001	Obesity-related traits	
PAAD	cis	1	rs61037750	chr11:43681372	HSD17B12	chr11:43702143-43878160:+	-0.43	-5.87	2.58E-8	Forced vital capacity	
PAAD	cis	1	rs61102033	chr1:46382441	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs6120974	chr20:34126827	CPNE1	chr20:34213968-34262539:-	-0.76	-6.91	1.25E-10	Triglycerides	
PAAD	cis	1	rs61270113	chr5:150226263	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs61316646	chr18:44610670	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs6133036	chr20:3349682	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6139064	chr20:3277050	ITPA	chr20:3190056-3204504:+	-0.39	-5.54	1.3E-7	IFN-related cytopenia	
PAAD	cis	1	rs6139068	chr20:3284393	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6139088	chr20:3329063	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs6139103	chr20:3361140	ITPA	chr20:3190056-3204504:+	-0.4	-5.78	4.1E-8	IFN-related cytopenia	
PAAD	cis	1	rs6139117	chr20:3387785	ITPA	chr20:3190056-3204504:+	-0.35	-4.82	3.4E-6	IFN-related cytopenia	
PAAD	cis	1	rs61394483	chr6:33751945	LEMD2	chr6:33738991-33756906:-	0.36	4.33	2.67E-5	Body mass index	
PAAD	cis	1	rs6141546	chr20:33949282	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6141548	chr20:33971085	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6141549	chr20:33974051	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6142358	chr20:33960308	UQCC	chr20:33890383-33999833:-	-0.34	-4.04	8.31E-5	Height	
PAAD	cis	1	rs6142359	chr20:33960450	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6142369	chr20:33973315	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6142370	chr20:33973378	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6142373	chr20:33983314	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6142374	chr20:33985568	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6142376	chr20:33992761	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6142379	chr20:33999267	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6151429	chr22:51063477	ARSA	chr22:51063450-51066607:-	-0.94	-8.8	2.77E-15	Blood metabolite levels	
PAAD	cis	1	rs61524473	chr15:45646283	SPATA5L1	chr15:45694519-45713614:+	0.56	5.78	4.05E-8	Metabolite levels (small molecules and protein measures)	
PAAD	cis	1	rs61530785	chr5:150261364	LOC134466	chr5:150310000-150326146:-	0.78	6.49	1.15E-9	Crohn's disease	
PAAD	cis	1	rs61662306	chr6:33746697	LEMD2	chr6:33738991-33756906:-	0.36	4.33	2.67E-5	Body mass index	
PAAD	cis	1	rs61744385	chr3:41756986	ULK4	chr3:41288091-42003660:-	0.83	7.23	2.18E-11	Diastolic blood pressure	
PAAD	cis	1	rs61744388	chr3:41756965	ULK4	chr3:41288091-42003660:-	0.83	7.23	2.18E-11	Diastolic blood pressure	
PAAD	cis	1	rs61783200	chr1:46297403	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.49	1.11E-9	Body mass index	
PAAD	cis	1	rs61783220	chr1:46335312	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.87E-9	Body mass index	
PAAD	cis	1	rs61818802	chr1:113181739	ST7L	chr1:113066142-113162405:-	0.44	5.74	4.93E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs61852630	chr1:247210193	ZNF670	chr1:247200087-247242069:-	-0.5	-5.5	1.54E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs61852637	chr1:247219636	ZNF670	chr1:247200087-247242069:-	-0.47	-5.06	1.2E-6	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs61898463	chr11:46873406	C11orf49	chr11:46958251-47185929:+	-0.46	-4.05	8.08E-5	Schizophrenia	
PAAD	cis	1	rs62021219	chr15:85256159	LOC388152	chr15:84867600-84898920:-	-0.35	-4.25	3.75E-5	Schizophrenia	
PAAD	cis	1	rs62026530	chr15:84775840	LOC388152	chr15:84867600-84898920:-	-0.35	-4.2	4.54E-5	Schizophrenia	
PAAD	cis	1	rs62070270	chr17:28263980	EFCAB5	chr17:28256874-28435469:+	0.36	4.26	3.58E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs62070312	chr17:28438877	EFCAB5	chr17:28256874-28435469:+	0.36	4.13	6.01E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs62096463	chr18:44628928	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs62096464	chr18:44629207	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs62096466	chr18:44636171	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs62096468	chr18:44637566	HDHD2	chr18:44633782-44676871:-	0.46	5.06	1.19E-6	Sitting height ratio	
PAAD	cis	1	rs62096469	chr18:44638298	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs62096470	chr18:44641466	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs62096471	chr18:44643814	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs62096474	chr18:44647504	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs62096476	chr18:44658621	HDHD2	chr18:44633782-44676871:-	0.47	5.12	9.21E-7	Sitting height ratio	
PAAD	cis	1	rs62096478	chr18:44662409	HDHD2	chr18:44633782-44676871:-	0.47	5.12	9.21E-7	Sitting height ratio	
PAAD	cis	1	rs62114501	chr2:231741	SH3YL1	chr2:218138-264810:-	-0.47	-7.53	4.01E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs62114505	chr2:242426	SH3YL1	chr2:218138-264810:-	-0.47	-7.56	3.43E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs62114544	chr2:269679	SH3YL1	chr2:218138-264810:-	-0.47	-7.75	1.2E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs62114548	chr2:274672	SH3YL1	chr2:218138-264810:-	-0.47	-7.51	4.59E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs62211529	chr20:33959315	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs62268732	chr3:121370455	IQCB1	chr3:121488610-121553926:-	0.59	6.2	5.1E-9	Cognitive performance	
PAAD	cis	1	rs62269547	chr3:134214042	ANAPC13	chr3:134196547-134204865:-	0.87	11.61	9.26E-23	Height	
PAAD	cis	1	rs62271513	chr3:134298412	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.77	3.63E-23	Height	
PAAD	cis	1	rs62271514	chr3:134298554	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.77	3.63E-23	Height	
PAAD	cis	1	rs62271515	chr3:134300507	ANAPC13	chr3:134196547-134204865:-	0.86	11.36	4.41E-22	Height	
PAAD	cis	1	rs62295634	chr4:17685346	MED28	chr4:17616273-17629791:+	0.44	5.16	7.66E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs62392365	chr6:25371369	BTN3A2	chr6:26365398-26378546:+	-0.91	-5.2	6.44E-7	Schizophrenia	
PAAD	cis	1	rs631114	chr1:35753492	C1orf216	chr1:36179477-36184790:-	-0.39	-4	9.89E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs641018	chr11:65655393	CTSW	chr11:65647284-65651212:+	-0.75	-10.33	2.59E-19	Crohn's disease	
PAAD	cis	1	rs641018	chr11:65655393	SNX32	chr11:65601410-65621170:+	0.63	6.02	1.22E-8	Crohn's disease	
PAAD	cis	1	rs6421571	chr11:118743772	TREH	chr11:118528942-118550381:-	0.49	4.9	2.41E-6	Primary biliary cirrhosis	
PAAD	cis	1	rs6422512	chr1:93024844	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs6429567	chr1:45956700	CCDC163P	chr1:45960581-45965646:-	-0.96	-13.52	6.53E-28	Homocysteine levels	
PAAD	cis	1	rs6429569	chr1:46001330	CCDC163P	chr1:45960581-45965646:-	-0.9	-11.83	2.5E-23	Homocysteine levels	
PAAD	cis	1	rs6429582	chr1:46321843	CCDC163P	chr1:45960581-45965646:-	0.48	5.64	8.06E-8	Body mass index	
PAAD	cis	1	rs6430585	chr2:136506927	DARS	chr2:136664254-136743222:-	-0.37	-4.34	2.61E-5	Corneal structure	
PAAD	cis	1	rs6439484	chr3:134249899	ANAPC13	chr3:134196547-134204865:-	0.86	11.37	4.15E-22	Height	
PAAD	cis	1	rs6439487	chr3:134260860	ANAPC13	chr3:134196547-134204865:-	0.86	11.37	4.15E-22	Height	
PAAD	cis	1	rs6442117	chr3:48419897	TREX1	chr3:48501186-48509043:+	0.37	5.3	4.05E-7	Longevity	
PAAD	cis	1	rs6442118	chr3:48440047	TREX1	chr3:48501186-48509043:+	-0.38	-5.54	1.31E-7	Longevity	
PAAD	cis	1	rs6442119	chr3:48440178	TREX1	chr3:48501186-48509043:+	-0.36	-5.37	2.91E-7	Longevity	
PAAD	cis	1	rs6442120	chr3:48464503	TREX1	chr3:48501186-48509043:+	-0.36	-5.33	3.45E-7	Longevity	
PAAD	cis	1	rs6442123	chr3:48500286	TREX1	chr3:48501186-48509043:+	-0.35	-5.12	8.89E-7	Longevity	
PAAD	cis	1	rs6449319	chr4:17640283	MED28	chr4:17616273-17629791:+	0.43	5.1	9.82E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs6449323	chr4:17683916	MED28	chr4:17616273-17629791:+	0.39	4.45	1.65E-5	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs6450408	chr5:56098146	C5orf35	chr5:56205103-56213010:+	1.05	9.95	2.77E-18	Type 2 diabetes	
PAAD	cis	1	rs6450409	chr5:56101399	C5orf35	chr5:56205103-56213010:+	0.99	8.93	1.22E-15	Type 2 diabetes	
PAAD	cis	1	rs6453424	chr5:78315367	BHMT2	chr5:78365583-78385273:+	-0.19	-4.52	1.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs6453429	chr5:78371861	BHMT2	chr5:78365583-78385273:+	0.21	4.32	2.84E-5	Urinary metabolites	
PAAD	cis	1	rs6454513	chr6:86720049	SNHG5	chr6:86386726-86388451:-	0.86	11.77	3.44E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs6458685	chr6:49379536	CENPQ	chr6:49431096-49460820:+	-0.58	-8.19	9.62E-14	Homocysteine levels	
PAAD	cis	1	rs6458688	chr6:49406056	CENPQ	chr6:49431096-49460820:+	-0.56	-7.69	1.63E-12	Homocysteine levels	
PAAD	cis	1	rs6458690	chr6:49411619	CENPQ	chr6:49431096-49460820:+	-0.35	-4.03	8.85E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs6458690	chr6:49411619	MUT	chr6:49398994-49431031:-	0.29	4.09	7.06E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs6458694	chr6:49445306	CENPQ	chr6:49431096-49460820:+	-0.35	-4.02	9.11E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs6458694	chr6:49445306	MUT	chr6:49398994-49431031:-	0.3	4.23	4.05E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs6460260	chr7:65215455	CCT6P1	chr7:65216092-65228661:+	-0.42	-4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs6460261	chr7:65215580	CCT6P1	chr7:65216092-65228661:+	-0.42	-4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs6464573	chr7:143748098	ARHGEF35	chr7:143883677-143892736:-	0.4	5.16	7.5E-7	Obesity-related traits	
PAAD	cis	1	rs6464574	chr7:143748257	ARHGEF35	chr7:143883677-143892736:-	-0.43	-5.66	7.15E-8	Obesity-related traits	
PAAD	cis	1	rs6465750	chr7:99235522	CYP3A5	chr7:99245818-99332821:-	0.76	7.4	8.45E-12	Blood metabolite levels	
PAAD	cis	1	rs646867	chr1:25709258	RHCE	chr1:25688741-25756683:-	0.57	7.11	4.08E-11	Erythrocyte sedimentation rate	
PAAD	cis	1	rs646867	chr1:25709258	RHD	chr1:25598981-25656935:+	-0.56	-5.87	2.65E-8	Erythrocyte sedimentation rate	
PAAD	cis	1	rs6478484	chr9:123652380	LOC253039	chr9:123605320-123616644:+	-0.57	-7.7	1.62E-12	Rheumatoid arthritis	
PAAD	cis	1	rs6478486	chr9:123655329	LOC253039	chr9:123605320-123616644:+	-0.56	-7.47	5.73E-12	Rheumatoid arthritis	
PAAD	cis	1	rs6478867	chr9:131903923	PPP2R4	chr9:131873244-131911223:+	-0.51	-5.22	5.8E-7	Blood metabolite ratios	
PAAD	cis	1	rs6485438	chr11:43686618	HSD17B12	chr11:43702143-43878160:+	-0.42	-5.79	3.8E-8	Forced vital capacity	
PAAD	cis	1	rs6485443	chr11:43696316	HSD17B12	chr11:43702143-43878160:+	0.46	6.24	4.18E-9	Forced vital capacity	
PAAD	cis	1	rs6485700	chr11:46875933	C11orf49	chr11:46958251-47185929:+	0.44	4	9.87E-5	Schizophrenia	
PAAD	cis	1	rs6495206	chr15:76870963	SCAPER	chr15:76640529-77197744:-	-0.24	-4.45	1.64E-5	Blood metabolite levels	
PAAD	cis	1	rs6496609	chr15:90379632	AP3S2	chr15:90373832-90456222:-	-0.83	-9.81	6.45E-18	Type 2 diabetes	
PAAD	cis	1	rs6503530	chr17:38161823	GSDMA	chr17:38119226-38134019:+	-0.57	-6.29	3.12E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs6505152	chr17:28331466	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.93E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs6508977	chr19:41909346	B3GNT8	chr19:41931265-41934635:-	-0.3	-4.62	8.21E-6	Height	
PAAD	cis	1	rs6510348	chr19:33601946	GPATCH1	chr19:33571786-33621318:+	0.45	4.01	9.34E-5	Bone properties (heel)	
PAAD	cis	1	rs6516891	chr21:30483070	NCRNA00189	chr21:30565801-30660525:+	0.47	5.16	7.55E-7	Dental caries	
PAAD	cis	1	rs6519611	chr22:25845855	CRYBB2	chr22:25615612-25627836:+	1.19	7.71	1.46E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs6532078	chr4:76920809	NAAA	chr4:76831809-76862166:-	-0.45	-5.52	1.45E-7	Longevity	
PAAD	cis	1	rs6545883	chr2:61772257	AHSA2	chr2:61404553-61414058:+	-0.3	-5.51	1.51E-7	Tuberculosis	
PAAD	cis	1	rs6545883	chr2:61772257	C2orf74	chr2:61372243-61391964:+	0.54	5.89	2.33E-8	Tuberculosis	
PAAD	cis	1	rs6547872	chr2:28978074	TRMT61B	chr2:29072690-29093175:-	-0.49	-5.87	2.63E-8	Body mass index	
PAAD	cis	1	rs6555293	chr5:4486674	KIAA0947	chr5:5422807-5490337:+	-0.22	-4.27	3.42E-5	DNA methylation (variation)	
PAAD	cis	1	rs656980	chr11:65656282	CTSW	chr11:65647284-65651212:+	-0.75	-10.33	2.59E-19	Crohn's disease	
PAAD	cis	1	rs656980	chr11:65656282	SNX32	chr11:65601410-65621170:+	0.63	6.02	1.22E-8	Crohn's disease	
PAAD	cis	1	rs6574278	chr14:76663838	ESRRB	chr14:76837690-76968178:+	0.46	4.03	8.74E-5	Blood pressure	
PAAD	cis	1	rs6579234	chr20:33983485	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs6579245	chr20:34125271	CPNE1	chr20:34213968-34262539:-	-0.76	-6.91	1.25E-10	Cholesterol, total	
PAAD	cis	1	rs6579803	chr5:150255559	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs6579804	chr5:150255931	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs6579806	chr5:150271084	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs6581155	chr12:58178162	FAM119B	chr12:58166383-58176323:+	0.46	5.76	4.43E-8	Multiple sclerosis	
PAAD	cis	1	rs6584347	chr10:101906963	CWF19L1	chr10:101992055-102027437:-	-0.54	-4.62	7.97E-6	Schizophrenia	
PAAD	cis	1	rs6584349	chr10:101942556	CWF19L1	chr10:101992055-102027437:-	-0.49	-4.14	5.63E-5	Schizophrenia	
PAAD	cis	1	rs6584379	chr10:102224490	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs6584383	chr10:102303065	SEC31B	chr10:102246403-102289636:-	-0.32	-5.12	9.01E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs6589589	chr11:116932428	PCSK7	chr11:117075789-117102811:-	-0.38	-4	0.0001	Protein quantitative trait loci	
PAAD	cis	1	rs6599170	chr3:41772718	ULK4	chr3:41288091-42003660:-	0.81	7	7.35E-11	Diastolic blood pressure	
PAAD	cis	1	rs6599175	chr3:41786009	ULK4	chr3:41288091-42003660:-	-0.85	-7.86	6.36E-13	Diastolic blood pressure	
PAAD	cis	1	rs6599176	chr3:41788492	ULK4	chr3:41288091-42003660:-	-0.81	-7.16	3.08E-11	Diastolic blood pressure	
PAAD	cis	1	rs6599178	chr3:41842129	ULK4	chr3:41288091-42003660:-	0.85	7.98	3.25E-13	Diastolic blood pressure	
PAAD	cis	1	rs6599179	chr3:41855284	ULK4	chr3:41288091-42003660:-	0.85	7.93	4.32E-13	Diastolic blood pressure	
PAAD	cis	1	rs6603975	chr1:92951239	EVI5	chr1:92974255-93257961:-	-0.39	-4.18	4.93E-5	Cholesterol, total	
PAAD	cis	1	rs6603979	chr1:92979354	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs6603981	chr1:92993807	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs6603982	chr1:92994033	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs6603984	chr1:93011572	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs6603985	chr1:93017159	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs6603987	chr1:93019313	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs6603990	chr1:93030735	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs66462353	chr15:56186767	PRTG	chr15:55903748-56035177:-	0.32	4.91	2.32E-6	Keloid	
PAAD	cis	1	rs6656432	chr1:93029453	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs6656992	chr1:46333068	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.87E-9	Body mass index	
PAAD	cis	1	rs6658127	chr1:21875390	ALPL	chr1:21835858-21904904:+	-0.4	-4.84	3.08E-6	Response to TNF-alpha inhibitors in rheumatoid arthritis	
PAAD	cis	1	rs6661134	chr1:93010908	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs6661910	chr1:46290632	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.42	1.62E-9	Body mass index	
PAAD	cis	1	rs6662641	chr1:46571509	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.99	1.48E-8	Body mass index	
PAAD	cis	1	rs6667191	chr1:45982844	CCDC163P	chr1:45960581-45965646:-	-0.96	-13.52	6.53E-28	Homocysteine levels	
PAAD	cis	1	rs6668284	chr1:46354510	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs6669522	chr1:46397941	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs6670533	chr1:24584490	C1orf130	chr1:24882602-24935816:+	0.6	4.3	3.02E-5	Fasting insulin-related traits (interaction with BMI)	
PAAD	cis	1	rs6671953	chr1:35802681	C1orf216	chr1:36179477-36184790:-	0.39	4	9.89E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs6672898	chr1:46290588	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.49	1.11E-9	Body mass index	
PAAD	cis	1	rs6675726	chr1:46560643	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs6675946	chr1:46371774	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs6677007	chr1:46400590	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs66775662	chr6:151876216	C6orf97	chr6:151815175-151942327:+	0.47	4.11	6.43E-5	Bone mineral density (spine)	
PAAD	cis	1	rs6679073	chr1:205756484	PM20D1	chr1:205797154-205819245:-	-0.39	-4.2	4.46E-5	Prostate-specific antigen levels	
PAAD	cis	1	rs6679	chr1:113243048	ST7L	chr1:113066142-113162405:-	0.46	5.96	1.7E-8	Diastolic blood pressure;Blood pressure	
PAAD	cis	1	rs6680380	chr1:46300189	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.49	1.11E-9	Body mass index	
PAAD	cis	1	rs6686643	chr1:165616588	MGST3	chr1:165600450-165624853:+	0.31	4.37	2.24E-5	Total ventricular volume	
PAAD	cis	1	rs6690764	chr1:92976590	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs6695809	chr1:46285461	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.49	1.11E-9	Body mass index	
PAAD	cis	1	rs66990486	chr9:100680919	C9orf156	chr9:100666772-100684852:-	-0.34	-4.66	6.76E-6	Quantitative traits	
PAAD	cis	1	rs6700597	chr1:46284246	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.5	1.1E-9	Body mass index	
PAAD	cis	1	rs6701614	chr1:46309420	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.49	1.11E-9	Body mass index	
PAAD	cis	1	rs6707848	chr2:28988083	TRMT61B	chr2:29072690-29093175:-	-0.49	-5.87	2.63E-8	Body mass index	
PAAD	cis	1	rs6708328	chr2:24412413	C2orf84	chr2:24397531-24414566:+	0.51	5.68	6.5E-8	Venous thromboembolism (SNP x SNP interaction)	
PAAD	cis	1	rs6709534	chr2:217334	SH3YL1	chr2:218138-264810:-	-0.47	-7.48	5.52E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs6710959	chr2:28958603	TRMT61B	chr2:29072690-29093175:-	-0.49	-5.93	1.97E-8	Body mass index	
PAAD	cis	1	rs6711941	chr2:202178130	PPIL3	chr2:201735680-201753999:-	-0.69	-4.16	5.22E-5	Rheumatoid arthritis	
PAAD	cis	1	rs6715284	chr2:202154397	PPIL3	chr2:201735680-201753999:-	-0.7	-4.46	1.56E-5	Rheumatoid arthritis	
PAAD	cis	1	rs67239267	chr7:143745116	ARHGEF35	chr7:143883677-143892736:-	-0.41	-5.42	2.29E-7	Obesity-related traits	
PAAD	cis	1	rs67257959	chr19:17158145	HAUS8	chr19:17160573-17186343:-	-0.4	-5.41	2.37E-7	Selective IgA deficiency	
PAAD	cis	1	rs6732236	chr2:136501509	DARS	chr2:136664254-136743222:-	0.36	4.08	7.36E-5	Corneal structure	
PAAD	cis	1	rs6740462	chr2:65667272	SERTAD2	chr2:64858756-64881046:-	0.36	4.11	6.48E-5	Crohn's disease;Inflammatory bowel disease	
PAAD	cis	1	rs6742276	chr2:61768745	AHSA2	chr2:61404553-61414058:+	-0.32	-6.4	1.84E-9	Tuberculosis	
PAAD	cis	1	rs6742276	chr2:61768745	C2orf74	chr2:61372243-61391964:+	0.56	6.37	2.12E-9	Tuberculosis	
PAAD	cis	1	rs67445790	chr6:151876730	C6orf97	chr6:151815175-151942327:+	0.47	4.11	6.43E-5	Bone mineral density (spine)	
PAAD	cis	1	rs67505007	chr15:56196253	PRTG	chr15:55903748-56035177:-	0.31	4.83	3.27E-6	Keloid	
PAAD	cis	1	rs6759004	chr2:202004676	PPIL3	chr2:201735680-201753999:-	-1.02	-7.49	5.17E-12	Triptolide cytotoxicity	
PAAD	cis	1	rs6763088	chr3:134254989	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.87	1.92E-23	Height	
PAAD	cis	1	rs6763093	chr3:134254995	ANAPC13	chr3:134196547-134204865:-	-0.87	-11.75	3.95E-23	Height	
PAAD	cis	1	rs6763829	chr3:41897046	ULK4	chr3:41288091-42003660:-	0.85	7.66	1.98E-12	Diastolic blood pressure	
PAAD	cis	1	rs6765505	chr3:134208132	ANAPC13	chr3:134196547-134204865:-	0.87	11.5	1.93E-22	Height	
PAAD	cis	1	rs6766818	chr3:134226159	ANAPC13	chr3:134196547-134204865:-	0.89	12.08	5.22E-24	Height	
PAAD	cis	1	rs6766897	chr3:134191303	ANAPC13	chr3:134196547-134204865:-	0.87	12.21	2.28E-24	Height	
PAAD	cis	1	rs6768128	chr3:41865080	ULK4	chr3:41288091-42003660:-	0.85	7.81	8.56E-13	Diastolic blood pressure	
PAAD	cis	1	rs6768542	chr3:41865474	ULK4	chr3:41288091-42003660:-	0.85	7.81	8.56E-13	Diastolic blood pressure	
PAAD	cis	1	rs6768563	chr3:41865541	ULK4	chr3:41288091-42003660:-	0.85	7.81	8.56E-13	Diastolic blood pressure	
PAAD	cis	1	rs6769885	chr3:134286913	ANAPC13	chr3:134196547-134204865:-	0.86	11.15	1.63E-21	Height	
PAAD	cis	1	rs6770470	chr3:48435123	TREX1	chr3:48501186-48509043:+	-0.38	-5.54	1.31E-7	Longevity	
PAAD	cis	1	rs67728539	chr7:65378124	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs6772896	chr3:134203347	ANAPC13	chr3:134196547-134204865:-	0.89	12.27	1.59E-24	Height	
PAAD	cis	1	rs6776700	chr3:48496758	TREX1	chr3:48501186-48509043:+	-0.36	-5.22	5.78E-7	Longevity	
PAAD	cis	1	rs677977	chr1:147083744	ACP6	chr1:147119168-147142634:-	-0.33	-4.2	4.47E-5	Schizophrenia (negative symptoms)	
PAAD	cis	1	rs6781326	chr3:41777028	ULK4	chr3:41288091-42003660:-	0.83	7.44	6.64E-12	Diastolic blood pressure	
PAAD	cis	1	rs6782563	chr3:134295959	ANAPC13	chr3:134196547-134204865:-	-0.86	-11.36	4.41E-22	Height	
PAAD	cis	1	rs6783001	chr3:41862232	ULK4	chr3:41288091-42003660:-	0.86	7.94	3.93E-13	Diastolic blood pressure	
PAAD	cis	1	rs6784322	chr3:48422235	TREX1	chr3:48501186-48509043:+	-0.39	-5.52	1.41E-7	Longevity	
PAAD	cis	1	rs6785027	chr3:134211649	ANAPC13	chr3:134196547-134204865:-	-0.86	-11.7	5.32E-23	Height	
PAAD	cis	1	rs6787371	chr3:134254991	ANAPC13	chr3:134196547-134204865:-	0.86	11.37	4.15E-22	Height	
PAAD	cis	1	rs6789260	chr3:41776350	ULK4	chr3:41288091-42003660:-	0.85	7.54	3.89E-12	Diastolic blood pressure	
PAAD	cis	1	rs6790466	chr3:134197740	ANAPC13	chr3:134196547-134204865:-	0.89	12.19	2.56E-24	Height	
PAAD	cis	1	rs6790732	chr3:41864872	ULK4	chr3:41288091-42003660:-	0.86	7.94	3.93E-13	Diastolic blood pressure	
PAAD	cis	1	rs6791806	chr3:41889995	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs67927699	chr2:61187415	C2orf74	chr2:61372243-61391964:+	0.48	5.08	1.1E-6	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
PAAD	cis	1	rs6793487	chr3:134299426	ANAPC13	chr3:134196547-134204865:-	-0.86	-11.36	4.41E-22	Height	
PAAD	cis	1	rs6794875	chr3:48455626	TREX1	chr3:48501186-48509043:+	-0.36	-5.29	4.26E-7	Longevity	
PAAD	cis	1	rs6796210	chr3:41851718	ULK4	chr3:41288091-42003660:-	0.85	7.93	4.32E-13	Diastolic blood pressure	
PAAD	cis	1	rs6796491	chr3:48430465	TREX1	chr3:48501186-48509043:+	-0.39	-5.64	7.81E-8	Longevity	
PAAD	cis	1	rs6797165	chr3:41887777	ULK4	chr3:41288091-42003660:-	0.85	7.67	1.86E-12	Diastolic blood pressure	
PAAD	cis	1	rs6800862	chr3:134228628	ANAPC13	chr3:134196547-134204865:-	0.87	11.86	2.04E-23	Height	
PAAD	cis	1	rs6801343	chr3:41767234	ULK4	chr3:41288091-42003660:-	0.81	7	7.35E-11	Diastolic blood pressure	
PAAD	cis	1	rs6801596	chr3:134252114	ANAPC13	chr3:134196547-134204865:-	0.86	11.61	9.4E-23	Height	
PAAD	cis	1	rs6802340	chr3:41894034	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs6802654	chr3:134217072	ANAPC13	chr3:134196547-134204865:-	0.87	11.61	9.26E-23	Height	
PAAD	cis	1	rs6803560	chr3:41824480	ULK4	chr3:41288091-42003660:-	0.85	7.92	4.5E-13	Diastolic blood pressure	
PAAD	cis	1	rs6803652	chr3:41824556	ULK4	chr3:41288091-42003660:-	0.85	7.92	4.5E-13	Diastolic blood pressure	
PAAD	cis	1	rs6804770	chr3:134230234	ANAPC13	chr3:134196547-134204865:-	0.87	11.61	9.26E-23	Height	
PAAD	cis	1	rs6804774	chr3:48430617	TREX1	chr3:48501186-48509043:+	-0.39	-5.64	7.81E-8	Longevity	
PAAD	cis	1	rs6805880	chr3:41865397	ULK4	chr3:41288091-42003660:-	0.85	7.81	8.56E-13	Diastolic blood pressure	
PAAD	cis	1	rs6806417	chr3:134211446	ANAPC13	chr3:134196547-134204865:-	-0.85	-11.47	2.23E-22	Height	
PAAD	cis	1	rs6807015	chr3:41754514	ULK4	chr3:41288091-42003660:-	0.84	7.32	1.31E-11	Diastolic blood pressure	
PAAD	cis	1	rs6810060	chr3:48434748	TREX1	chr3:48501186-48509043:+	-0.38	-5.54	1.31E-7	Longevity	
PAAD	cis	1	rs6811887	chr4:17640858	MED28	chr4:17616273-17629791:+	0.45	5.36	2.96E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs68171315	chr6:86707400	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs6818639	chr4:17633049	MED28	chr4:17616273-17629791:+	0.46	5.47	1.83E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs68189316	chr7:65409169	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs6827617	chr4:76916146	NAAA	chr4:76831809-76862166:-	-0.45	-5.52	1.45E-7	Longevity	
PAAD	cis	1	rs6832503	chr4:48028442	CNGA1	chr4:47937996-48018610:-	-0.46	-5.16	7.52E-7	Renal underexcretion gout;Gout	
PAAD	cis	1	rs6832503	chr4:48028442	NIPAL1	chr4:48018791-48039078:+	-0.41	-7.01	7.31E-11	Renal underexcretion gout;Gout	
PAAD	cis	1	rs6846238	chr4:17629939	MED28	chr4:17616273-17629791:+	0.48	5.77	4.25E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs6848360	chr4:17634442	MED28	chr4:17616273-17629791:+	0.42	5.09	1.04E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs6849704	chr4:17652031	MED28	chr4:17616273-17629791:+	0.46	5.49	1.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs6854733	chr4:17640526	MED28	chr4:17616273-17629791:+	0.46	5.49	1.67E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs6862814	chr5:150245259	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs6863111	chr5:4485808	KIAA0947	chr5:5422807-5490337:+	-0.23	-4.45	1.63E-5	DNA methylation (variation)	
PAAD	cis	1	rs6865893	chr5:78324767	BHMT2	chr5:78365583-78385273:+	0.18	4.37	2.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs6874560	chr5:150182713	LOC134466	chr5:150310000-150326146:-	0.85	6.85	1.72E-10	Crohn's disease	
PAAD	cis	1	rs6875011	chr5:150182710	LOC134466	chr5:150310000-150326146:-	0.76	6.3	2.97E-9	Crohn's disease	
PAAD	cis	1	rs687672	chr11:65649984	CTSW	chr11:65647284-65651212:+	0.75	10.33	2.59E-19	Crohn's disease	
PAAD	cis	1	rs687672	chr11:65649984	SNX32	chr11:65601410-65621170:+	-0.63	-6.02	1.22E-8	Crohn's disease	
PAAD	cis	1	rs6877621	chr5:78314379	BHMT2	chr5:78365583-78385273:+	0.19	4.52	1.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs6882500	chr5:4485755	KIAA0947	chr5:5422807-5490337:+	-0.22	-4.27	3.42E-5	DNA methylation (variation)	
PAAD	cis	1	rs6885541	chr5:56110857	C5orf35	chr5:56205103-56213010:+	1.06	10.16	7.59E-19	Type 2 diabetes	
PAAD	cis	1	rs6901575	chr6:28250984	ZSCAN23	chr6:28393287-28411279:-	0.44	4.4	2.04E-5	Depression	
PAAD	cis	1	rs6902429	chr6:49393500	CENPQ	chr6:49431096-49460820:+	-0.56	-7.72	1.45E-12	Homocysteine levels	
PAAD	cis	1	rs6904133	chr6:151881805	C6orf97	chr6:151815175-151942327:+	0.48	4.08	7.35E-5	Bone mineral density (spine)	
PAAD	cis	1	rs6904991	chr6:33732262	LEMD2	chr6:33738991-33756906:-	-0.32	-4.66	6.76E-6	Crohn's disease	
PAAD	cis	1	rs6905391	chr6:28262686	ZSCAN23	chr6:28393287-28411279:-	0.47	4.67	6.61E-6	Depression	
PAAD	cis	1	rs6908390	chr6:25609756	HIST1H3D	chr6:26197013-26199464:-	0.38	4.19	4.67E-5	Uric acid levels	
PAAD	cis	1	rs6914463	chr6:86653415	SNHG5	chr6:86386726-86388451:-	-0.87	-12.26	1.72E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs6915187	chr6:49423547	CENPQ	chr6:49431096-49460820:+	-0.6	-8.45	2.13E-14	Homocysteine levels	
PAAD	cis	1	rs6916888	chr6:49383804	CENPQ	chr6:49431096-49460820:+	-0.56	-7.74	1.27E-12	Homocysteine levels	
PAAD	cis	1	rs6918347	chr6:49406348	CENPQ	chr6:49431096-49460820:+	-0.56	-7.69	1.63E-12	Homocysteine levels	
PAAD	cis	1	rs6920075	chr6:33731797	LEMD2	chr6:33738991-33756906:-	-0.32	-4.66	6.71E-6	Crohn's disease	
PAAD	cis	1	rs6921487	chr6:33749293	LEMD2	chr6:33738991-33756906:-	0.33	4.05	8.24E-5	Body mass index	
PAAD	cis	1	rs6923124	chr6:49419864	CENPQ	chr6:49431096-49460820:+	-0.35	-4.09	6.99E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs6923124	chr6:49419864	MUT	chr6:49398994-49431031:-	0.3	4.24	3.78E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs6923148	chr6:86767786	SNHG5	chr6:86386726-86388451:-	0.87	11.98	9.48E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs6925273	chr6:33732448	LEMD2	chr6:33738991-33756906:-	-0.31	-4.54	1.13E-5	Crohn's disease	
PAAD	cis	1	rs6930201	chr6:33738749	LEMD2	chr6:33738991-33756906:-	0.33	4.05	8.24E-5	Body mass index	
PAAD	cis	1	rs6933174	chr6:33751003	LEMD2	chr6:33738991-33756906:-	0.36	4.33	2.67E-5	Body mass index	
PAAD	cis	1	rs6933377	chr6:86705255	SNHG5	chr6:86386726-86388451:-	0.7	9.58	2.54E-17	Response to antipsychotic treatment	
PAAD	cis	1	rs6933568	chr6:33751261	LEMD2	chr6:33738991-33756906:-	0.36	4.33	2.67E-5	Body mass index	
PAAD	cis	1	rs6933607	chr6:33743997	LEMD2	chr6:33738991-33756906:-	0.36	4.33	2.67E-5	Body mass index	
PAAD	cis	1	rs6936048	chr6:86702608	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.85E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs693824	chr11:65654783	CTSW	chr11:65647284-65651212:+	-0.75	-10.33	2.59E-19	Crohn's disease	
PAAD	cis	1	rs693824	chr11:65654783	SNX32	chr11:65601410-65621170:+	0.63	6.02	1.22E-8	Crohn's disease	
PAAD	cis	1	rs6940353	chr6:33752550	LEMD2	chr6:33738991-33756906:-	0.36	4.33	2.67E-5	Body mass index	
PAAD	cis	1	rs6940458	chr6:86644992	SNHG5	chr6:86386726-86388451:-	-0.84	-11.44	2.8E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs6948775	chr7:98945480	CYP3A5	chr7:99245818-99332821:-	0.59	5.54	1.32E-7	Blood metabolite levels	
PAAD	cis	1	rs6949812	chr7:65387101	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs694994	chr11:65653309	CTSW	chr11:65647284-65651212:+	-0.75	-10.41	1.59E-19	Crohn's disease	
PAAD	cis	1	rs694994	chr11:65653309	SNX32	chr11:65601410-65621170:+	0.63	6.06	9.96E-9	Crohn's disease	
PAAD	cis	1	rs6951245	chr7:1058193	ZFAND2A	chr7:1192544-1199855:-	-0.55	-4.47	1.51E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs6970243	chr7:65388490	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs6974373	chr7:99590893	CYP3A5	chr7:99245818-99332821:-	-0.25	-4.1	6.7E-5	Interstitial lung disease	
PAAD	cis	1	rs6974373	chr7:99590893	TRIM4	chr7:99488037-99517154:-	-0.4	-5.33	3.39E-7	Interstitial lung disease	
PAAD	cis	1	rs7007450	chr8:71640269	XKR9	chr8:71581600-71648176:+	0.5	8.01	2.76E-13	Bone mineral density	
PAAD	cis	1	rs7014273	chr8:67358694	ADHFE1	chr8:67344718-67381042:+	0.3	4.02	9.08E-5	Blood metabolite levels	
PAAD	cis	1	rs7017914	chr8:71591203	XKR9	chr8:71581600-71648176:+	0.5	8.02	2.6E-13	Bone mineral density	
PAAD	cis	1	rs7020708	chr9:131885131	PPP2R4	chr9:131873244-131911223:+	0.44	4.41	1.9E-5	Blood metabolite ratios	
PAAD	cis	1	rs7021449	chr9:131899312	PPP2R4	chr9:131873244-131911223:+	0.49	5	1.57E-6	Blood metabolite ratios	
PAAD	cis	1	rs7023900	chr9:131891152	PPP2R4	chr9:131873244-131911223:+	0.5	5.07	1.13E-6	Blood metabolite ratios	
PAAD	cis	1	rs7030887	chr9:100688511	C9orf156	chr9:100666772-100684852:-	-0.33	-4.61	8.38E-6	Quantitative traits	
PAAD	cis	1	rs7030907	chr9:100688577	C9orf156	chr9:100666772-100684852:-	-0.33	-4.61	8.38E-6	Quantitative traits	
PAAD	cis	1	rs7036114	chr9:131893406	PPP2R4	chr9:131873244-131911223:+	0.5	5.07	1.13E-6	Blood metabolite ratios	
PAAD	cis	1	rs7036236	chr9:131899299	PPP2R4	chr9:131873244-131911223:+	0.43	4.33	2.72E-5	Blood metabolite ratios	
PAAD	cis	1	rs7037140	chr9:123656327	LOC253039	chr9:123605320-123616644:+	-0.56	-7.47	5.73E-12	Rheumatoid arthritis	
PAAD	cis	1	rs7037163	chr9:131894340	PPP2R4	chr9:131873244-131911223:+	0.43	4.37	2.32E-5	Blood metabolite ratios	
PAAD	cis	1	rs703842	chr12:58162739	FAM119B	chr12:58166383-58176323:+	-0.47	-5.91	2.16E-8	Multiple sclerosis	
PAAD	cis	1	rs705696	chr12:56480648	RPS26	chr12:56435686-56438005:+	0.54	6.11	7.95E-9	Cognitive function	
PAAD	cis	1	rs7061710	chr1:171080615	FMO3	chr1:171060018-171086957:+	-0.53	-6.24	4.02E-9	Blood metabolite levels	
PAAD	cis	1	rs7070296	chr10:65070438	NRBF2	chr10:64893007-64914785:+	-0.38	-5.16	7.4E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs7070776	chr10:102264672	SEC31B	chr10:102246403-102289636:-	-0.35	-5.75	4.71E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7071271	chr10:102264824	SEC31B	chr10:102246403-102289636:-	-0.35	-5.8	3.65E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7072216	chr10:100156853	PYROXD2	chr10:100143323-100174978:-	0.62	7.49	5.03E-12	Metabolite levels	
PAAD	cis	1	rs7073586	chr10:102307671	SEC31B	chr10:102246403-102289636:-	-0.33	-5.45	1.95E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7073746	chr10:64904071	NRBF2	chr10:64893007-64914785:+	-0.37	-5.07	1.15E-6	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs7078799	chr10:102301447	SEC31B	chr10:102246403-102289636:-	-0.34	-5.46	1.9E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7079136	chr10:102292709	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7079756	chr10:102302105	SEC31B	chr10:102246403-102289636:-	-0.33	-5.45	1.95E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7080356	chr10:102266735	SEC31B	chr10:102246403-102289636:-	-0.35	-5.75	4.74E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7084810	chr10:102297546	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7085439	chr10:102210100	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7088512	chr10:102303498	SEC31B	chr10:102246403-102289636:-	-0.33	-5.45	1.94E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7088827	chr10:102303865	SEC31B	chr10:102246403-102289636:-	-0.34	-5.51	1.51E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7090431	chr10:102261753	SEC31B	chr10:102246403-102289636:-	-0.35	-5.75	4.74E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs709592	chr17:38175553	GSDMA	chr17:38119226-38134019:+	-0.56	-6.21	4.72E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs7095944	chr10:126302936	METTL10	chr10:126447406-126480439:-	-0.44	-4.85	3.01E-6	Asthma	
PAAD	cis	1	rs709607	chr7:65449541	CCT6P1	chr7:65216092-65228661:+	-0.43	-4.26	3.61E-5	Diabetic kidney disease	
PAAD	cis	1	rs7099913	chr10:102314777	SEC31B	chr10:102246403-102289636:-	-0.32	-5.12	8.98E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7099965	chr10:102301165	SEC31B	chr10:102246403-102289636:-	-0.34	-5.46	1.9E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7100386	chr10:102301417	SEC31B	chr10:102246403-102289636:-	-0.34	-5.46	1.9E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7111	chr15:90373873	AP3S2	chr15:90373832-90456222:-	-0.83	-9.81	6.45E-18	Type 2 diabetes	
PAAD	cis	1	rs7112060	chr11:46891901	C11orf49	chr11:46958251-47185929:+	-0.46	-4.1	6.76E-5	Schizophrenia	
PAAD	cis	1	rs7115737	chr11:43681249	HSD17B12	chr11:43702143-43878160:+	-0.43	-5.87	2.58E-8	Forced vital capacity	
PAAD	cis	1	rs713219	chr9:131900920	PPP2R4	chr9:131873244-131911223:+	0.49	5	1.57E-6	Blood metabolite ratios	
PAAD	cis	1	rs71327718	chr3:125592857	LOC100125556	chr3:125635444-125648865:+	0.77	6.49	1.12E-9	Metabolite levels (HVA/5-HIAA ratio)	
PAAD	cis	1	rs7134594	chr12:110000193	MYO1H	chr12:109826524-109886176:+	0.49	4.61	8.6E-6	HDL cholesterol	
PAAD	cis	1	rs7142235	chr14:75559963	EIF2B2	chr14:75469612-75476292:+	0.39	4.36	2.38E-5	Height	
PAAD	cis	1	rs7144423	chr14:35572547	PPP2R3C	chr14:35554679-35591679:-	0.54	5.44	2.11E-7	Atopic dermatitis	
PAAD	cis	1	rs7145159	chr14:75583268	EIF2B2	chr14:75469612-75476292:+	0.36	4.09	7.0E-5	Height	
PAAD	cis	1	rs7147118	chr14:75610170	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs7153160	chr14:74509377	LIN52	chr14:74551656-74667117:+	0.42	7.4	8.58E-12	Common traits (Other)	
PAAD	cis	1	rs7153587	chr14:74509660	LIN52	chr14:74551656-74667117:+	0.43	7.66	2.01E-12	Common traits (Other)	
PAAD	cis	1	rs7154306	chr14:35540499	PPP2R3C	chr14:35554679-35591679:-	0.56	5.79	3.87E-8	Atopic dermatitis	
PAAD	cis	1	rs71550519	chr6:56780272	BEND6	chr6:56819773-56892138:+	-0.41	-5.1	9.73E-7	Menarche (age at onset)	
PAAD	cis	1	rs7155454	chr14:65502239	CHURC1	chr14:65381140-65411309:+	0.34	4.07	7.53E-5	Red blood cell traits	
PAAD	cis	1	rs7156105	chr14:75541954	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs7156322	chr14:35544330	PPP2R3C	chr14:35554679-35591679:-	0.56	5.79	3.87E-8	Atopic dermatitis	
PAAD	cis	1	rs71564866	chr6:56771207	BEND6	chr6:56819773-56892138:+	-0.41	-5.1	9.73E-7	Menarche (age at onset)	
PAAD	cis	1	rs71564868	chr6:56798441	BEND6	chr6:56819773-56892138:+	-0.39	-4.78	4.0E-6	Menarche (age at onset)	
PAAD	cis	1	rs7157566	chr14:74649129	LIN52	chr14:74551656-74667117:+	-0.43	-7.66	2.01E-12	Common traits (Other)	
PAAD	cis	1	rs7157940	chr14:94563193	IFI27L1	chr14:94547639-94569059:+	0.39	5.35	3.15E-7	Anthropometric traits	
PAAD	cis	1	rs7162435	chr15:56121334	PRTG	chr15:55903748-56035177:-	-0.29	-4.51	1.3E-5	Keloid	
PAAD	cis	1	rs7164132	chr15:40675155	C15orf23	chr15:40674922-40686488:+	0.73	8.96	1.03E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs7166991	chr15:40671957	C15orf23	chr15:40674922-40686488:+	0.76	9.24	2.01E-16	Heschl's gyrus morphology	
PAAD	cis	1	rs7169404	chr15:40675443	C15orf23	chr15:40674922-40686488:+	0.73	8.96	1.03E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs7176225	chr15:56126857	PRTG	chr15:55903748-56035177:-	0.32	4.93	2.16E-6	Keloid	
PAAD	cis	1	rs7191665	chr16:74688948	RFWD3	chr16:74655298-74700779:-	-0.3	-4.39	2.09E-5	Testicular germ cell tumor	
PAAD	cis	1	rs7201320	chr16:74694058	RFWD3	chr16:74655298-74700779:-	-0.3	-4.39	2.09E-5	Testicular germ cell tumor	
PAAD	cis	1	rs7205409	chr16:642610	WFIKKN1	chr16:679239-684116:+	0.32	4.36	2.42E-5	Height	
PAAD	cis	1	rs7207021	chr17:28400516	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.03	8.6E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs7209180	chr17:79581519	TSPAN10	chr17:79609349-79615778:+	0.74	9.99	2.09E-18	Eye color traits	
PAAD	cis	1	rs7210738	chr17:45757598	C17orf57	chr17:45401142-45518675:+	-0.44	-5.22	5.88E-7	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs7210738	chr17:45757598	TBKBP1	chr17:45772630-45789427:+	0.27	4.24	3.88E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs7212497	chr17:28335949	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.93E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs7213129	chr17:79581573	TSPAN10	chr17:79609349-79615778:+	0.74	9.99	2.09E-18	Eye color traits	
PAAD	cis	1	rs7214085	chr17:38169095	GSDMA	chr17:38119226-38134019:+	-0.57	-6.29	3.12E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs7221109	chr17:38770286	SMARCE1	chr17:38783976-38804103:-	-0.35	-4.11	6.52E-5	Type 1 diabetes	
PAAD	cis	1	rs7222241	chr17:79574714	TSPAN10	chr17:79609349-79615778:+	0.75	10.07	1.27E-18	Eye color traits	
PAAD	cis	1	rs7222308	chr17:28277041	EFCAB5	chr17:28256874-28435469:+	0.36	4.12	6.28E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs7223613	chr17:79574803	TSPAN10	chr17:79609349-79615778:+	-0.74	-9.99	2.09E-18	Eye color traits	
PAAD	cis	1	rs7223786	chr17:28332107	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.93E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs725309	chr3:48418708	TREX1	chr3:48501186-48509043:+	0.36	5.23	5.39E-7	Longevity	
PAAD	cis	1	rs725310	chr3:48418571	TREX1	chr3:48501186-48509043:+	0.36	5.25	4.93E-7	Longevity	
PAAD	cis	1	rs7254758	chr19:33608047	GPATCH1	chr19:33571786-33621318:+	0.46	4.14	5.67E-5	Bone properties (heel)	
PAAD	cis	1	rs7255679	chr19:42063981	CEACAM21	chr19:42055886-42093196:+	0.51	7.64	2.19E-12	Schizophrenia	
PAAD	cis	1	rs7259376	chr19:22507705	ZNF98	chr19:22573899-22605148:-	-0.29	-4.19	4.75E-5	Telomere length	
PAAD	cis	1	rs72644211	chr10:81781695	LOC219347	chr10:81805991-81838949:-	0.94	9.08	5.0E-16	Chronic obstructive pulmonary disease-related biomarkers	
PAAD	cis	1	rs72644212	chr10:81782514	LOC219347	chr10:81805991-81838949:-	0.94	9.39	8.1E-17	Chronic obstructive pulmonary disease-related biomarkers	
PAAD	cis	1	rs72644213	chr10:81783660	LOC219347	chr10:81805991-81838949:-	0.94	9.56	2.85E-17	Chronic obstructive pulmonary disease-related biomarkers	
PAAD	cis	1	rs72696952	chr1:152172694	FLG	chr1:152274651-152297679:-	0.47	4.91	2.32E-6	Atopic dermatitis	
PAAD	cis	1	rs72696963	chr1:152181189	FLG	chr1:152274651-152297679:-	0.49	5.05	1.23E-6	Atopic dermatitis	
PAAD	cis	1	rs72696969	chr1:152196339	FLG	chr1:152274651-152297679:-	0.47	4.97	1.81E-6	Atopic dermatitis	
PAAD	cis	1	rs72696989	chr1:152248674	FLG	chr1:152274651-152297679:-	0.48	4.82	3.48E-6	Atopic dermatitis	
PAAD	cis	1	rs72697000	chr1:152276772	FLG	chr1:152274651-152297679:-	0.49	4.72	5.23E-6	Atopic dermatitis	
PAAD	cis	1	rs72698906	chr1:152307184	FLG	chr1:152274651-152297679:-	0.48	4.92	2.2E-6	Atopic dermatitis	
PAAD	cis	1	rs727005	chr1:36281336	C1orf216	chr1:36179477-36184790:-	-0.32	-4.17	5.03E-5	Schizophrenia	
PAAD	cis	1	rs72768397	chr1:247219411	ZNF670	chr1:247200087-247242069:-	-0.47	-5.1	1.0E-6	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs72782294	chr2:28953390	TRMT61B	chr2:29072690-29093175:-	0.49	5.93	1.97E-8	Body mass index	
PAAD	cis	1	rs72800847	chr16:31022639	MYST1	chr16:31128985-31142713:+	0.34	4.3	3.07E-5	Response to metformin (IC50)	
PAAD	cis	1	rs72819593	chr17:2199489	SRR	chr17:2207248-2228553:+	-0.53	-9.19	2.61E-16	Esophageal cancer (squamous cell)	
PAAD	cis	1	rs72840063	chr2:85550396	TGOLN2	chr2:85545147-85555374:-	-0.32	-4.86	2.85E-6	Ear protrusion	
PAAD	cis	1	rs72843784	chr6:26498758	BTN3A2	chr6:26365398-26378546:+	-1.04	-8.31	4.68E-14	Schizophrenia	
PAAD	cis	1	rs7285549	chr22:25874580	CRYBB2	chr22:25615612-25627836:+	1.19	7.71	1.46E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs72874862	chr1:24583939	C1orf130	chr1:24882602-24935816:+	0.59	4.25	3.74E-5	Fasting insulin-related traits (interaction with BMI)	
PAAD	cis	1	rs72922733	chr11:65520746	SNX32	chr11:65601410-65621170:+	0.67	5.61	9.06E-8	Systemic lupus erythematosus	
PAAD	cis	1	rs73069392	chr3:41787009	ULK4	chr3:41288091-42003660:-	0.84	7.42	7.58E-12	Diastolic blood pressure	
PAAD	cis	1	rs73069394	chr3:41787233	ULK4	chr3:41288091-42003660:-	0.84	7.73	1.3E-12	Diastolic blood pressure	
PAAD	cis	1	rs73069396	chr3:41787236	ULK4	chr3:41288091-42003660:-	0.84	7.73	1.3E-12	Diastolic blood pressure	
PAAD	cis	1	rs73071329	chr3:41810539	ULK4	chr3:41288091-42003660:-	0.86	8.02	2.54E-13	Diastolic blood pressure	
PAAD	cis	1	rs73074358	chr3:48427247	TREX1	chr3:48501186-48509043:+	-0.39	-5.64	7.81E-8	Longevity	
PAAD	cis	1	rs73077367	chr3:41851959	ULK4	chr3:41288091-42003660:-	0.87	8.19	9.59E-14	Diastolic blood pressure	
PAAD	cis	1	rs73079316	chr3:41863859	ULK4	chr3:41288091-42003660:-	0.86	7.96	3.64E-13	Diastolic blood pressure	
PAAD	cis	1	rs73079321	chr3:41863910	ULK4	chr3:41288091-42003660:-	0.86	8.03	2.38E-13	Diastolic blood pressure	
PAAD	cis	1	rs73081353	chr3:41906448	ULK4	chr3:41288091-42003660:-	0.85	7.51	4.7E-12	Diastolic blood pressure	
PAAD	cis	1	rs73081364	chr3:41913616	ULK4	chr3:41288091-42003660:-	0.85	7.51	4.7E-12	Diastolic blood pressure	
PAAD	cis	1	rs731123	chr5:78317728	BHMT2	chr5:78365583-78385273:+	0.18	4.36	2.35E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs731124	chr5:78317413	BHMT2	chr5:78365583-78385273:+	0.18	4.37	2.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs73116394	chr2:242367915	SEPT2	chr2:242254723-242293439:+	0.63	6.47	1.26E-9	Chronic lymphocytic leukemia	
PAAD	cis	1	rs73116396	chr2:242368693	SEPT2	chr2:242254723-242293439:+	0.62	6.4	1.83E-9	Chronic lymphocytic leukemia	
PAAD	cis	1	rs73142121	chr7:65311206	CCT6P1	chr7:65216092-65228661:+	0.45	4.46	1.59E-5	Diabetic kidney disease	
PAAD	cis	1	rs73142122	chr7:65311298	CCT6P1	chr7:65216092-65228661:+	0.42	4.15	5.53E-5	Diabetic kidney disease	
PAAD	cis	1	rs73142162	chr7:65374296	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs73142166	chr7:65375832	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs73150014	chr7:65450919	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs73198787	chr3:126787210	CHST13	chr3:126243176-126262133:+	0.48	4.58	9.68E-6	Amyotrophic lateral sclerosis (sporadic)	
PAAD	cis	1	rs732172	chr16:31050033	MYST1	chr16:31128985-31142713:+	0.38	4.84	3.11E-6	Response to metformin (IC50)	
PAAD	cis	1	rs732173	chr16:31050023	MYST1	chr16:31128985-31142713:+	0.38	4.84	3.11E-6	Response to metformin (IC50)	
PAAD	cis	1	rs73282209	chr5:150174959	LOC134466	chr5:150310000-150326146:-	0.75	6.3	2.96E-9	Crohn's disease	
PAAD	cis	1	rs73282234	chr5:150195924	LOC134466	chr5:150310000-150326146:-	0.76	6.3	2.97E-9	Crohn's disease	
PAAD	cis	1	rs73282255	chr5:150223647	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs73284126	chr5:150261307	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs73284141	chr5:150266086	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs73348070	chr5:127893533	FBN2	chr5:127593602-127873916:-	0.71	4.95	1.94E-6	Multiple system atrophy	
PAAD	cis	1	rs73395547	chr7:98922746	CYP3A5	chr7:99245818-99332821:-	0.59	5.54	1.32E-7	Blood metabolite levels	
PAAD	cis	1	rs73395557	chr7:98934424	CYP3A5	chr7:99245818-99332821:-	0.59	5.54	1.32E-7	Blood metabolite levels	
PAAD	cis	1	rs73412140	chr6:33757014	LEMD2	chr6:33738991-33756906:-	0.36	4.33	2.67E-5	Body mass index	
PAAD	cis	1	rs73552468	chr19:21772097	ZNF429	chr19:21688437-21739068:+	0.4	4.57	1.01E-5	Colorectal or endometrial cancer	
PAAD	cis	1	rs73552479	chr19:21778816	ZNF429	chr19:21688437-21739068:+	0.4	4.68	6.24E-6	Colorectal or endometrial cancer	
PAAD	cis	1	rs735531	chr20:33947730	UQCC	chr20:33890383-33999833:-	0.34	4.04	8.31E-5	Height	
PAAD	cis	1	rs7356093	chr3:134238753	ANAPC13	chr3:134196547-134204865:-	0.88	11.91	1.49E-23	Height	
PAAD	cis	1	rs735765	chr6:28170297	ZSCAN23	chr6:28393287-28411279:-	0.47	4.36	2.39E-5	Depression	
PAAD	cis	1	rs736344	chr12:110001195	MYO1H	chr12:109826524-109886176:+	0.49	4.61	8.6E-6	HDL cholesterol	
PAAD	cis	1	rs7371896	chr3:134249769	ANAPC13	chr3:134196547-134204865:-	0.86	11.41	3.33E-22	Height	
PAAD	cis	1	rs7372217	chr3:41990122	ULK4	chr3:41288091-42003660:-	-0.92	-8.85	2.05E-15	Diastolic blood pressure	
PAAD	cis	1	rs7374158	chr3:134270156	ANAPC13	chr3:134196547-134204865:-	0.87	11.51	1.83E-22	Height	
PAAD	cis	1	rs7374325	chr3:134275601	ANAPC13	chr3:134196547-134204865:-	0.89	11.96	1.07E-23	Height	
PAAD	cis	1	rs7394190	chr10:75421648	NUDT13	chr10:74870210-74891580:+	-0.5	-5.12	9.07E-7	Atrial fibrillation	
PAAD	cis	1	rs7395213	chr11:87869579	RAB38	chr11:87846431-87908599:-	-0.38	-4.31	2.96E-5	Frontotemporal dementia	
PAAD	cis	1	rs73958618	chr2:136500475	DARS	chr2:136664254-136743222:-	0.37	4.23	4.03E-5	Corneal structure	
PAAD	cis	1	rs7406003	chr17:79597597	TSPAN10	chr17:79609349-79615778:+	0.74	9.99	2.05E-18	Eye color traits	
PAAD	cis	1	rs74210981	chr10:102287520	SEC31B	chr10:102246403-102289636:-	-0.36	-5.9	2.2E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7426847	chr3:134267519	ANAPC13	chr3:134196547-134204865:-	-0.88	-12	8.57E-24	Height	
PAAD	cis	1	rs7427165	chr3:121364624	IQCB1	chr3:121488610-121553926:-	0.56	5.78	4.13E-8	Cognitive performance	
PAAD	cis	1	rs7427492	chr3:134261654	ANAPC13	chr3:134196547-134204865:-	0.88	11.82	2.55E-23	Height	
PAAD	cis	1	rs7428326	chr3:134251184	ANAPC13	chr3:134196547-134204865:-	0.86	11.37	4.15E-22	Height	
PAAD	cis	1	rs7428	chr2:85545490	TGOLN2	chr2:85545147-85555374:-	0.33	4.95	1.98E-6	Ear protrusion	
PAAD	cis	1	rs7429866	chr3:134236306	ANAPC13	chr3:134196547-134204865:-	-0.88	-11.96	1.1E-23	Height	
PAAD	cis	1	rs7432268	chr3:134242051	ANAPC13	chr3:134196547-134204865:-	0.88	11.82	2.55E-23	Height	
PAAD	cis	1	rs7433663	chr3:134235790	ANAPC13	chr3:134196547-134204865:-	0.86	11.46	2.5E-22	Height	
PAAD	cis	1	rs7433991	chr3:134312292	ANAPC13	chr3:134196547-134204865:-	0.86	11.36	4.41E-22	Height	
PAAD	cis	1	rs74347384	chr7:1072440	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs7436021	chr4:76905472	NAAA	chr4:76831809-76862166:-	-0.45	-5.5	1.53E-7	Longevity	
PAAD	cis	1	rs7436403	chr4:17692685	MED28	chr4:17616273-17629791:+	-0.43	-4.86	2.91E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs74366004	chr7:1088630	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.34	2.6E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs74369356	chr7:1071711	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs74372131	chr10:81787214	LOC219347	chr10:81805991-81838949:-	0.89	9.08	5.26E-16	Chronic obstructive pulmonary disease-related biomarkers	
PAAD	cis	1	rs74544416	chr8:82657745	CHMP4C	chr8:82644688-82671746:+	-0.81	-6.07	9.77E-9	Epithelial ovarian cancer;Ovarian cancer	
PAAD	cis	1	rs7456042	chr7:65299778	CCT6P1	chr7:65216092-65228661:+	0.45	4.38	2.23E-5	Diabetic kidney disease	
PAAD	cis	1	rs746489	chr9:131910093	PPP2R4	chr9:131873244-131911223:+	0.43	4.35	2.47E-5	Blood metabolite ratios	
PAAD	cis	1	rs74650218	chr10:102293830	SEC31B	chr10:102246403-102289636:-	-0.35	-5.76	4.54E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs74652290	chr7:1090109	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.71	5.44E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs7475154	chr10:131440584	MGMT	chr10:131265454-131565783:+	-0.38	-5.71	5.84E-8	Response to temozolomide	
PAAD	cis	1	rs74758321	chr8:82667320	CHMP4C	chr8:82644688-82671746:+	-0.81	-6.07	9.77E-9	Epithelial ovarian cancer;Ovarian cancer	
PAAD	cis	1	rs747692	chr6:33737436	LEMD2	chr6:33738991-33756906:-	0.37	4.53	1.2E-5	Body mass index	
PAAD	cis	1	rs747695	chr6:33736672	LEMD2	chr6:33738991-33756906:-	-0.29	-4.23	4.07E-5	Crohn's disease	
PAAD	cis	1	rs7477246	chr10:102261538	SEC31B	chr10:102246403-102289636:-	-0.35	-5.8	3.65E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs74785791	chr7:1088494	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.34	2.6E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs74887741	chr7:1110658	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs74955473	chr5:150174558	LOC134466	chr5:150310000-150326146:-	0.85	6.84	1.76E-10	Crohn's disease	
PAAD	cis	1	rs75016635	chr7:1094121	ZFAND2A	chr7:1192544-1199855:-	-0.5	-4.21	4.41E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs7503679	chr17:79583843	TSPAN10	chr17:79609349-79615778:+	0.74	9.99	2.09E-18	Eye color traits	
PAAD	cis	1	rs75063298	chr10:102213600	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs75071288	chr5:150224379	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs75079001	chr19:21757375	ZNF429	chr19:21688437-21739068:+	0.4	4.53	1.17E-5	Colorectal or endometrial cancer	
PAAD	cis	1	rs751096	chr6:33742838	LEMD2	chr6:33738991-33756906:-	-0.41	-4.75	4.64E-6	Body mass index	
PAAD	cis	1	rs7511962	chr1:247212122	ZNF670	chr1:247200087-247242069:-	-0.5	-5.5	1.54E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs7512150	chr1:247212326	ZNF670	chr1:247200087-247242069:-	-0.5	-5.54	1.3E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs7512552	chr1:150265704	C1orf54	chr1:150244773-150253325:+	0.22	4.39	2.11E-5	Atopic dermatitis	
PAAD	cis	1	rs7515491	chr1:46355079	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.07	9.54E-9	Body mass index	
PAAD	cis	1	rs7515577	chr1:93009438	EVI5	chr1:92974255-93257961:-	-0.41	-4.35	2.46E-5	Cholesterol, total	
PAAD	cis	1	rs75159543	chr15:40665228	C15orf23	chr15:40674922-40686488:+	0.76	8.95	1.09E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs751728	chr6:33764033	LEMD2	chr6:33738991-33756906:-	-0.29	-4.39	2.07E-5	Crohn's disease	
PAAD	cis	1	rs7519795	chr1:247212126	ZNF670	chr1:247200087-247242069:-	-0.5	-5.5	1.54E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs75211977	chr19:21760201	ZNF429	chr19:21688437-21739068:+	0.4	4.67	6.57E-6	Colorectal or endometrial cancer	
PAAD	cis	1	rs7522601	chr1:46419021	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs7522705	chr1:45992300	CCDC163P	chr1:45960581-45965646:-	0.9	11.47	2.3E-22	Homocysteine levels	
PAAD	cis	1	rs7524495	chr1:46266932	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.5	1.1E-9	Body mass index	
PAAD	cis	1	rs75278386	chr15:40678312	C15orf23	chr15:40674922-40686488:+	0.73	8.96	1.03E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs7528684	chr1:157670816	FCRL3	chr1:157646278-157670775:-	0.23	4.14	5.65E-5	Type 1 diabetes autoantibodies	
PAAD	cis	1	rs75294883	chr5:150196503	LOC134466	chr5:150310000-150326146:-	0.88	6.45	1.42E-9	Crohn's disease	
PAAD	cis	1	rs7534467	chr1:45988691	CCDC163P	chr1:45960581-45965646:-	-0.96	-13.34	2.03E-27	Homocysteine levels	
PAAD	cis	1	rs7536557	chr1:45992114	CCDC163P	chr1:45960581-45965646:-	-0.9	-11.89	1.67E-23	Homocysteine levels	
PAAD	cis	1	rs7539932	chr1:46292354	CCDC163P	chr1:45960581-45965646:-	-0.53	-6.49	1.11E-9	Body mass index	
PAAD	cis	1	rs7540325	chr1:46338217	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.87E-9	Body mass index	
PAAD	cis	1	rs7540584	chr1:35748672	C1orf216	chr1:36179477-36184790:-	-0.39	-4	9.89E-5	Systemic lupus erythematosus and Systemic sclerosis	
PAAD	cis	1	rs7546342	chr1:247213292	ZNF670	chr1:247200087-247242069:-	-0.5	-5.54	1.3E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs75488469	chr7:1102122	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs7549410	chr1:247214167	ZNF670	chr1:247200087-247242069:-	-0.5	-5.5	1.54E-7	Response to taxane treatment (docetaxel)	
PAAD	cis	1	rs7550746	chr1:46351719	CCDC163P	chr1:45960581-45965646:-	-0.5	-6	1.34E-8	Body mass index	
PAAD	cis	1	rs755109	chr9:100696203	C9orf156	chr9:100666772-100684852:-	0.3	4.09	7.07E-5	Quantitative traits	
PAAD	cis	1	rs755495	chr6:33734128	LEMD2	chr6:33738991-33756906:-	-0.36	-4.37	2.27E-5	Body mass index	
PAAD	cis	1	rs755496	chr6:33734376	LEMD2	chr6:33738991-33756906:-	-0.3	-4.34	2.58E-5	Crohn's disease	
PAAD	cis	1	rs7556436	chr1:46363880	CCDC163P	chr1:45960581-45965646:-	0.5	6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs7556615	chr1:46461369	CCDC163P	chr1:45960581-45965646:-	-0.5	-6.01	1.31E-8	Body mass index	
PAAD	cis	1	rs7562170	chr2:28943516	TRMT61B	chr2:29072690-29093175:-	0.49	5.92	2.04E-8	Body mass index	
PAAD	cis	1	rs7566279	chr2:281178	SH3YL1	chr2:218138-264810:-	-0.47	-7.75	1.2E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs75774363	chr5:150223722	LOC134466	chr5:150310000-150326146:-	0.72	6.14	6.69E-9	Crohn's disease	
PAAD	cis	1	rs7579277	chr2:28996295	TRMT61B	chr2:29072690-29093175:-	-0.47	-5.69	6.24E-8	Body mass index	
PAAD	cis	1	rs757978	chr2:242371101	SEPT2	chr2:242254723-242293439:+	0.62	6.4	1.83E-9	Chronic lymphocytic leukemia	
PAAD	cis	1	rs75800624	chr18:44633605	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs7580658	chr2:128159261	PROC	chr2:128176017-128186816:+	0.39	4.62	8.24E-6	Protein C levels	
PAAD	cis	1	rs75824542	chr14:74523047	LIN52	chr14:74551656-74667117:+	0.43	7.66	2.01E-12	Common traits (Other)	
PAAD	cis	1	rs75889859	chr14:35539054	PPP2R3C	chr14:35554679-35591679:-	0.56	5.79	3.87E-8	Atopic dermatitis	
PAAD	cis	1	rs75913297	chr10:81789845	LOC219347	chr10:81805991-81838949:-	0.89	8.1	1.62E-13	Chronic obstructive pulmonary disease-related biomarkers	
PAAD	cis	1	rs7591472	chr2:201889751	PPIL3	chr2:201735680-201753999:-	-1.05	-9.32	1.22E-16	Triptolide cytotoxicity	
PAAD	cis	1	rs7595075	chr2:264019	SH3YL1	chr2:218138-264810:-	-0.47	-7.54	3.87E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs7596362	chr2:61204688	C2orf74	chr2:61372243-61391964:+	0.45	4.78	4.11E-6	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
PAAD	cis	1	rs7598876	chr2:28974466	TRMT61B	chr2:29072690-29093175:-	-0.49	-5.93	1.97E-8	Body mass index	
PAAD	cis	1	rs7601738	chr2:242375813	SEPT2	chr2:242254723-242293439:+	-0.62	-6.4	1.83E-9	Chronic lymphocytic leukemia	
PAAD	cis	1	rs760554	chr22:25872592	CRYBB2	chr22:25615612-25627836:+	1.19	7.71	1.46E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs760555	chr22:25872837	CRYBB2	chr22:25615612-25627836:+	1.19	7.71	1.46E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs7605824	chr2:280819	SH3YL1	chr2:218138-264810:-	0.46	7.51	4.5E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs7608697	chr2:61204641	C2orf74	chr2:61372243-61391964:+	0.48	5.03	1.33E-6	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
PAAD	cis	1	rs7608697	chr2:61204641	PEX13	chr2:61244697-61279124:+	0.28	4	9.96E-5	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
PAAD	cis	1	rs7608910	chr2:61204856	C2orf74	chr2:61372243-61391964:+	-0.5	-5.32	3.7E-7	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
PAAD	cis	1	rs7611611	chr3:134307877	ANAPC13	chr3:134196547-134204865:-	0.86	11.36	4.41E-22	Height	
PAAD	cis	1	rs7611828	chr3:134250325	ANAPC13	chr3:134196547-134204865:-	0.86	11.37	4.15E-22	Height	
PAAD	cis	1	rs76129108	chr7:1089159	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.34	2.6E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs7615952	chr3:125649403	LOC100125556	chr3:125635444-125648865:+	-0.55	-6.09	8.96E-9	Blood pressure (smoking interaction)	
PAAD	cis	1	rs7616044	chr3:125649354	LOC100125556	chr3:125635444-125648865:+	0.55	6.09	8.96E-9	Blood pressure (smoking interaction)	
PAAD	cis	1	rs7616844	chr3:41874343	ULK4	chr3:41288091-42003660:-	0.86	8.12	1.48E-13	Diastolic blood pressure	
PAAD	cis	1	rs7617397	chr3:41959037	ULK4	chr3:41288091-42003660:-	-0.89	-8.22	8.19E-14	Diastolic blood pressure	
PAAD	cis	1	rs7619451	chr3:134233238	ANAPC13	chr3:134196547-134204865:-	0.84	9.78	7.53E-18	Height	
PAAD	cis	1	rs76214082	chr7:1102097	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs7622259	chr3:41881351	ULK4	chr3:41288091-42003660:-	0.86	7.94	3.93E-13	Diastolic blood pressure	
PAAD	cis	1	rs7624372	chr3:41881107	ULK4	chr3:41288091-42003660:-	0.86	7.94	3.93E-13	Diastolic blood pressure	
PAAD	cis	1	rs76277863	chr15:40649863	C15orf23	chr15:40674922-40686488:+	0.74	8.41	2.65E-14	Heschl's gyrus morphology	
PAAD	cis	1	rs763014	chr16:675680	WFIKKN1	chr16:679239-684116:+	0.36	4.83	3.3E-6	Height	
PAAD	cis	1	rs7630741	chr3:48419723	TREX1	chr3:48501186-48509043:+	-0.38	-5.4	2.45E-7	Longevity	
PAAD	cis	1	rs7630874	chr3:134293291	ANAPC13	chr3:134196547-134204865:-	-0.88	-11.62	9.09E-23	Height	
PAAD	cis	1	rs7631057	chr3:41817951	ULK4	chr3:41288091-42003660:-	0.85	7.79	9.28E-13	Diastolic blood pressure	
PAAD	cis	1	rs7632387	chr3:41853161	ULK4	chr3:41288091-42003660:-	0.79	7.51	4.71E-12	Diastolic blood pressure	
PAAD	cis	1	rs7634377	chr3:48421258	TREX1	chr3:48501186-48509043:+	-0.38	-5.39	2.6E-7	Longevity	
PAAD	cis	1	rs7635522	chr3:48423656	TREX1	chr3:48501186-48509043:+	-0.37	-5.52	1.45E-7	Longevity	
PAAD	cis	1	rs7636044	chr3:48484560	TREX1	chr3:48501186-48509043:+	-0.35	-5.22	5.71E-7	Longevity	
PAAD	cis	1	rs7636782	chr3:48421387	TREX1	chr3:48501186-48509043:+	-0.36	-5.28	4.41E-7	Longevity	
PAAD	cis	1	rs7637227	chr3:134244155	ANAPC13	chr3:134196547-134204865:-	0.86	11.37	4.15E-22	Height	
PAAD	cis	1	rs76388414	chr7:1100694	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs76433514	chr5:150306532	LOC134466	chr5:150310000-150326146:-	0.88	7.27	1.77E-11	Crohn's disease	
PAAD	cis	1	rs7645295	chr3:134307734	ANAPC13	chr3:134196547-134204865:-	0.85	11.31	6.19E-22	Height	
PAAD	cis	1	rs7646144	chr3:41853125	ULK4	chr3:41288091-42003660:-	0.79	7.51	4.71E-12	Diastolic blood pressure	
PAAD	cis	1	rs76471037	chr3:41799414	ULK4	chr3:41288091-42003660:-	0.83	7.51	4.66E-12	Diastolic blood pressure	
PAAD	cis	1	rs7648357	chr3:41849670	ULK4	chr3:41288091-42003660:-	0.89	8.39	2.94E-14	Diastolic blood pressure	
PAAD	cis	1	rs7648578	chr3:41858731	ULK4	chr3:41288091-42003660:-	0.85	7.93	4.32E-13	Diastolic blood pressure	
PAAD	cis	1	rs7648990	chr3:134244390	ANAPC13	chr3:134196547-134204865:-	0.86	11.37	4.15E-22	Height	
PAAD	cis	1	rs7650227	chr3:41794937	ULK4	chr3:41288091-42003660:-	0.8	7.18	2.91E-11	Diastolic blood pressure	
PAAD	cis	1	rs7651407	chr3:48443816	TREX1	chr3:48501186-48509043:+	-0.38	-5.54	1.31E-7	Longevity	
PAAD	cis	1	rs7653691	chr3:48419689	TREX1	chr3:48501186-48509043:+	0.37	5.31	3.83E-7	Longevity	
PAAD	cis	1	rs76542740	chr15:43891512	ADAL	chr15:43622872-43646094:+	-0.65	-4.81	3.54E-6	Tumor biomarkers	
PAAD	cis	1	rs7654345	chr4:17691796	MED28	chr4:17616273-17629791:+	0.41	4.68	6.2E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs76548544	chr5:150223515	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs765527	chr19:22129555	ZNF257	chr19:22235266-22273901:+	-0.5	-5.78	4.0E-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs7655841	chr4:129890790	C4orf33	chr4:130014829-130033842:+	0.48	5.85	2.81E-8	Chronic obstructive pulmonary disease (moderate to severe)	
PAAD	cis	1	rs7656037	chr4:39717965	RPL9	chr4:39455747-39460568:-	-0.4	-4.33	2.64E-5	Plasma amyloid beta peptide concentrations (ABx-40)	
PAAD	cis	1	rs76594057	chr18:44637272	HDHD2	chr18:44633782-44676871:-	0.47	5.25	4.9E-7	Sitting height ratio	
PAAD	cis	1	rs7659718	chr4:17638020	MED28	chr4:17616273-17629791:+	0.43	5.1	9.82E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs7661070	chr4:39724365	RPL9	chr4:39455747-39460568:-	-0.41	-4.42	1.89E-5	Plasma amyloid beta peptide concentrations (ABx-40)	
PAAD	cis	1	rs7661631	chr4:17679751	MED28	chr4:17616273-17629791:+	-0.39	-4.45	1.65E-5	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs76683169	chr10:102358397	SEC31B	chr10:102246403-102289636:-	-0.34	-4.97	1.75E-6	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7671752	chr4:17661398	MED28	chr4:17616273-17629791:+	0.45	5.37	2.92E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs7673500	chr4:17621383	MED28	chr4:17616273-17629791:+	0.46	5.47	1.81E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs76804143	chr7:1082021	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs76812330	chr19:50531860	SIGLEC16	chr19:50472912-50479075:+	0.91	4.97	1.8E-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs76833820	chr7:1070278	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs76837345	chr8:82668818	CHMP4C	chr8:82644688-82671746:+	-0.84	-5.9	2.27E-8	Epithelial ovarian cancer;Ovarian cancer	
PAAD	cis	1	rs76872831	chr5:150171559	LOC134466	chr5:150310000-150326146:-	0.85	6.85	1.72E-10	Crohn's disease	
PAAD	cis	1	rs7687557	chr4:39769260	RPL9	chr4:39455747-39460568:-	-0.4	-4.37	2.3E-5	Plasma amyloid beta peptide concentrations (ABx-40)	
PAAD	cis	1	rs7688682	chr4:17693794	MED28	chr4:17616273-17629791:+	-0.4	-4.65	7.18E-6	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs7694020	chr4:17682597	MED28	chr4:17616273-17629791:+	0.46	5.43	2.19E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs7697889	chr4:17617961	MED28	chr4:17616273-17629791:+	0.48	5.77	4.25E-8	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs76994419	chr15:40714150	C15orf23	chr15:40674922-40686488:+	0.72	8.66	6.14E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs7705093	chr5:96290647	ERAP2	chr5:96211644-96255398:+	1.16	21.02	5.67E-47	Birdshot chorioretinopathy	
PAAD	cis	1	rs7705542	chr5:150228318	LOC134466	chr5:150310000-150326146:-	0.65	5.73	5.25E-8	Crohn's disease	
PAAD	cis	1	rs7705658	chr5:78315305	BHMT2	chr5:78365583-78385273:+	0.19	4.52	1.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs77083167	chr7:1071823	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs7709388	chr5:150246539	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs7709464	chr5:150269441	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs7709472	chr5:78315151	BHMT2	chr5:78365583-78385273:+	0.18	4.51	1.27E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs7709650	chr5:150246685	LOC134466	chr5:150310000-150326146:-	0.7	5.99	1.46E-8	Crohn's disease	
PAAD	cis	1	rs7709757	chr5:78315329	BHMT2	chr5:78365583-78385273:+	0.19	4.52	1.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs7714415	chr5:150270292	LOC134466	chr5:150310000-150326146:-	0.64	5.66	7.41E-8	Crohn's disease	
PAAD	cis	1	rs7714584	chr5:150270420	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs7715981	chr5:150258107	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs7716903	chr5:150258574	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs77187281	chr19:50507667	SIGLEC16	chr19:50472912-50479075:+	1	5.46	1.86E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs7724036	chr5:150284808	LOC134466	chr5:150310000-150326146:-	-0.6	-5.72	5.38E-8	Crohn's disease	
PAAD	cis	1	rs7724558	chr5:150328866	LOC134466	chr5:150310000-150326146:-	0.72	5.85	2.9E-8	Crohn's disease	
PAAD	cis	1	rs77305932	chr7:1100861	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs7731142	chr5:78325519	BHMT2	chr5:78365583-78385273:+	0.18	4.34	2.59E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs7732643	chr5:150261436	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs7732945	chr5:150261601	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs77346188	chr7:1114023	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.33	2.7E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs7734778	chr5:150256556	LOC134466	chr5:150310000-150326146:-	0.67	5.73	5.29E-8	Crohn's disease	
PAAD	cis	1	rs7734928	chr5:150256613	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs7735031	chr5:78325380	BHMT2	chr5:78365583-78385273:+	0.18	4.37	2.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs7736554	chr5:150258308	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs7736873	chr5:150258482	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs7745098	chr6:135415004	ALDH8A1	chr6:135238529-135271244:-	-0.4	-4.71	5.4E-6	Hodgkin's lymphoma	
PAAD	cis	1	rs77477310	chr14:35615793	PPP2R3C	chr14:35554679-35591679:-	0.51	5.3	3.95E-7	Atopic dermatitis	
PAAD	cis	1	rs7747824	chr6:86647106	SNHG5	chr6:86386726-86388451:-	-0.87	-12.29	1.4E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs77531164	chr15:40673466	C15orf23	chr15:40674922-40686488:+	0.73	8.87	1.76E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs7755323	chr6:33761159	LEMD2	chr6:33738991-33756906:-	0.33	4.05	8.24E-5	Body mass index	
PAAD	cis	1	rs7756203	chr6:86627707	SNHG5	chr6:86386726-86388451:-	-0.84	-11.44	2.8E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs7759071	chr6:49433198	CENPQ	chr6:49431096-49460820:+	-0.58	-7.95	3.83E-13	Homocysteine levels	
PAAD	cis	1	rs7760207	chr6:86721700	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs7766645	chr6:86622238	SNHG5	chr6:86386726-86388451:-	-0.87	-12.29	1.4E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs776746	chr7:99270539	CYP3A5	chr7:99245818-99332821:-	-0.76	-7.4	8.45E-12	Blood metabolite levels	
PAAD	cis	1	rs77698001	chr5:150250367	LOC134466	chr5:150310000-150326146:-	0.7	5.99	1.46E-8	Crohn's disease	
PAAD	cis	1	rs77702926	chr7:1088838	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.34	2.6E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs7771342	chr6:86631936	SNHG5	chr6:86386726-86388451:-	-0.84	-11.44	2.8E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs7774688	chr6:49387292	CENPQ	chr6:49431096-49460820:+	-0.56	-7.72	1.45E-12	Homocysteine levels	
PAAD	cis	1	rs77760339	chr7:1083927	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs77763497	chr20:3250007	ITPA	chr20:3190056-3204504:+	-0.4	-5.7	5.92E-8	IFN-related cytopenia	
PAAD	cis	1	rs7777389	chr7:143744802	ARHGEF35	chr7:143883677-143892736:-	-0.41	-5.42	2.29E-7	Obesity-related traits	
PAAD	cis	1	rs77868187	chr7:1093968	ZFAND2A	chr7:1192544-1199855:-	-0.5	-4.21	4.41E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs778758	chr2:61782161	AHSA2	chr2:61404553-61414058:+	-0.32	-6.4	1.84E-9	Tuberculosis	
PAAD	cis	1	rs778758	chr2:61782161	C2orf74	chr2:61372243-61391964:+	0.53	6.06	1.01E-8	Tuberculosis	
PAAD	cis	1	rs778762	chr2:61782921	AHSA2	chr2:61404553-61414058:+	-0.31	-6.14	6.96E-9	Tuberculosis	
PAAD	cis	1	rs778762	chr2:61782921	C2orf74	chr2:61372243-61391964:+	0.52	5.85	2.91E-8	Tuberculosis	
PAAD	cis	1	rs778763	chr2:61785639	AHSA2	chr2:61404553-61414058:+	-0.31	-6.01	1.33E-8	Tuberculosis	
PAAD	cis	1	rs778763	chr2:61785639	C2orf74	chr2:61372243-61391964:+	0.52	5.75	4.67E-8	Tuberculosis	
PAAD	cis	1	rs7794661	chr7:65389730	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs7795242	chr7:65390094	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs780672	chr10:73113246	ADAMTS14	chr10:72432559-72522193:+	0.26	3.99	0.000102	Gestational age at birth (child effect)	
PAAD	cis	1	rs780675	chr10:73113790	ADAMTS14	chr10:72432559-72522193:+	0.26	3.99	0.000102	Gestational age at birth (child effect)	
PAAD	cis	1	rs780677	chr10:73114402	ADAMTS14	chr10:72432559-72522193:+	0.26	3.99	0.000102	Gestational age at birth (child effect)	
PAAD	cis	1	rs780678	chr10:73114486	ADAMTS14	chr10:72432559-72522193:+	0.31	4.63	7.81E-6	Gestational age at birth (child effect)	
PAAD	cis	1	rs7806994	chr7:56139505	ZNF713	chr7:55955162-56008433:+	-0.41	-4.36	2.34E-5	PR interval in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs7808022	chr7:99220083	CYP3A5	chr7:99245818-99332821:-	0.75	7.04	6.14E-11	Blood metabolite levels	
PAAD	cis	1	rs7809615	chr7:99184778	ARPC1B	chr7:98972329-98992402:+	0.53	4.16	5.3E-5	Blood metabolite ratios	
PAAD	cis	1	rs781142	chr7:65438778	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs781149	chr7:65481284	CCT6P1	chr7:65216092-65228661:+	0.44	4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs781150	chr7:65480973	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs781156	chr7:65479141	CCT6P1	chr7:65216092-65228661:+	0.44	4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs781157	chr7:65478311	CCT6P1	chr7:65216092-65228661:+	0.44	4.3	2.97E-5	Diabetic kidney disease	
PAAD	cis	1	rs78143408	chr7:1096846	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs78153629	chr15:40673465	C15orf23	chr15:40674922-40686488:+	0.73	8.87	1.76E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs78158942	chr7:1090440	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.44	1.68E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs78185558	chr7:1090183	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.7	5.78E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs78185801	chr7:1096367	ZFAND2A	chr7:1192544-1199855:-	-0.5	-4.21	4.41E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs78207779	chr14:35506387	PPP2R3C	chr14:35554679-35591679:-	0.55	5.52	1.43E-7	Atopic dermatitis	
PAAD	cis	1	rs78308415	chr7:1072634	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.41	1.92E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs78523927	chr7:1089458	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.34	2.6E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs785464	chr1:46523089	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs785471	chr1:46518677	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.05	1.07E-8	Body mass index	
PAAD	cis	1	rs785479	chr1:46492144	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.99	1.46E-8	Body mass index	
PAAD	cis	1	rs785481	chr1:46554518	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs785485	chr1:46574424	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.73E-9	Body mass index	
PAAD	cis	1	rs785488	chr1:46576095	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs785489	chr1:46576390	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs785491	chr1:46583418	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs785492	chr1:46583607	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.99	1.48E-8	Body mass index	
PAAD	cis	1	rs785494	chr1:46586626	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs785495	chr1:46587887	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.07	9.47E-9	Body mass index	
PAAD	cis	1	rs785503	chr1:46595868	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs785520	chr1:46568836	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs7855278	chr9:131921365	PPP2R4	chr9:131873244-131911223:+	-0.44	-4.31	2.85E-5	Blood metabolite ratios	
PAAD	cis	1	rs78604110	chr15:40681854	C15orf23	chr15:40674922-40686488:+	0.73	8.89	1.62E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs7861658	chr9:100679954	C9orf156	chr9:100666772-100684852:-	-0.33	-4.51	1.3E-5	Quantitative traits	
PAAD	cis	1	rs78628466	chr7:1068453	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs786425	chr12:124085502	ATP6V0A2	chr12:124196865-124246299:+	-0.4	-4.8	3.69E-6	Pubertal anthropometrics	
PAAD	cis	1	rs7869804	chr9:131913144	PPP2R4	chr9:131873244-131911223:+	0.43	4.35	2.47E-5	Blood metabolite ratios	
PAAD	cis	1	rs78724141	chr8:82659661	CHMP4C	chr8:82644688-82671746:+	-0.81	-6.07	9.77E-9	Epithelial ovarian cancer;Ovarian cancer	
PAAD	cis	1	rs78740005	chr8:82659306	CHMP4C	chr8:82644688-82671746:+	-0.81	-6.07	9.77E-9	Epithelial ovarian cancer;Ovarian cancer	
PAAD	cis	1	rs78803505	chr7:65382572	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs78861357	chr7:1095418	ZFAND2A	chr7:1192544-1199855:-	-0.5	-4.21	4.41E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs78896566	chr7:1080182	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs78953187	chr1:93000574	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs79044944	chr15:40676285	C15orf23	chr15:40674922-40686488:+	0.73	8.96	1.03E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs7905961	chr10:102297391	SEC31B	chr10:102246403-102289636:-	-0.35	-5.75	4.74E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs7910927	chr10:65138910	NRBF2	chr10:64893007-64914785:+	-0.38	-5.16	7.4E-7	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs7912631	chr10:101915265	CWF19L1	chr10:101992055-102027437:-	-0.48	-4.07	7.42E-5	Schizophrenia	
PAAD	cis	1	rs7915944	chr10:101942253	CWF19L1	chr10:101992055-102027437:-	-0.49	-4.17	5.05E-5	Schizophrenia	
PAAD	cis	1	rs791856	chr6:86681841	SNHG5	chr6:86386726-86388451:-	0.86	11.77	3.44E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs79199019	chr14:35581125	PPP2R3C	chr14:35554679-35591679:-	0.54	5.39	2.65E-7	Atopic dermatitis	
PAAD	cis	1	rs7923609	chr10:65133822	NRBF2	chr10:64893007-64914785:+	-0.37	-5.05	1.23E-6	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
PAAD	cis	1	rs79318564	chr15:84786150	LOC388152	chr15:84867600-84898920:-	-0.35	-4.15	5.57E-5	Schizophrenia	
PAAD	cis	1	rs79327308	chr7:1108141	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.26	3.61E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs7938380	chr11:64034866	C11orf20	chr11:64067863-64072238:+	-0.53	-4.01	9.47E-5	Mean platelet volume	
PAAD	cis	1	rs7938960	chr11:46877082	C11orf49	chr11:46958251-47185929:+	-0.46	-4.05	8.08E-5	Schizophrenia	
PAAD	cis	1	rs7939107	chr11:64034773	C11orf20	chr11:64067863-64072238:+	-0.53	-4.01	9.47E-5	Mean platelet volume	
PAAD	cis	1	rs79422648	chr7:1080241	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs79436302	chr14:35578797	PPP2R3C	chr14:35554679-35591679:-	0.54	5.34	3.36E-7	Atopic dermatitis	
PAAD	cis	1	rs79442859	chr5:150171210	LOC134466	chr5:150310000-150326146:-	0.85	6.75	2.9E-10	Crohn's disease	
PAAD	cis	1	rs79443843	chr7:1075245	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs7945548	chr11:46900280	C11orf49	chr11:46958251-47185929:+	-0.46	-4.05	8.08E-5	Schizophrenia	
PAAD	cis	1	rs7953014	chr12:109998097	MYO1H	chr12:109826524-109886176:+	0.49	4.61	8.6E-6	HDL cholesterol	
PAAD	cis	1	rs7953150	chr12:112941571	TMEM116	chr12:112369103-112450989:-	0.35	4.14	5.78E-5	Oral cavity and pharyngeal cancer	
PAAD	cis	1	rs7954144	chr12:110015893	MYO1H	chr12:109826524-109886176:+	0.47	4.47	1.5E-5	HDL cholesterol	
PAAD	cis	1	rs79548696	chr3:41803385	ULK4	chr3:41288091-42003660:-	0.81	7.27	1.69E-11	Diastolic blood pressure	
PAAD	cis	1	rs79602855	chr19:50525725	SIGLEC16	chr19:50472912-50479075:+	0.93	5.14	8.39E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs7960884	chr12:31360640	DDX11	chr12:31226779-31257725:+	0.47	5.19	6.48E-7	Systolic blood pressure response to hydrochlorothiazide in hypertension	
PAAD	cis	1	rs79617366	chr7:1111958	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs79633979	chr19:50488612	SIGLEC16	chr19:50472912-50479075:+	1.01	5.52	1.42E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs7964021	chr12:109997645	MYO1H	chr12:109826524-109886176:+	0.5	4.68	6.14E-6	HDL cholesterol	
PAAD	cis	1	rs79683221	chr7:1096139	ZFAND2A	chr7:1192544-1199855:-	-0.5	-4.21	4.41E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs79702597	chr14:35558856	PPP2R3C	chr14:35554679-35591679:-	0.56	5.79	3.81E-8	Atopic dermatitis	
PAAD	cis	1	rs79716074	chr2:277003	SH3YL1	chr2:218138-264810:-	-0.48	-7.89	5.27E-13	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs79765398	chr7:1073764	ZFAND2A	chr7:1192544-1199855:-	-0.53	-4.37	2.29E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs79780973	chr5:150174810	LOC134466	chr5:150310000-150326146:-	0.85	6.84	1.76E-10	Crohn's disease	
PAAD	cis	1	rs79831012	chr10:102237059	SEC31B	chr10:102246403-102289636:-	-0.34	-5.75	4.66E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs798536	chr7:2766383	AMZ1	chr7:2719163-2755069:+	-0.38	-4.04	8.36E-5	Height	
PAAD	cis	1	rs798540	chr7:2764130	AMZ1	chr7:2719163-2755069:+	-0.38	-4.08	7.23E-5	Height	
PAAD	cis	1	rs79888893	chr14:35510676	PPP2R3C	chr14:35554679-35591679:-	0.55	5.74	4.84E-8	Atopic dermatitis	
PAAD	cis	1	rs8002861	chr13:44474517	CCDC122	chr13:44410491-44453826:-	-0.36	-4.06	7.9E-5	Leprosy	
PAAD	cis	1	rs80031817	chr7:1096793	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs8003506	chr14:75586288	EIF2B2	chr14:75469612-75476292:+	-0.42	-4.88	2.67E-6	Height	
PAAD	cis	1	rs8003506	chr14:75586288	MLH3	chr14:75480467-75518235:-	-0.34	-4.22	4.14E-5	Height	
PAAD	cis	1	rs8005686	chr14:76633967	ESRRB	chr14:76837690-76968178:+	0.47	4.15	5.4E-5	Blood pressure	
PAAD	cis	1	rs8006048	chr14:76683508	ESRRB	chr14:76837690-76968178:+	0.48	4.14	5.76E-5	Blood pressure	
PAAD	cis	1	rs8006419	chr14:65500735	CHURC1	chr14:65381140-65411309:+	-0.33	-4.02	9.25E-5	Red blood cell traits	
PAAD	cis	1	rs80075680	chr5:150223737	LOC134466	chr5:150310000-150326146:-	0.68	6.02	1.25E-8	Crohn's disease	
PAAD	cis	1	rs80085676	chr2:242347907	SEPT2	chr2:242254723-242293439:+	0.62	6.34	2.41E-9	Chronic lymphocytic leukemia	
PAAD	cis	1	rs80094748	chr7:1103958	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.32	2.81E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs8010715	chr14:24609147	FAM158A	chr14:24608175-24610797:-	-0.38	-6.16	6.13E-9	IgG glycosylation	
PAAD	cis	1	rs8013540	chr14:35513760	PPP2R3C	chr14:35554679-35591679:-	0.56	5.79	3.87E-8	Atopic dermatitis	
PAAD	cis	1	rs8017642	chr14:75590822	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.34E-5	Height	
PAAD	cis	1	rs8018967	chr14:73976934	HEATR4	chr14:73945193-74025651:-	-0.52	-5.63	8.42E-8	Blood metabolite ratios	
PAAD	cis	1	rs80202648	chr19:50494386	SIGLEC16	chr19:50472912-50479075:+	1	5.46	1.86E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs80212261	chr7:1114012	ZFAND2A	chr7:1192544-1199855:-	-0.54	-4.33	2.7E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs8024944	chr15:56125135	PRTG	chr15:55903748-56035177:-	0.32	4.93	2.16E-6	Keloid	
PAAD	cis	1	rs8026172	chr15:56125182	PRTG	chr15:55903748-56035177:-	0.32	4.93	2.16E-6	Keloid	
PAAD	cis	1	rs8026523	chr15:40654066	C15orf23	chr15:40674922-40686488:+	0.75	8.63	7.24E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs8027487	chr15:40654067	C15orf23	chr15:40674922-40686488:+	0.75	8.63	7.24E-15	Heschl's gyrus morphology	
PAAD	cis	1	rs80285556	chr19:50540170	SIGLEC16	chr19:50472912-50479075:+	0.95	5.45	1.97E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs8029247	chr15:56273446	PRTG	chr15:55903748-56035177:-	-0.31	-4.85	3.0E-6	Keloid	
PAAD	cis	1	rs80314222	chr19:50525514	SIGLEC16	chr19:50472912-50479075:+	1	5.46	1.86E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
PAAD	cis	1	rs8031576	chr15:90380214	AP3S2	chr15:90373832-90456222:-	-0.83	-9.47	4.99E-17	Type 2 diabetes	
PAAD	cis	1	rs8032158	chr15:56194877	PRTG	chr15:55903748-56035177:-	0.31	4.77	4.28E-6	Keloid	
PAAD	cis	1	rs8033938	chr15:40703114	C15orf23	chr15:40674922-40686488:+	0.71	8.49	1.64E-14	Heschl's gyrus morphology	
PAAD	cis	1	rs8049439	chr16:28837515	EIF3CL	chr16:28699879-28747052:+;chr16	0.46	5.94	1.84E-8	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
PAAD	cis	1	rs8049439	chr16:28837515	TUFM	chr16:28853732-28857729:-	0.28	5.22	5.83E-7	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
PAAD	cis	1	rs8062783	chr16:74691264	RFWD3	chr16:74655298-74700779:-	0.3	4.34	2.56E-5	Testicular germ cell tumor	
PAAD	cis	1	rs8065059	chr17:28417376	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.83E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs8065261	chr17:28418041	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.09	6.99E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs8065437	chr17:45721653	C17orf57	chr17:45401142-45518675:+	0.43	5.08	1.1E-6	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs8065437	chr17:45721653	TBKBP1	chr17:45772630-45789427:+	-0.26	-4.12	6.18E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs8065669	chr17:45724996	C17orf57	chr17:45401142-45518675:+	0.42	4.9	2.39E-6	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs8065669	chr17:45724996	TBKBP1	chr17:45772630-45789427:+	-0.26	-4.08	7.2E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs8070454	chr17:38160754	GSDMA	chr17:38119226-38134019:+	-0.57	-6.35	2.34E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs8071789	chr17:38006333	GSDMB	chr17:38060850-38074903:-	-0.23	-4.06	7.7E-5	Selective IgA deficiency	
PAAD	cis	1	rs8072100	chr17:45674687	C17orf57	chr17:45401142-45518675:+	-0.42	-4.97	1.76E-6	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs8072100	chr17:45674687	TBKBP1	chr17:45772630-45789427:+	0.26	4.09	6.84E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
PAAD	cis	1	rs807669	chr22:19154522	SLC25A1	chr22:19163095-19166301:-	-0.34	-5.12	8.92E-7	Metabolite levels	
PAAD	cis	1	rs807670	chr22:19154608	SLC25A1	chr22:19163095-19166301:-	-0.3	-4.85	3.02E-6	Metabolite levels	
PAAD	cis	1	rs8078723	chr17:38166879	GSDMA	chr17:38119226-38134019:+	-0.56	-6.23	4.3E-9	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
PAAD	cis	1	rs809775	chr1:46538040	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs8105833	chr19:41896145	B3GNT8	chr19:41931265-41934635:-	-0.32	-4.96	1.82E-6	Height	
PAAD	cis	1	rs8123289	chr20:3253831	ITPA	chr20:3190056-3204504:+	-0.4	-5.71	5.63E-8	IFN-related cytopenia	
PAAD	cis	1	rs8131214	chr21:30483386	NCRNA00189	chr21:30565801-30660525:+	0.47	5.17	7.17E-7	Dental caries	
PAAD	cis	1	rs8138799	chr22:24556902	SUSD2	chr22:24577444-24585074:+	0.91	7.14	3.52E-11	Amyotrophic lateral sclerosis	
PAAD	cis	1	rs8141797	chr22:24582041	SUSD2	chr22:24577444-24585074:+	-0.89	-7.02	6.92E-11	Amyotrophic lateral sclerosis	
PAAD	cis	1	rs8181644	chr12:58173466	FAM119B	chr12:58166383-58176323:+	0.45	5.47	1.78E-7	Multiple sclerosis	
PAAD	cis	1	rs8181644	chr12:58173466	TSFM	chr12:58176536-58191367:+	-0.34	-4.1	6.76E-5	Multiple sclerosis	
PAAD	cis	1	rs832551	chr5:56180112	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs832553	chr5:56114786	C5orf35	chr5:56205103-56213010:+	1.08	10.06	1.37E-18	Type 2 diabetes	
PAAD	cis	1	rs832554	chr5:56115036	C5orf35	chr5:56205103-56213010:+	1.07	9.85	5.07E-18	Type 2 diabetes	
PAAD	cis	1	rs832565	chr5:56150803	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs832568	chr5:56153776	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs832569	chr5:56154584	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs832578	chr5:56164223	C5orf35	chr5:56205103-56213010:+	1.1	10.39	1.78E-19	Type 2 diabetes	
PAAD	cis	1	rs832582	chr5:56177743	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs832583	chr5:56178217	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs832584	chr5:56179212	C5orf35	chr5:56205103-56213010:+	-1.06	-10.4	1.67E-19	Type 2 diabetes	
PAAD	cis	1	rs853676	chr6:28299687	ZSCAN23	chr6:28393287-28411279:-	0.49	4.87	2.75E-6	Depression	
PAAD	cis	1	rs853678	chr6:28297313	ZSCAN23	chr6:28393287-28411279:-	0.45	4.58	9.51E-6	Depression	
PAAD	cis	1	rs853679	chr6:28296863	ZSCAN23	chr6:28393287-28411279:-	0.45	4.58	9.51E-6	Depression	
PAAD	cis	1	rs853685	chr6:28288785	ZSCAN23	chr6:28393287-28411279:-	0.45	4.58	9.51E-6	Depression	
PAAD	cis	1	rs853694	chr6:28279100	HIST1H4J	chr6:27791903-27792257:+	-0.45	-4.1	6.78E-5	Depression	
PAAD	cis	1	rs853694	chr6:28279100	ZSCAN23	chr6:28393287-28411279:-	0.45	4.62	7.96E-6	Depression	
PAAD	cis	1	rs8589	chr6:49403282	CENPQ	chr6:49431096-49460820:+	-0.56	-7.69	1.63E-12	Homocysteine levels	
PAAD	cis	1	rs860580	chr5:56149429	C5orf35	chr5:56205103-56213010:+	-1.1	-10.39	1.78E-19	Type 2 diabetes	
PAAD	cis	1	rs861283	chr5:56184610	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs863840	chr5:56128999	C5orf35	chr5:56205103-56213010:+	1.05	9.55	3.11E-17	Type 2 diabetes	
PAAD	cis	1	rs866222	chr5:56184444	C5orf35	chr5:56205103-56213010:+	1.11	10.48	1.06E-19	Type 2 diabetes	
PAAD	cis	1	rs873686	chr4:185638876	MLF1IP	chr4:185615220-185655286:-	0.42	6.77	2.65E-10	Kawasaki disease	
PAAD	cis	1	rs876402	chr14:75601862	EIF2B2	chr14:75469612-75476292:+	-0.37	-4.16	5.28E-5	Height	
PAAD	cis	1	rs876403	chr14:75602834	EIF2B2	chr14:75469612-75476292:+	0.37	4.17	5.13E-5	Height	
PAAD	cis	1	rs877636	chr12:56480583	RPS26	chr12:56435686-56438005:+	-0.53	-6.21	4.77E-9	Cognitive function	
PAAD	cis	1	rs877710	chr12:109993976	MYO1H	chr12:109826524-109886176:+	0.5	4.63	7.71E-6	HDL cholesterol	
PAAD	cis	1	rs878082	chr19:41897674	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.82	3.42E-6	Height	
PAAD	cis	1	rs878083	chr19:41897688	B3GNT8	chr19:41931265-41934635:-	-0.31	-4.76	4.41E-6	Height	
PAAD	cis	1	rs881375	chr9:123652898	LOC253039	chr9:123605320-123616644:+	-0.57	-7.62	2.46E-12	Rheumatoid arthritis	
PAAD	cis	1	rs882803	chr1:45976147	CCDC163P	chr1:45960581-45965646:-	-0.9	-12.01	7.92E-24	Homocysteine levels	
PAAD	cis	1	rs883565	chr3:39055317	TTC21A	chr3:39149152-39180394:+	0.38	5.21	5.98E-7	Handedness	
PAAD	cis	1	rs884841	chr6:86680300	SNHG5	chr6:86386726-86388451:-	-0.83	-11.25	8.68E-22	Response to antipsychotic treatment	
PAAD	cis	1	rs884977	chr7:1066410	ZFAND2A	chr7:1192544-1199855:-	-0.49	-4.19	4.69E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
PAAD	cis	1	rs885814	chr1:21875916	ALPL	chr1:21835858-21904904:+	-0.4	-4.85	3.06E-6	Response to TNF-alpha inhibitors in rheumatoid arthritis	
PAAD	cis	1	rs888192	chr12:109995097	MYO1H	chr12:109826524-109886176:+	-0.5	-4.63	7.71E-6	HDL cholesterol	
PAAD	cis	1	rs891368	chr3:53123273	RFT1	chr3:53122503-53164470:-	-0.49	-5.69	6.25E-8	Height	
PAAD	cis	1	rs891386	chr18:21103971	NPC1	chr18:21108363-21166581:-	0.32	4.15	5.54E-5	Body mass index	
PAAD	cis	1	rs892864	chr5:127835859	FBN2	chr5:127593602-127873916:-	0.75	5.07	1.14E-6	Multiple system atrophy	
PAAD	cis	1	rs898225	chr3:48413179	TREX1	chr3:48501186-48509043:+	0.36	5.19	6.48E-7	Longevity	
PAAD	cis	1	rs906134	chr7:65444288	CCT6P1	chr7:65216092-65228661:+	0.42	4.12	6.12E-5	Diabetic kidney disease	
PAAD	cis	1	rs910316	chr14:75626042	EIF2B2	chr14:75469612-75476292:+	0.37	4.07	7.49E-5	Height	
PAAD	cis	1	rs9174	chr4:25419283	ANAPC4	chr4:25378848-25420119:+	-0.32	-4.33	2.68E-5	Rheumatoid arthritis	
PAAD	cis	1	rs917665	chr4:17668504	MED28	chr4:17616273-17629791:+	-0.47	-5.54	1.29E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs917911	chr12:9905851	CLECL1	chr12:9868457-9885860:-	0.25	4.17	5.09E-5	Type 1 diabetes	
PAAD	cis	1	rs9213	chr2:218386	SH3YL1	chr2:218138-264810:-	-0.47	-7.5	4.87E-12	Spherical equivalent (joint main effects and education interaction)	
PAAD	cis	1	rs921943	chr5:78316476	BHMT2	chr5:78365583-78385273:+	0.19	4.52	1.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs922075	chr3:48489398	TREX1	chr3:48501186-48509043:+	0.33	4.81	3.55E-6	Longevity	
PAAD	cis	1	rs9257809	chr6:29356331	ZFP57	chr6:29640171-29648887:-	0.95	4.79	3.83E-6	Barrett's esophagus;Barrett's esophagus  or Esophageal adenocarcinoma	
PAAD	cis	1	rs9283717	chr5:56078659	C5orf35	chr5:56205103-56213010:+	1.03	10.16	7.47E-19	Type 2 diabetes	
PAAD	cis	1	rs9289275	chr3:125648659	LOC100125556	chr3:125635444-125648865:+	0.57	6.1	8.41E-9	Blood pressure (smoking interaction)	
PAAD	cis	1	rs9289471	chr3:134230811	ANAPC13	chr3:134196547-134204865:-	0.87	11.61	9.26E-23	Height	
PAAD	cis	1	rs9289475	chr3:134236459	ANAPC13	chr3:134196547-134204865:-	0.86	11.46	2.5E-22	Height	
PAAD	cis	1	rs9289476	chr3:134237103	ANAPC13	chr3:134196547-134204865:-	0.86	11.69	5.78E-23	Height	
PAAD	cis	1	rs9289478	chr3:134268619	ANAPC13	chr3:134196547-134204865:-	0.88	11.96	1.09E-23	Height	
PAAD	cis	1	rs9291659	chr4:17662360	MED28	chr4:17616273-17629791:+	0.45	5.37	2.92E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs9296404	chr6:42925803	PEX6	chr6:42931613-42946981:-	0.67	8.61	8.14E-15	Plasma homocysteine levels (post-methionine load test)	
PAAD	cis	1	rs9296617	chr6:49428360	CENPQ	chr6:49431096-49460820:+	-0.36	-4.13	6.02E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9296617	chr6:49428360	MUT	chr6:49398994-49431031:-	0.29	4.18	4.87E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9304593	chr19:41942875	B3GNT8	chr19:41931265-41934635:-	0.32	4.96	1.82E-6	Height	
PAAD	cis	1	rs9307050	chr4:76905649	NAAA	chr4:76831809-76862166:-	-0.45	-5.5	1.53E-7	Longevity	
PAAD	cis	1	rs9309473	chr2:73743982	ALMS1P	chr2:73872046-73912692:+	0.43	4	9.71E-5	Metabolite levels	
PAAD	cis	1	rs931058	chr5:150333698	LOC134466	chr5:150310000-150326146:-	0.76	5.8	3.77E-8	Crohn's disease	
PAAD	cis	1	rs9311288	chr3:41804581	ULK4	chr3:41288091-42003660:-	0.81	7.43	7.17E-12	Diastolic blood pressure	
PAAD	cis	1	rs9311423	chr3:48420308	TREX1	chr3:48501186-48509043:+	-0.38	-5.39	2.6E-7	Longevity	
PAAD	cis	1	rs9313085	chr5:4489021	KIAA0947	chr5:5422807-5490337:+	-0.22	-4.25	3.68E-5	DNA methylation (variation)	
PAAD	cis	1	rs9322193	chr6:149919143	NUP43	chr6:150045453-150067688:-	-0.43	-6.06	1.02E-8	Lung cancer	
PAAD	cis	1	rs9324660	chr5:150257054	LOC134466	chr5:150310000-150326146:-	0.67	5.72	5.44E-8	Crohn's disease	
PAAD	cis	1	rs932833	chr9:131884041	PPP2R4	chr9:131873244-131911223:+	0.43	4.41	1.91E-5	Blood metabolite ratios	
PAAD	cis	1	rs932835	chr9:131887071	PPP2R4	chr9:131873244-131911223:+	0.5	5.12	9.04E-7	Blood metabolite ratios	
PAAD	cis	1	rs933683	chr5:78324003	BHMT2	chr5:78365583-78385273:+	0.17	4.18	4.82E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs933684	chr5:78324075	BHMT2	chr5:78365583-78385273:+	0.18	4.37	2.24E-5	Blood trace element (Se levels);Blood and toenail selenium levels	
PAAD	cis	1	rs934093	chr3:134195885	ANAPC13	chr3:134196547-134204865:-	0.89	12.14	3.54E-24	Height	
PAAD	cis	1	rs9349804	chr6:56098876	COL21A1	chr6:55921389-56258892:-	0.28	4.01	9.3E-5	Pulse pressure	
PAAD	cis	1	rs935334	chr14:76613678	ESRRB	chr14:76837690-76968178:+	0.44	3.99	0.000102	Blood pressure	
PAAD	cis	1	rs9369898	chr6:49382193	CENPQ	chr6:49431096-49460820:+	-0.56	-7.74	1.27E-12	Homocysteine levels	
PAAD	cis	1	rs937108	chr7:65428452	CCT6P1	chr7:65216092-65228661:+	0.45	4.43	1.76E-5	Diabetic kidney disease	
PAAD	cis	1	rs9371537	chr6:151872500	C6orf97	chr6:151815175-151942327:+	-0.45	-4.05	8.14E-5	Bone mineral density (spine)	
PAAD	cis	1	rs9377228	chr6:149921998	KATNA1	chr6:149916172-149969850:-	-0.33	-4.09	6.84E-5	Lung cancer	
PAAD	cis	1	rs9377228	chr6:149921998	NUP43	chr6:150045453-150067688:-	-0.45	-6.52	9.83E-10	Lung cancer	
PAAD	cis	1	rs9377229	chr6:149928791	NUP43	chr6:150045453-150067688:-	-0.42	-5.98	1.55E-8	Lung cancer	
PAAD	cis	1	rs9380378	chr6:33765479	LEMD2	chr6:33738991-33756906:-	-0.29	-4.29	3.15E-5	Crohn's disease	
PAAD	cis	1	rs9381784	chr6:49398115	CENPQ	chr6:49431096-49460820:+	0.56	7.44	6.86E-12	Homocysteine levels	
PAAD	cis	1	rs9381813	chr6:49638243	CRISP2	chr6:49660072-49681299:-	-0.39	-4.04	8.36E-5	Prothrombin fragments F1+2 levels in ischemic stroke	
PAAD	cis	1	rs9394166	chr6:33751122	LEMD2	chr6:33738991-33756906:-	-0.3	-4.43	1.76E-5	Crohn's disease	
PAAD	cis	1	rs9394931	chr6:42873245	PEX6	chr6:42931613-42946981:-	-0.46	-5.32	3.7E-7	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	
PAAD	cis	1	rs9395493	chr6:49427409	CENPQ	chr6:49431096-49460820:+	-0.58	-7.99	3.08E-13	Homocysteine levels	
PAAD	cis	1	rs9395521	chr6:49637947	CRISP2	chr6:49660072-49681299:-	-0.39	-4.04	8.36E-5	Prothrombin fragments F1+2 levels in ischemic stroke	
PAAD	cis	1	rs939558	chr3:41976040	ULK4	chr3:41288091-42003660:-	-0.89	-8.22	8.19E-14	Diastolic blood pressure	
PAAD	cis	1	rs9397424	chr6:151872791	C6orf97	chr6:151815175-151942327:+	0.45	4.05	8.14E-5	Bone mineral density (spine)	
PAAD	cis	1	rs9397429	chr6:151877569	C6orf97	chr6:151815175-151942327:+	0.48	4.07	7.39E-5	Bone mineral density (spine)	
PAAD	cis	1	rs9397431	chr6:151883930	C6orf97	chr6:151815175-151942327:+	0.48	4.08	7.35E-5	Bone mineral density (spine)	
PAAD	cis	1	rs9399693	chr6:149933854	KATNA1	chr6:149916172-149969850:-	-0.33	-4.08	7.33E-5	Lung cancer	
PAAD	cis	1	rs9399693	chr6:149933854	NUP43	chr6:150045453-150067688:-	-0.44	-6.32	2.76E-9	Lung cancer	
PAAD	cis	1	rs941653	chr14:35592538	PPP2R3C	chr14:35554679-35591679:-	0.53	5.47	1.78E-7	Atopic dermatitis	
PAAD	cis	1	rs9419897	chr10:102246125	SEC31B	chr10:102246403-102289636:-	-0.34	-5.68	6.69E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs9420782	chr10:102235015	SEC31B	chr10:102246403-102289636:-	-0.33	-5.6	9.52E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs9420785	chr10:102240451	SEC31B	chr10:102246403-102289636:-	-0.33	-5.6	9.56E-8	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs9420797	chr10:102331147	SEC31B	chr10:102246403-102289636:-	-0.32	-5.35	3.15E-7	Palmitoleic acid (16:1n-7) plasma levels	
PAAD	cis	1	rs9425766	chr1:173853127	RABGAP1L	chr1:174128634-174959724:+	0.35	4.72	5.21E-6	Life satisfaction	
PAAD	cis	1	rs9429183	chr1:46524582	CCDC163P	chr1:45960581-45965646:-	-0.51	-6.17	5.86E-9	Body mass index	
PAAD	cis	1	rs943461	chr6:33769409	LEMD2	chr6:33738991-33756906:-	0.36	4.28	3.29E-5	Body mass index	
PAAD	cis	1	rs943462	chr6:33769578	LEMD2	chr6:33738991-33756906:-	0.36	4.28	3.29E-5	Body mass index	
PAAD	cis	1	rs943466	chr6:33731787	LEMD2	chr6:33738991-33756906:-	-0.36	-4.28	3.29E-5	Body mass index	
PAAD	cis	1	rs943477	chr6:33750931	LEMD2	chr6:33738991-33756906:-	-0.31	-4.49	1.37E-5	Crohn's disease	
PAAD	cis	1	rs945635	chr1:157670290	FCRL3	chr1:157646278-157670775:-	0.23	4.17	5.05E-5	Type 1 diabetes autoantibodies	
PAAD	cis	1	rs9463473	chr6:49380121	CENPQ	chr6:49431096-49460820:+	-0.34	-4.04	8.39E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9463473	chr6:49380121	MUT	chr6:49398994-49431031:-	0.28	4	9.84E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9463474	chr6:49380199	CENPQ	chr6:49431096-49460820:+	-0.34	-4.04	8.39E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9463474	chr6:49380199	MUT	chr6:49398994-49431031:-	0.28	4	9.84E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9463475	chr6:49380899	CENPQ	chr6:49431096-49460820:+	0.34	4.04	8.39E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9463475	chr6:49380899	MUT	chr6:49398994-49431031:-	-0.28	-4	9.84E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9463477	chr6:49386446	CENPQ	chr6:49431096-49460820:+	-0.34	-4.04	8.39E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9463477	chr6:49386446	MUT	chr6:49398994-49431031:-	0.28	4	9.84E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9463478	chr6:49386564	CENPQ	chr6:49431096-49460820:+	-0.56	-7.74	1.27E-12	Homocysteine levels	
PAAD	cis	1	rs9463479	chr6:49393275	CENPQ	chr6:49431096-49460820:+	-0.34	-4.01	9.5E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9463479	chr6:49393275	MUT	chr6:49398994-49431031:-	0.29	4.1	6.67E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9463480	chr6:49400795	CENPQ	chr6:49431096-49460820:+	-0.35	-4.03	8.85E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9463480	chr6:49400795	MUT	chr6:49398994-49431031:-	0.29	4.09	7.06E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs946529	chr1:46485548	CCDC163P	chr1:45960581-45965646:-	-0.5	-5.99	1.46E-8	Body mass index	
PAAD	cis	1	rs9473550	chr6:49385182	CENPQ	chr6:49431096-49460820:+	-0.57	-7.91	4.85E-13	Homocysteine levels	
PAAD	cis	1	rs9473552	chr6:49387154	CENPQ	chr6:49431096-49460820:+	-0.34	-4.01	9.5E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9473552	chr6:49387154	MUT	chr6:49398994-49431031:-	0.29	4.1	6.67E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9473553	chr6:49395977	CENPQ	chr6:49431096-49460820:+	-0.34	-4.01	9.5E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9473553	chr6:49395977	MUT	chr6:49398994-49431031:-	0.29	4.1	6.67E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9473555	chr6:49409487	CENPQ	chr6:49431096-49460820:+	-0.35	-4.03	8.85E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9473555	chr6:49409487	MUT	chr6:49398994-49431031:-	0.29	4.09	7.06E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9473560	chr6:49427918	CENPQ	chr6:49431096-49460820:+	-0.36	-4.13	6.02E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9473560	chr6:49427918	MUT	chr6:49398994-49431031:-	0.29	4.18	4.87E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9473561	chr6:49428755	CENPQ	chr6:49431096-49460820:+	-0.36	-4.13	6.02E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9473561	chr6:49428755	MUT	chr6:49398994-49431031:-	0.29	4.18	4.87E-5	Folate pathway vitamin levels	
PAAD	cis	1	rs9475752	chr6:56780741	BEND6	chr6:56819773-56892138:+	-0.41	-5.57	1.1E-7	Menarche (age at onset)	
PAAD	cis	1	rs9487605	chr6:111582885	KIAA1919	chr6:111580482-111590259:+	-0.51	-6.43	1.54E-9	Inflammatory skin disease	
PAAD	cis	1	rs950169	chr15:84706461	LOC388152	chr15:84867600-84898920:-	-0.34	-4.07	7.56E-5	Schizophrenia	
PAAD	cis	1	rs9527	chr10:104623578	AS3MT	chr10:104613967-104661653:+	-0.53	-5.91	2.09E-8	Arsenic metabolism	
PAAD	cis	1	rs9527	chr10:104623578	C10orf32	chr10:104613967-104624718:+	-0.62	-9	8.35E-16	Arsenic metabolism	
PAAD	cis	1	rs955196	chr6:86729951	SNHG5	chr6:86386726-86388451:-	0.83	11.15	1.71E-21	Response to antipsychotic treatment	
PAAD	cis	1	rs955197	chr6:86729675	SNHG5	chr6:86386726-86388451:-	-0.86	-11.86	2.01E-23	Response to antipsychotic treatment	
PAAD	cis	1	rs955227	chr6:86651032	SNHG5	chr6:86386726-86388451:-	-0.87	-11.99	9.11E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs957644	chr1:165616157	MGST3	chr1:165600450-165624853:+	0.31	4.37	2.33E-5	Total ventricular volume	
PAAD	cis	1	rs9585327	chr13:100689354	ZIC2	chr13:100634319-100639018:+	-0.36	-4	9.7E-5	Hyperopia	
PAAD	cis	1	rs9593	chr12:109994870	MYO1H	chr12:109826524-109886176:+	0.5	4.63	7.71E-6	HDL cholesterol	
PAAD	cis	1	rs959617	chr1:165616881	MGST3	chr1:165600450-165624853:+	0.31	4.3	3.01E-5	Total ventricular volume	
PAAD	cis	1	rs9609078	chr22:31153276	C22orf30	chr22:32072242-32146120:-	0.48	4.33	2.64E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)	
PAAD	cis	1	rs962221	chr1:92970770	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs962222	chr1:92970953	EVI5	chr1:92974255-93257961:-	-0.37	-4.13	5.92E-5	Cholesterol, total	
PAAD	cis	1	rs9624834	chr22:25846015	CRYBB2	chr22:25615612-25627836:+	1.21	7.84	7.08E-13	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs9624835	chr22:25846021	CRYBB2	chr22:25615612-25627836:+	1.21	7.84	7.08E-13	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs9624836	chr22:25846087	CRYBB2	chr22:25615612-25627836:+	1.21	7.84	7.08E-13	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs9647603	chr6:86639341	SNHG5	chr6:86386726-86388451:-	-0.87	-12.29	1.4E-24	Response to antipsychotic treatment	
PAAD	cis	1	rs965469	chr20:3381549	ITPA	chr20:3190056-3204504:+	-0.41	-5.8	3.65E-8	IFN-related cytopenia	
PAAD	cis	1	rs9674872	chr17:79581931	TSPAN10	chr17:79609349-79615778:+	0.74	9.99	2.09E-18	Eye color traits	
PAAD	cis	1	rs968567	chr11:61595564	FADS2	chr11:61583728-61634825:+	0.72	6.68	4.09E-10	Blood metabolite levels;Rheumatoid arthritis;Glycerophospholipid levels	
PAAD	cis	1	rs9689	chr1:25688276	RHCE	chr1:25688741-25756683:-	0.54	6.54	8.68E-10	Erythrocyte sedimentation rate	
PAAD	cis	1	rs9689	chr1:25688276	RHD	chr1:25598981-25656935:+	-0.66	-7.04	6.07E-11	Erythrocyte sedimentation rate	
PAAD	cis	1	rs9697030	chr9:131920181	PPP2R4	chr9:131873244-131911223:+	0.42	4.04	8.32E-5	Blood metabolite ratios	
PAAD	cis	1	rs9747349	chr17:79584297	TSPAN10	chr17:79609349-79615778:+	0.74	9.99	2.09E-18	Eye color traits	
PAAD	cis	1	rs9748176	chr17:79584043	TSPAN10	chr17:79609349-79615778:+	0.74	9.99	2.09E-18	Eye color traits	
PAAD	cis	1	rs975459	chr6:151876909	C6orf97	chr6:151815175-151942327:+	0.47	4.11	6.43E-5	Bone mineral density (spine)	
PAAD	cis	1	rs9767077	chr6:150109615	NUP43	chr6:150045453-150067688:-	-0.45	-6.1	8.15E-9	Lung cancer	
PAAD	cis	1	rs9783304	chr11:43660255	HSD17B12	chr11:43702143-43878160:+	0.43	5.79	3.78E-8	Forced vital capacity	
PAAD	cis	1	rs9783747	chr16:69458193	PDPR	chr16:70147529-70195184:+	-0.36	-4.06	7.79E-5	Blood pressure (smoking interaction)	
PAAD	cis	1	rs9805979	chr14:75566209	EIF2B2	chr14:75469612-75476292:+	0.37	4.16	5.28E-5	Height	
PAAD	cis	1	rs9809619	chr3:134280948	ANAPC13	chr3:134196547-134204865:-	0.86	11.15	1.63E-21	Height	
PAAD	cis	1	rs9809843	chr3:48434398	TREX1	chr3:48501186-48509043:+	-0.39	-5.64	7.81E-8	Longevity	
PAAD	cis	1	rs9812647	chr3:48448914	TREX1	chr3:48501186-48509043:+	0.36	5.27	4.52E-7	Longevity	
PAAD	cis	1	rs9813774	chr3:134227100	ANAPC13	chr3:134196547-134204865:-	0.87	11.61	9.26E-23	Height	
PAAD	cis	1	rs9814567	chr3:134218557	ANAPC13	chr3:134196547-134204865:-	-0.89	-12.25	1.79E-24	Height	
PAAD	cis	1	rs9815103	chr3:48414215	TREX1	chr3:48501186-48509043:+	-0.36	-5.19	6.74E-7	Longevity	
PAAD	cis	1	rs9815354	chr3:41912651	ULK4	chr3:41288091-42003660:-	0.85	7.37	9.98E-12	Diastolic blood pressure	
PAAD	cis	1	rs9817615	chr3:48470756	TREX1	chr3:48501186-48509043:+	-0.35	-5.22	5.71E-7	Longevity	
PAAD	cis	1	rs9818169	chr3:41860599	ULK4	chr3:41288091-42003660:-	0.86	7.99	2.98E-13	Diastolic blood pressure	
PAAD	cis	1	rs9819532	chr3:134288644	ANAPC13	chr3:134196547-134204865:-	0.86	11.15	1.63E-21	Height	
PAAD	cis	1	rs9820192	chr3:41889281	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs9823254	chr3:41894768	ULK4	chr3:41288091-42003660:-	0.85	7.51	4.7E-12	Diastolic blood pressure	
PAAD	cis	1	rs9823696	chr3:183783353	YEATS2	chr3:183415606-183530413:+	-0.29	-4.26	3.49E-5	Esophageal adenocarcinoma	
PAAD	cis	1	rs9824731	chr3:41889698	ULK4	chr3:41288091-42003660:-	0.85	7.51	4.7E-12	Diastolic blood pressure	
PAAD	cis	1	rs9825741	chr3:41761828	ULK4	chr3:41288091-42003660:-	-0.84	-7.59	3.0E-12	Diastolic blood pressure	
PAAD	cis	1	rs9826058	chr3:41762062	ULK4	chr3:41288091-42003660:-	0.82	7.14	3.62E-11	Diastolic blood pressure	
PAAD	cis	1	rs9826195	chr3:48433635	TREX1	chr3:48501186-48509043:+	-0.39	-5.64	7.81E-8	Longevity	
PAAD	cis	1	rs9826496	chr3:134224437	ANAPC13	chr3:134196547-134204865:-	0.87	11.72	4.97E-23	Height	
PAAD	cis	1	rs9827987	chr3:134272621	ANAPC13	chr3:134196547-134204865:-	0.89	11.96	1.07E-23	Height	
PAAD	cis	1	rs9828398	chr3:41895893	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs9828815	chr3:134265749	ANAPC13	chr3:134196547-134204865:-	0.87	11.51	1.83E-22	Height	
PAAD	cis	1	rs9829092	chr3:134229866	ANAPC13	chr3:134196547-134204865:-	0.88	11.99	9.11E-24	Height	
PAAD	cis	1	rs9830064	chr3:41881801	ULK4	chr3:41288091-42003660:-	0.85	7.91	4.85E-13	Diastolic blood pressure	
PAAD	cis	1	rs9830469	chr3:41762535	ULK4	chr3:41288091-42003660:-	0.83	7.26	1.79E-11	Diastolic blood pressure	
PAAD	cis	1	rs9832785	chr3:134213070	ANAPC13	chr3:134196547-134204865:-	0.89	12.08	5.22E-24	Height	
PAAD	cis	1	rs9834098	chr3:41833493	ULK4	chr3:41288091-42003660:-	0.88	8.26	6.42E-14	Diastolic blood pressure	
PAAD	cis	1	rs9834755	chr3:134206845	ANAPC13	chr3:134196547-134204865:-	0.89	11.95	1.15E-23	Height	
PAAD	cis	1	rs9835204	chr3:134261342	ANAPC13	chr3:134196547-134204865:-	0.86	11.37	4.15E-22	Height	
PAAD	cis	1	rs9838618	chr3:48487353	TREX1	chr3:48501186-48509043:+	-0.37	-5.35	3.19E-7	Longevity	
PAAD	cis	1	rs9838965	chr3:41927938	ULK4	chr3:41288091-42003660:-	-0.86	-7.82	8.15E-13	Diastolic blood pressure	
PAAD	cis	1	rs9839399	chr3:41928044	ULK4	chr3:41288091-42003660:-	-0.86	-7.82	8.15E-13	Diastolic blood pressure	
PAAD	cis	1	rs9840037	chr3:41827522	ULK4	chr3:41288091-42003660:-	0.88	8.2	9.17E-14	Diastolic blood pressure	
PAAD	cis	1	rs9840532	chr3:41885697	ULK4	chr3:41288091-42003660:-	0.86	7.94	3.93E-13	Diastolic blood pressure	
PAAD	cis	1	rs9841212	chr3:134191938	ANAPC13	chr3:134196547-134204865:-	0.88	11.84	2.33E-23	Height	
PAAD	cis	1	rs984222	chr1:119503843	WARS2	chr1:119573841-119683295:-	-0.52	-5.66	7.21E-8	Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio	
PAAD	cis	1	rs9842261	chr3:41822708	ULK4	chr3:41288091-42003660:-	-0.86	-8.03	2.43E-13	Diastolic blood pressure	
PAAD	cis	1	rs9842305	chr3:41998412	ULK4	chr3:41288091-42003660:-	-0.92	-8.85	2.05E-15	Diastolic blood pressure	
PAAD	cis	1	rs9844351	chr3:126787782	CHST13	chr3:126243176-126262133:+	0.48	4.58	9.68E-6	Amyotrophic lateral sclerosis (sporadic)	
PAAD	cis	1	rs9846634	chr3:41894049	ULK4	chr3:41288091-42003660:-	0.85	7.51	4.7E-12	Diastolic blood pressure	
PAAD	cis	1	rs9847006	chr3:41755359	ULK4	chr3:41288091-42003660:-	0.82	7.21	2.4E-11	Diastolic blood pressure	
PAAD	cis	1	rs9847975	chr3:41786904	ULK4	chr3:41288091-42003660:-	0.83	7.37	9.9E-12	Diastolic blood pressure	
PAAD	cis	1	rs9848754	chr3:41753647	ULK4	chr3:41288091-42003660:-	0.83	7.01	7.19E-11	Diastolic blood pressure	
PAAD	cis	1	rs9849509	chr3:48483432	TREX1	chr3:48501186-48509043:+	-0.33	-4.78	4.12E-6	Longevity	
PAAD	cis	1	rs9850015	chr3:134269541	ANAPC13	chr3:134196547-134204865:-	0.89	11.96	1.07E-23	Height	
PAAD	cis	1	rs9851441	chr3:134315091	ANAPC13	chr3:134196547-134204865:-	0.86	11.54	1.5E-22	Height	
PAAD	cis	1	rs9852303	chr3:41759525	ULK4	chr3:41288091-42003660:-	0.83	7.26	1.79E-11	Diastolic blood pressure	
PAAD	cis	1	rs9854299	chr3:134206728	ANAPC13	chr3:134196547-134204865:-	0.87	11.5	1.93E-22	Height	
PAAD	cis	1	rs9854833	chr3:41775577	ULK4	chr3:41288091-42003660:-	0.84	7.1	4.31E-11	Diastolic blood pressure	
PAAD	cis	1	rs9854838	chr3:41805670	ULK4	chr3:41288091-42003660:-	0.81	7.43	7.17E-12	Diastolic blood pressure	
PAAD	cis	1	rs9855965	chr3:41860508	ULK4	chr3:41288091-42003660:-	0.86	7.99	2.98E-13	Diastolic blood pressure	
PAAD	cis	1	rs9856088	chr3:41860482	ULK4	chr3:41288091-42003660:-	0.86	7.99	2.98E-13	Diastolic blood pressure	
PAAD	cis	1	rs9856633	chr3:42013850	ULK4	chr3:41288091-42003660:-	0.91	8.74	3.98E-15	Diastolic blood pressure	
PAAD	cis	1	rs9856693	chr3:134306913	ANAPC13	chr3:134196547-134204865:-	0.86	11.36	4.41E-22	Height	
PAAD	cis	1	rs9857175	chr3:41822054	ULK4	chr3:41288091-42003660:-	0.87	8.15	1.19E-13	Diastolic blood pressure	
PAAD	cis	1	rs9863786	chr3:134247203	ANAPC13	chr3:134196547-134204865:-	0.85	11.06	2.84E-21	Height	
PAAD	cis	1	rs9863915	chr3:41762002	ULK4	chr3:41288091-42003660:-	0.83	7.26	1.79E-11	Diastolic blood pressure	
PAAD	cis	1	rs9864217	chr3:41762206	ULK4	chr3:41288091-42003660:-	0.83	7.05	5.85E-11	Diastolic blood pressure	
PAAD	cis	1	rs9864346	chr3:134312352	ANAPC13	chr3:134196547-134204865:-	0.87	11.4	3.43E-22	Height	
PAAD	cis	1	rs9864371	chr3:48426766	TREX1	chr3:48501186-48509043:+	-0.39	-5.64	7.81E-8	Longevity	
PAAD	cis	1	rs9864439	chr3:134298671	ANAPC13	chr3:134196547-134204865:-	0.86	11.36	4.41E-22	Height	
PAAD	cis	1	rs9865127	chr3:41807448	ULK4	chr3:41288091-42003660:-	0.82	7.54	3.81E-12	Diastolic blood pressure	
PAAD	cis	1	rs9865780	chr3:41895802	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs9866092	chr3:41895967	ULK4	chr3:41288091-42003660:-	0.85	7.52	4.43E-12	Diastolic blood pressure	
PAAD	cis	1	rs9866759	chr3:41758418	ULK4	chr3:41288091-42003660:-	0.82	7.21	2.4E-11	Diastolic blood pressure	
PAAD	cis	1	rs9867627	chr3:41795841	ULK4	chr3:41288091-42003660:-	-0.7	-6.24	4.17E-9	Diastolic blood pressure	
PAAD	cis	1	rs9868809	chr3:48681053	CCDC36	chr3:49235861-49295537:+	-0.49	-4.04	8.3E-5	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
PAAD	cis	1	rs9869207	chr3:41878661	ULK4	chr3:41288091-42003660:-	0.86	7.94	3.93E-13	Diastolic blood pressure	
PAAD	cis	1	rs9869282	chr3:41756064	ULK4	chr3:41288091-42003660:-	0.82	7.21	2.4E-11	Diastolic blood pressure	
PAAD	cis	1	rs9869440	chr3:41763155	ULK4	chr3:41288091-42003660:-	0.83	7.23	2.16E-11	Diastolic blood pressure	
PAAD	cis	1	rs9869981	chr3:134248801	ANAPC13	chr3:134196547-134204865:-	0.86	11.37	4.15E-22	Height	
PAAD	cis	1	rs9871305	chr3:134213538	ANAPC13	chr3:134196547-134204865:-	0.88	11.99	9.11E-24	Height	
PAAD	cis	1	rs9873207	chr3:41884750	ULK4	chr3:41288091-42003660:-	0.86	7.96	3.64E-13	Diastolic blood pressure	
PAAD	cis	1	rs9874513	chr3:41909508	ULK4	chr3:41288091-42003660:-	0.85	7.51	4.7E-12	Diastolic blood pressure	
PAAD	cis	1	rs9874975	chr3:41764300	ULK4	chr3:41288091-42003660:-	0.81	7	7.35E-11	Diastolic blood pressure	
PAAD	cis	1	rs9875083	chr3:41775786	ULK4	chr3:41288091-42003660:-	0.84	7.1	4.31E-11	Diastolic blood pressure	
PAAD	cis	1	rs9875107	chr3:41822313	ULK4	chr3:41288091-42003660:-	0.86	8.02	2.54E-13	Diastolic blood pressure	
PAAD	cis	1	rs9876658	chr3:134179453	ANAPC13	chr3:134196547-134204865:-	-0.84	-11.62	8.72E-23	Height	
PAAD	cis	1	rs9876781	chr3:48487338	TREX1	chr3:48501186-48509043:+	-0.35	-5.22	5.71E-7	Longevity	
PAAD	cis	1	rs9876960	chr3:41985812	ULK4	chr3:41288091-42003660:-	-0.91	-8.68	5.67E-15	Diastolic blood pressure	
PAAD	cis	1	rs9881491	chr3:48487911	TREX1	chr3:48501186-48509043:+	-0.36	-5.33	3.45E-7	Longevity	
PAAD	cis	1	rs9882329	chr3:41767154	ULK4	chr3:41288091-42003660:-	0.81	7	7.35E-11	Diastolic blood pressure	
PAAD	cis	1	rs9883753	chr3:134247231	ANAPC13	chr3:134196547-134204865:-	0.86	11.61	9.4E-23	Height	
PAAD	cis	1	rs9883759	chr3:48463618	TREX1	chr3:48501186-48509043:+	-0.36	-5.33	3.45E-7	Longevity	
PAAD	cis	1	rs9883927	chr3:48463711	TREX1	chr3:48501186-48509043:+	-0.35	-5.22	5.71E-7	Longevity	
PAAD	cis	1	rs9884031	chr3:134256500	ANAPC13	chr3:134196547-134204865:-	0.86	11.37	4.15E-22	Height	
PAAD	cis	1	rs9890205	chr17:28382704	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.92E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs9890886	chr17:28391076	EFCAB5	chr17:28256874-28435469:+	-0.36	-4.16	5.3E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs9891871	chr17:28370191	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.92E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs9894429	chr17:79596811	TSPAN10	chr17:79609349-79615778:+	0.74	9.99	2.05E-18	Eye color traits	
PAAD	cis	1	rs9896062	chr17:28357047	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.93E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs9897206	chr17:28406108	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.03	8.6E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs9909940	chr17:80689036	FN3KRP	chr17:80674582-80685889:+	-0.46	-4.43	1.81E-5	Glycated hemoglobin levels	
PAAD	cis	1	rs9912741	chr17:28359511	EFCAB5	chr17:28256874-28435469:+	-0.35	-4.06	7.92E-5	Coffee consumption (cups per day)	
PAAD	cis	1	rs9920762	chr15:90368171	AP3S2	chr15:90373832-90456222:-	-0.81	-9.29	1.45E-16	Type 2 diabetes	
PAAD	cis	1	rs9923145	chr16:74686166	RFWD3	chr16:74655298-74700779:-	-0.3	-4.39	2.09E-5	Testicular germ cell tumor	
PAAD	cis	1	rs9925964	chr16:31129895	MYST1	chr16:31128985-31142713:+	-0.39	-5.15	7.88E-7	Body mass index	
PAAD	cis	1	rs9929496	chr16:74668473	RFWD3	chr16:74655298-74700779:-	-0.29	-4.23	4.02E-5	Testicular germ cell tumor	
PAAD	cis	1	rs9931225	chr16:74699293	RFWD3	chr16:74655298-74700779:-	-0.31	-4.56	1.03E-5	Testicular germ cell tumor	
PAAD	cis	1	rs9968172	chr3:134231251	ANAPC13	chr3:134196547-134204865:-	-0.88	-12.11	4.22E-24	Height	
PAAD	cis	1	rs997872	chr22:25878614	CRYBB2	chr22:25615612-25627836:+	1.21	7.7	1.57E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs997873	chr22:25878282	CRYBB2	chr22:25615612-25627836:+	1.21	7.7	1.57E-12	Bipolar disorder with mood-incongruent psychosis	
PAAD	cis	1	rs9981595	chr21:40560678	HMGN1	chr21:40714247-40721270:-	-0.45	-4.1	6.69E-5	Venous thromboembolism (SNP x SNP interaction)	
PAAD	cis	1	rs9984793	chr21:30486471	NCRNA00189	chr21:30565801-30660525:+	0.47	5.2	6.31E-7	Dental caries	
PAAD	cis	1	rs9985341	chr3:134232840	ANAPC13	chr3:134196547-134204865:-	0.63	7.27	1.74E-11	Height	
PAAD	cis	1	rs9985356	chr3:134232920	ANAPC13	chr3:134196547-134204865:-	-0.86	-11.23	1.01E-21	Height	
PAAD	cis	1	rs9989967	chr3:134238964	ANAPC13	chr3:134196547-134204865:-	0.86	11.69	5.78E-23	Height	
PAAD	cis	1	rs9990351	chr3:134239191	ANAPC13	chr3:134196547-134204865:-	-0.89	-12.2	2.4E-24	Height	
PAAD	cis	1	rs9991307	chr4:17662408	MED28	chr4:17616273-17629791:+	0.45	5.37	2.92E-7	Parasitemia in Tripanosoma cruzi seropositivity	
PAAD	cis	1	rs9995007	chr4:76897791	NAAA	chr4:76831809-76862166:-	-0.45	-5.5	1.53E-7	Longevity	
PAAD	trans	1	rs10037055	chr5:176691279	LOC388955	chr2:63849182-63850159:-	-0.64	-7.34	1.2E-11	Migraine without aura	
PAAD	trans	1	rs6886255	chr5:176718361	LOC388955	chr2:63849182-63850159:-	0.66	7.53	4.16E-12	Migraine without aura	
PAAD	trans	1	rs735765	chr6:28170297	BTN3A2	chr6:26365398-26378546:+	-0.81	-7.14	3.54E-11	Depression	
